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ABSTRACT
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Genomic Data Analysis: populations, patients & pipelines
by
Reuben John Pengelly MBiol
Methods for the ascertainment of genotype data have become more cost efficient by
orders of magnitude with the use of high-density genotyping arrays and the advent
of next generation sequencing (NGS). The resulting deluge of data has required ever
advancing analytical approaches in order for the maximal information to be gleaned
from these extensive data.
In this work, many application of NGS to clinical research are discussed. This includes
the application of targeted gene sequencing to a cohort of 83 patients with chronic kidney
disease, whole-exome investigations of eight families with cleft lip/palate phenotypes,
as well as five cases where analytical lessons can be learned from exome sequenced cases
harbouring pathogenic variants refractory to identification. Additionally, a novel QC
tool for the unambiguous tracking of samples undergoing exome sequencing is presented.
Furthermore, work is presented investigating the linkage disequilibrium (LD) pat-
terns in populations applying the Male´cot-Morton model. We demonstrate that array
genotyping is insufficient for the accurate determination of fine LD patterns in the
human genome, with whole-genome sequencing providing more representative LD maps.
Finally, we apply similar methods to Gallus gallus, generating the highest resolution
maps of LD presented to date, showing that the patterns are highly discordant between
commercial lines, and define features associated with recombination.
Overall, we highlight the diversity of ways in which genetic data can be utilised
effectively in the age of genomic ‘big data’, and present tools which may be of benefit
to other researchers utilising these technologies.
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Introduction
1
Chapter 1
Foundations of Genetics
“The science of genetics is in a transition period, becoming an exact science
just as the chemistry in the times of [Antoine] Lavoisier, who made the
balance an indispensable implement in chemical research.”
Wilhelm Johannsen, 1911 [1]
1.1 A primer on molecular biology
Genetics, the study of the transfer of traits in discrete heritable units, largely
stems from the works of Gregor Mendel in the mid 19th century on inheritance in
Pisum sativum (the common pea). Mendel observed that traits passed down through
generations of the pea in predictable patterns, abiding by ratios that stem from the
biallelic inheritance of the traits[2]. It was not until the 1940s that the chemical basis of
this inheritance was identified. Avery et al. investigated the transformation of benign
Streptococcus pneumoniae to a pathogenic form through incubation of benign cells with
cellular lysate of the pathogenic form. Following isolation of the ‘transforming principle’,
chemical analyses determined it to be deoxyribonucleic acid (DNA)[3].
Further to the identification of DNA as the vehicle for inheritance, an appreciation of
the properties of the molecule has allowed further advancements in molecular biology.
Discoveries such as the elucidation of the semi-conservative nature of the process by
which DNA replicates[4], along with the solving of the characteristic double helix crystal
structure[5], have laid the groundwork for the burgeoning field. DNA is formed from a
dictionary of four nucleotide bases (adenine, thymine, cytosine and guanine; A, T, C
and G respectively), coding under the so-called ‘central dogma’ of molecular biology
for proteins with a complement of 20 directly translated amino-acids monomers via
trinucleotide codons (Figure 1.1)[6].
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Figure 1.1: Information transfer paths available under the ‘central dogma’ of molecular biology.
The major transfers of information in human molecular biology are shown in bold arrows:
DNA, which will self-replicate, is transcribed into RNA, which may in turn be translated into
polypeptides. Special cases of RNA self-replication and reverse transcription are also seen, though
are not performed by integral human cellular mechanisms. Translation of DNA is a rare case,
possible to perform experimentally. Adapted from Crick, 1970[7].
1.2 The Human genome
Humans have a diploid genome with a haploid size of ∼3 Gbp, comprising 22 auto-
somal homologous chromosome pairs (1–22), and two allosomes (X & Y), totalling 46
chromosomes within somatic cells for a euploid individual (Figure 1.2). Being diploid,
one of each chromosome is received from each haploid parental gamete upon fertilisation
of the oocyte[8].
Figure 1.2: Ideogram showing representative human prometaphase chromosomes as observed
following Giemsa staining. Pink regions indicate centromeric regions, while blue represent non-
centromeric heterochromatin. Dark bands indicate AT-rich regions of chromosomes. Taken from
www.ncbi.nlm.nih.gov/projects/genome/assembly/grc/human/[9].
Within the genomic DNA (gDNA), there are 20,000–22,000 protein coding genes,
in addition to functional ribonucleic acids (RNA), such as transfer, ribosomal and
micro RNAs. From these ∼20,000 protein coding genes, a large array of discrete mRNA
transcripts can be generated by alternative splicing of the pre-mRNA, allowing for the
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complexity of the human cellular processes[8]. Transcribed DNA is estimated to make
up 1–2% of the human genome, with the majority of the remainder formed of repeat
elements and other ‘junk’ DNA. Recent advances in our understanding of the function
of many DNA elements however show that the vast majority of this ‘junk’ DNA is
functional in some regard[10,11].
1.3 Mutation types
There is a wide gamut of mutation types that can occur. A range of small coding
mutations that may occur in the exons of a gene are shown in Figure 1.3. These
mutations will have diverse effect upon the translated protein, and thus also on any
potential ultimate phenotypic effects. In addition to the small mutations shown, larger
mutations also occur, including gross structural changes at a chromosomal level and
nucleotide repeat expansions.
Synonymous substitution
ATG TGG CAA TAA
Met-Trp-Gln-Stop
Stop loss
ATG TGG CAG TAT
Met-Trp-Gln-Tyr...
ATG TGG CAG TAA
Met-Trp-Gln-Stop
Non-frameshift insertion
ATG TGG CAGCCC TAA
Met-Trp-Pro-Gln-Stop
Start loss
ATT TGG CAG TAA
-
Frameshift deletion
ATG TGC AGT AA...
Met-Cys-Ser...
Nonsense substitution
ATG TGA CAG TAA
Met-Stop
Missense substitution
ATG TGG CAC TAA
Met-Trp-His-Stop
Figure 1.3: Summary of coding mutation types and effect on protein. The open reading
frame for a hypothetical tripeptide is shown in the centre, with seven possible small mutation
types shown surrounding this. Sequence changes are underlined. Note that frameshift and
non frameshift variants may both be insertions or deletions, this has not been illustrated due
to space constraints. Though synonymous substitutions are not expected to cause a protein
change due to coding alterations, but may affect other factors, for instance altering a binding
site motif. All other mutation types are expected to alter the primary sequence of the resultant
protein. Frameshifts and stop loss mutations may result in the read through of a previous stop
codon; therefore, translation may continue until an in-frame stop codon is reached. For start loss
mutations, no translation is expected, unless there is a proximal alternative start codon, in which
case this mutation would merely cause N-terminal truncation of the peptide.
1.4 Population structure
The genomes of humans are diverse, with several million deviations from the reference
genome in any one individual. Many of these variants are highly common, with a high
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alternate-allele frequency (AF), and some will be private to the individual. However,
these variants are far from uniformly distributed across populations. A variant may be
vanishingly rare in one population, or absent, and common in another[12]. If care is not
taken, these population differences can hinder some studies.
1.5 Inheritance
As in peas, inherited traits in humans often follow predictable patterns in heredity.
There are many possible modes of inheritance for a genetic trait (say, for simplicity a
disease), even if we presume adherence to Mendelian monogenic inheritance of a trait.
This predictability is due to the consistent passage of a proportion of DNA through
generations.
With each separating meiosis between individuals, the proportion of alleles with
identity by descent (IBD or Φ) is halved. The anticipated proportion of IBD between
two relatives (denoted a and b for this example) can be calculated, presuming that all
pedigree founders are unrelated for simplicity:
Φab = 0.5
mf (1.1)
where m is the number of matings separating a and b via the nearest common founder,
and f is the number of shared founders (example values are shown in Table 1.1; adapted
from Lange, 1997[13])[14]. It should be noted that even for an entirely non-consanguineous
pedigree, the identity by state (IBS) is expected to be greater than this calculated
IBD due to the common alleles recurring within the pedigree derived from independent
founders.
Table 1.1: Expected proportion of autosomal IBD for relatives within an outbred pedigree.
Relationship f m Φ
Monozygotic twin 2 1 1
Parent 1 1 0.5
Sibling 2 2 0.5
Half-sibling 1 2 0.25
Grandparent 1 2 0.25
Aunt/Uncle 2 3 0.25
1st Cousin 2 4 0.125
Several modes of inheritance are discussed below, in the context of disease alleles for
clarity, though it should be noted that this is not an exhaustive list.
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1.5.1 Autosomal dominant
The inheritance of a single pathogenic allele will be sufficient for the manifestation
of the disease. Molecular mechanisms underlying dominant conditions may include
haploinsufficiency, where the half-dosage of the functional gene copy is insufficient for
cellular processes, and dominant negative effects, for example as seen in proteins that
form homodimers such as receptor tyrosine-kinases. Here, because the non-functional
monomers still bind with the functional monomers, the homodimer is non-functional due
to the required reciprocity of function between the monomers. An affected individual
will have a 50% probability of passing the disease onto their child. Huntingdon’s disease
is a classical example of an autosomal dominant condition[8].
1.5.2 Autosomal recessive
Both inherited alleles of the disease locus are required to be pathogenic for the
manifestation of the disease. Recessive conditions may be caused by the absence of a
metabolic process: where half-dosage of function would have been sufficient, abrogation
of function is pathogenic. For autosomal recessive conditions, there is a 100% chance
that an affected individual will pass on a pathogenic allele, but where the partner is
unaffected, the probability of them also passing on a disease allele will be dependant
upon the carriage rate in the population and any family-history of the disease. It is of
note that both pathogenic alleles in a gene are not required to be the same pathogenic
allele; compound heterozygosity is often a more likely cause of autosomal recessive
disease in non-consanguineous families. Cystic fibrosis is a canonical autosomal recessive
disorder[8].
1.5.3 Sex-linked
Conditions can be either X-linked or Y-linked. In the case of an X-linked recessive
condition, the same requirements for pathogenesis apply in females as with AR conditions.
As males typically possess a single X-chromosome, there is not the allelic redundancy as
with autosomes, so this hemizygosity for a pathogenic allele will be sufficient to cause
disease. X-linked dominant conditions will manifest in both males and females; as in
some autosomal dominant conditions, homozygosity for a pathogenic allele tends to
be more severe, and may be lethal at some stage of development. As such, X-linked
dominant conditions can tend to manifest more severely in males than heterozygous
females, due to the obligate hemizygosity for the allele. Y-linked disease will manifest
purely in males. Genes within the pseudoautosomal region, being homologous between
the X and Y chromosomes, will exhibit an inheritance pattern more similar to autosomal
loci. Allosome aneuploidies may interfere with the inference of mode of inheritance,
6 Section 1.5
Foundations of genetics
for instance, a male with Klinefelter’s syndrome (karyotype 47,XXY) may carry an
X-linked recessive allele without manifestation[8].
1.5.4 Alternative modes
In addition to the above Mendelian modes of inheritance, many diseases have al-
ternative modes. For example, mitochondria contain a small genome (mtDNA) of
∼16,500 bp, with a high coding density. As only the oocytic mitochondria are retained
post-fertilisation, inheritance will only be apparent though the maternal lineage. Fur-
thermore, due to the high copy-number of heterogeneous mtDNA in a cell, the resultant
heteroplasmy may lead to variable penetrance in carriers of the variant[15]. In many
cases a presumption of monogenic, completely penetrant inheritance of a trait is unfoun-
ded, and several genes may be involved in the disease processes, or require additional
environmental triggers. The ultimate realisations of this concept, aptly named ‘complex
diseases’, are those that require a complex interplay of factors for manifestation, with
genetic variants merely predisposing an individual to the disease, and thus require
different approaches for the identification of genes involved in Mendelian disease, as
discussed in Chapter 2.
1.6 Genetics as aetiology
Aetiology in disease can be broadly considered to have several main classes, including
deficiency, where disease is brought about by the lack of an essential nutrient (e.g.
microcytic anaemia caused by iron deficiency), and pathogenic disease, caused by
the uncontrolled presence of pathogenic micro-organisms, parasites or particles (e.g.
hepatitis C virus). In addition to these exogenous aetiologies, endogenous factors can
lead to disease. An inborn genetic defect in a metabolic or signalling pathway may
manifest in a clinical phenotype, for example defects in the hedgehog signalling pathway
may result in erroneous growth patterning during foetal development[16]. Furthermore,
acquired somatic mutations may contribute to the development of malignant neoplasia.
In the vast majority of cases, these are not discrete factors and there will be some
degree of interplay. For example, an individual may be born with cystic fibrosis, but the
disease course is modified throughout life by events such as infection with respiratory
pathogens (e.g. Pseudomonas aeruginosa). The focus of the research detailed herein
is on congenital diseases which have a clear associated phenotype, regardless of the
intervening factors, and are therefore expected to have a strong genetic cause. The study
of these genetic diseases has enjoyed accelerating success as regards the identification
of disease genes (Figure 1.4), driven largely by advances in associated technologies, as
discussed in detail in Chapter 2.
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Figure 1.4: Accelerating rate of disease gene identification, 1996–2013. Cumulative count of
the creation of additional disease entries in the Online Mendelian Inheritance in Man (OMIM)
database[17] for which a causal gene is known, with 1995 as the baseline. Diseases for which only
a locus is identified, as opposed to the specific gene, are not included in the count. Values based
upon data-freeze downloaded 18th February, 2014.
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Medical Genetic Research as
Driven by Emergent Technologies
The field of human medical genetics is a rapidly evolving, and accelerating field,
with this continued progress being driven by the availability of new technologies for
the determination and analysis of genetic data. Here I will discuss a few of the most
significant methods that have been used for medical genetic research since the latter
half of the 20th century, with a critical analysis of the methods.
2.1 Linkage mapping
One of the earliest approaches to the mapping of disease genes was linkage mapping.
In linkage studies, related individuals exhibiting the disease are genotyped for a low
density of markers. As technologies have progressed, so greater marker densities have
been available to researchers, progressing from single point markers such as ABO
blood-type, to several 1,000 independent microsatellite/single nucleotide polymorphism
(SNP) markers. Statistical analyses are undertaken in order to determine which (if any)
marker most closely cosegregates with disease (Figure 2.1). The seminal statistic for
linkage analysis is the logarithm of odds (lod) score. Despite complex mathematics, the
fundamental principle of the lod score can be expressed as:
lod = log10
(
Lobserved
Lunlinked
)
(2.1)
where Lobserved is the likelihood, as empirically determined, of co-inheritance of the
marker allele with the trait-defining locus, and Lunlinked is the likelihood calculated
presuming the marker and locus are independent (equal to 0.5 for the residual co-
transmission in a fully-stochastic manner)[18]. Determination of the lod should be
carried out in several independent families to allow for pooling of results and resultant
increased certainty afforded due to the additive nature of lod scores.
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Figure 2.1: Principle of linkage mapping as applied to a pedigree exhibiting episodic ataxia.
Haplotypes within 1q42, indicated below individuals, are shaded in black to denote the 10-3-1-3
putative risk haplotype; the risk halotype can be seen to segregate with disease in the majority
of cases. 1q42 was previously found to be the most strongly linked region to the condition in
a genome-wide linkage analysis prior to fine mapping, with a lod score of 3.65. Deviations are
however seen from the expected pattern, marked with *, e.g. in individuals II-10 and III-9, this
may be due to incomplete penetrance and phenocopy phenotypes. Taken from Cader et al.,
2005[19]. Reprinted by permission from Wolters Kluwer Health, © 2005.
Linkage studies, as with all methodologies, have many limitations; foremost of these
is the sensitivity to errors in both genotyping and phenotyping which can greatly affect
results given the small sample size within a family. Initial ascertainment of extended
families with the disease of interest may also prove problematic, particularly where the
disease has a strongly detrimental effect on fitness. Secondly, the parametric lod score
is best suited for total-penetrance Mendelian traits, as deviation from this will reduce
the power of locus detection, though can be compensated for[20]. Additionally, once a
genomic region has been identified as linked, the fine mapping of the locus is non-trivial.
Despite these issues, linkage mapping has had many successes in the identification
of disease loci such as that for Huntingdon’s disease[21]. Alternate non-parametric
statistical methods for linkage mapping have also been used with some successes for
complex diseases[22].
2.2 The Human Genome Project & reference gen-
ome
True ‘genomics’ could arguably be thought to have initiated with the advent of the
publicly-funded Human Genome Project (HGP)[23–25]. The HGP stands out as one of
the largest, most ambitious, non-military scientific endeavours so far completed, being
particularly impressive for the sheer scale of international collaboration involved. The
HGP had a broad array of goals in addition to the generation of a human genome
reference sequence. These included educational initiatives to ensure maximum advantage
could be taken of the completed genome, continuation of the development of technologies
for genomic analysis and to produce similar reference resources for model organisms.
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As with any newly emerging field, the early years of genomics have been marked by a
lag between the rapidly advancing science and the ethico-legal framework within which
it is be expected to function. This was by no means an unexpected issue, being another
of the target areas of research within the HGP[24].
A draft reference sequence of the human genome was published in 2001[23], followed
by the final release from the HGP in 2004[25]. Taking up the work of the HGP, the
Genome Reference Consortium (GRC) now maintains the reference genomes of several
species, releasing regular intermediate patches as required and major releases for the
human reference currently approximately every 3 years[9]. An accurate reference genome
is essential to facilitate modern genomic research, as discussed in subsection 4.3. There
have been significant economic benefits resulting from the HGP; a report on the economic
impact concluded in part that:
“The federal government invested $3.8 billion [USD] in the HGP through
its completion in 2003. . . generating the economic output of $796 billion,
and thus shows a return on investment to the U.S. of 141 to 1. . . .
The HGP is arguably the single most influential investment to have been
made in modern science and a foundation for progress in the biological
sciences moving forward.”
Simon Tripp & Martin Grueber, 2011 [26].
Since the initial HGP, significant improvements to the quality of the reference genome
have been made with each release; two crude statistics are presented below by means of
illustration (Table 2.1). The number of discrete contigs initially decreases from the draft
sequence as adjacent contigs are successfully merged; also the N50 length, a measure
of the length of contigs becomes greater. Other quality metrics for the releases tend
to follow the same clear pattern of improvement. Note here the large increase in the
number of contigs for the GRCh38 release; this increase is due to alternative assemblies
being created for highly variable regions where we observe diverse haplotypes such
as the human leukocyte antigen (HLA) region on chromosome 6[9]. The existence of
alternative assemblies for these regions ensures that accurate alignment can still be
obtained for individuals where the genome does not agree with the canonical reference
sufficiently to allow for accurate alignment of short reads. The continued increase of
the N50 for the contigs bear testament to the work assembling the reference.
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Table 2.1: Contiguity statistics for major releases of the human reference genome.
Draft NCBI35 NCBI36 GRCh37 GRCh38
(2001) (2004) (2006) (2009) (2013)
Contigs 87,757 390 388 461 1,385b
N50a (bp) 274,300 38,509,590 38,440,852 46,395,641 56,413,054
aThe size at which contigs of length ≥ N50 comprise ≥ 50% of the total assembly length.
bGRCh38 contains a large increase in the number of alternative assemblies for highly variable regions,
accounting for this increase.
2.3 Association studies
The investigation of association of alleles with disease has been a successful methodo-
logy for studying complex disease. The methodology of these studies is relatively simple
(using the example of a binary trait). A large cohort of unrelated individuals containing
cases (individuals affected with your trait of interest) and controls (individuals matched
to the case cohort, particularly as regards ethnicity) are genotyped. Following this,
standard statistical approaches are applied to see if an allele is significantly overrepres-
ented in the cases vs. controls. Early examples of this methodology involved testing
the association with a single locus, such as the ABO blood-type (albeit indirectly
via phenotypic characterisation)[27] or HLA loci[28]. As genotyping technologies have
progressed, the numbers of markers assayed has increased dramatically.
2.3.1 Genome-wide association studies
With the availability of high-density genotyping arrays, the concept of the genome wide
association study (GWAS) was made feasible. In a GWAS a large number of markers,
generally SNPs, are genotyped using these high-density genotyping arrays, followed by
testing of SNPs for association[29]. Commonly utilised high-density genotyping platforms
are the genome-wide human SNP array 6.0 (Affymetrix) as well as the BeadChip range
(Illumina), with many allowing for simultaneous genotyping of ∼1,000,000 SNPs.
The rationale of a GWAS is that, due to LD, the genotyped ‘tag’ SNPs can be
utilised to identify genomic regions of significance when one allele of the tag SNP is
over-represented in disease cases when compared to controls for example[29–31]. Tag SNPs
used are considered surrogate markers for their encompassing haplotype (Figure 2.2).
Elucidation of the exact pathogenic variant can be undertaken following identification of
an associated haplotype. Initial selection of tag SNPs, as well as analysis and refinement
of data from GWAS requires a catalogue of sites of genetic variation and alternate-allele
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frequencies (AF); for this purpose the International HapMap (haplotype map) Project
was initiated[32–35].
↓ ↓ ↓
C...T ...C ...A...A ...A ...G ...T...A ...C
G...T ...G ...A...T ...T ...G ...C...G ...C
C...C ...C ...G...A ...T ...C ...T...G ...T
G...C ...G ...G...T ...T ...C ...C...G ...C
Figure 2.2: Rationale for the use of tag SNPs as surrogate markers for haplotypes. Three
biallelic tag SNPs (indicated with arrows) are shown within the encompassing 4 haplotypes
(coloured) present within the hypothetical population (as concatenates of variant sites). These
three appropriate tag SNPs are sufficiently informative to uniquely identify each haplotype, and
can thus be used as an efficient surrogate for haplotype determination within the population.
Adapted from International HapMap Consortium, 2003[32].
One of the first successful GWAS studies was reported by Klein et al. in 2005[36].
This exemplar study utilised a cohort of 96 European patients with age-related macular
degeneration, and an age matched control cohort of 50. Even with this small sample
size, the authors were able to identify an associated SNP (rs380390) with a large
effect size of a 7.4 fold increase in risk for individuals homozygous for the minor allele.
Further to this, the pathogenic variant (rs1061170) was elucidated by sequencing of
the encompassing gene in the cases and controls and validated based on experimental
evidence.
Some authors have criticised the standard approaches of tag SNP selection as relying
largely on unwarranted assumptions on the nature of LD patterns across the human
genome[37,38]. Specifically, Terwilliger and Hiekkalinna published an ‘utter refutation’
of the core rationale behind the HapMap project, raising several concerns on largely
statistical grounds regarding underpowered studies, and the assumption that pathogeni-
city of an allele would not affect LD patterns, which of course it would under strong
negative selection pressures[37]. This in part explains the bias towards small effect sizes
common in GWAS results; highly penetrant aetiological variants circulating within
the population will tend to be present in only a minority of the founder haplotype in
which it arose, hindering detection by GWAS[39]. It is of note that family-based linkage
mapping will not suffer from this limitation.
Limitations of GWAS can be reduced with the infilling of intervening genotypes
between tag SNPs by statistical inference, termed imputation. This imputation poten-
tially allows for the prediction of rare non-genotyped intervening SNPs (AF < 0.05)
with a stronger disease association that the tag SNPs, though with decreasing efficiency
with decreasing AF, and does not allow for the detection of highly rare variation
(AF < 0.003)[40]. More recently, bypassing this issue, arrays investigating rare variation
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uncovered through large-scale resequencing projects have become available, with the
intention to directly genotype functional coding variants within the cohort, already
affording some success[41–43]. These rare-variant arrays however provide far less efficient
imputation, and therefore allow for information on a much smaller proportion of the
genome and are thus complementary, and not a viable replacement to, genome-wide
arrays[44].
Despite the raising of some concerns, GWAS have been fairly successful in the
identification of associated loci with complex disease. Large consortia such as the
Wellcome Trust Case Control Consortium, which performed analyses with 3,000 common
controls and 7 case cohorts of 2,000 individuals, were successful in the identification
of associated variants, particularly for Crohn’s disease and type I diabetes mellitus[45].
This one study (albeit a large one) identified 24 independent signals which achieved
GWAS significance (p < 5× 10−7) and a further 58 ‘suggestive’ signals (p < 5× 10−5)
across the 7 diseases[45]. Many studies have had similar successes, with many significant
regions being identified through the ‘GWAS era’.
The vast majority of reported associations to date have an effect-size of much less
than twofold; the challenge remains in the refinements of GWAS signals, and ultimately
the clinical application of these associations. To illustrate this, the NHGRI GWAS
catalogue[46] contains 9,947 GWAS significant (p ≤ 5× 10−8) records for all traits, with
a median odds ratio of 1.064 (inter-quartile range 0.075–1.310). The odds ratios seen
are highly variable by trait, for instance, for height, this is 1.044 (1.030–1.084) compared
to 1.190 (1.129–1.380) for Crohn’s disease.
2.3.2 Statistical considerations
There are two main considerations that hinder the identification of medically meaning-
ful associated loci. Firstly, given the large number of statistical tests performed (most
commonly one test per marker, so let us say for the sake of example 1,000,000), multiple
testing correction must be applied to reduce the risks of false-positive findings[47]. There
are many approaches for the limitation of false positive rates, the Bonferroni correction
method is the simplest and can be informally presented as:
αset =
α
nset
(2.2)
where α is the desired significance level for the set of tests (typically α = 0.05), nset is
the number of tests being performed, and αset is the corrected significance level that
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must be used for each test in the set. Presuming the numbers mentioned above, this will
give us αset = 5× 10−8. Bonferroni corrections are often considered overly conservative
as they presume that all tests are independent[47,48], which will not be the case in a
GWAS due to the LD. The number of tests performed may be far higher in some cases,
for instance where pairwise epistatic interations are investigated. Additionally, due to
concerns over false-discovery, replication of results in an independent cohort is critical to
validate initial results[49]. This correction for multiple testing means that large cohorts
must be ascertained to provide the best possible power. The pressure for large cohorts
may require the relaxation of criteria for inclusion; additional heterogeneity within the
cohort may counter-productively reduce the power of the study.
The second consideration in GWAS interpretation is that the effect size of an associated
haplotype is often modest. An odds-ratio of 4 would be considered substantial as an
outcome for a GWAS[29,50], the issue becomes whether this readily translates into
clinical utility. Whilst often it may not, the identification of these loci allows for
the elucidation of pathways of importance and potential biological mechanisms for
disease manifestation. This leads to the final challenge in GWAS interpretation, that
of missing heritability. For most traits GWAS have characterised a small percentage
of the observed heritability (measured by methods such as rates in siblings), with the
remainder currently unexplained[50].
One striking example of this challenge of missing heritability is the analysis by Allen
et al.[51] to identify genetic variation associated with height. The study utilised 180,000
individuals, identifying 180 associated loci; these identified loci collectively account
for just 10% of the phenotypic heredity. There are several potential explanations for
this missing heritability: the effects of rare variation (omitted by design from GWAS);
other forms of genetic variation such as copy number variation; and also epistatic
and epigenetic mechanisms. A further interesting possibility is that common variation
as a whole contributes to the heritability of traits, as opposed to specific arbitrarily
significant SNPs[50–53]. This hypothesis has profound implications for the potential
translational application of genetics to complex disease. Further study of a broad range
of hypotheses will hopefully help fill in this missing heritability[11,29,43,50,54,55].
2.4 Next-generation sequencing
Next-generation sequencing (NGS) is the massively parallel sequencing of DNA
molecules, allowing for a sequencing throughput several orders of magnitude greater
than Sanger sequencing; therefore the cost of sequencing a human genome has dropped
by several orders of magnitude over the past 5 years (Figure 2.3). NGS has the capacity
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for a far higher genotyping density than even the highest density array. NGS reads
provide direct information for each nucleotide covered; as such, the loss of power due to
recombination between the aetiological and tag variants seen in GWAS will not apply.
Furthermore, no prior knowledge of potential variant sites is required, allowing the
identification of rare and novel variants.
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Figure 2.3: Cost of sequencing a human genome, 2001–2013. Costs (in USD) include all
essential supplementary costs such as purchase of equipment and personnel costs. The sharp
decline in cost beginning January 2008 is concomitant with the introduction of NGS. Note
the logarithmic scale. The cost stands at $5,096/genome as of October, 2013. Data from
www.genome.gov/sequencingcosts[56].
2.4.1 Applications of NGS
The development of high-throughput next-generation sequencing NGS platforms has
allowed for rapid, cost-effective population re-sequencing projects in many prokaryotic
and eukaryotic species including Arabidopsis thaliana [57], and of course Homo sapi-
ens [12,58,59], as well as entire eukaryotic genera such as the Saccharomyces [60–62], allowing
for comprehensive evolutionary analyses and comparative genomics[61,62]. Establishing
a high-resolution catalogue of variation within population-specific cohorts provides re-
searchers with a baseline of supposedly tolerated genetic variation; this baseline provides
a hugely powerful filtering tool for the exclusion of common, and thus presumably
relatively benign, variation when looking at genomic data derived from an individual
sample[63]. Furthermore, projects to systematically catalogue the phenotypic effect of
gene knockouts in mice allow a better understanding of gene function[64].
This distinction between benign and pathogenic variants is blurred when investigating
complex diseases, contributory alleles for disease may be present at high frequency in a
population, conferring a small increase in risk[30]. Now that NGS technologies have led
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to vastly reduced sequencing costs compared to Sanger sequencing, it is now also possible
to utilise re-sequencing to investigate specific traits, essentially with case-control designs,
utilising existing variation databases as a shared control between studies[12,35,65,66]. This
has the potential to identify some proportion of the missing heritability in complex
diseases that remains following the GWAS-era.
Due to the increased power per sample, small sample-sizes can prove sufficient for
identification of novel loci with Mendelian disease causality. Indeed, trio studies have
been shown to have a high success rate for causal gene identification across diverse
disorders with varying modes of inheritance, including dominant, recessive and de novo
arising mutations, though alternative study designs are also effective, such as small
cohorts and singletons[67]. The ability to identify causal variants from small cohorts
allows investigation of very rare disorders, including those with incomplete penetrance,
and unidentified biological causes. A recent study detailing the experience of clinical
application of whole-exome sequencing (WES) reported a 25% rate of putative molecular
diagnoses across large cohorts with diverse Mendelian disease[68,69].
Whole-genome sequencing (WGS) costs are currently prohibitively expensive for
many research groups and clinical application. This, twinned with the computational
challenges posed by the vast amounts of sequence data produced in WGS has led many
investigators instead to currently utilise methods that target sequencing. Sequencing
a desired small minority of the genome as opposed to the entirety further decreases
costs and improves sequencing sample throughput[70]. With decreasing sequencing costs
however, it is becoming increasingly viable to forego the exome enrichment phase and
perform WGS.
Recent cohort studies have shown that WGS provides a greater diagnostic yield
that WES, with a 34% diagnosis rate in Mendelian disease, increasing to 57% in trio
analyses[71]. The greatly improved diagnostic rates when analysing trios highlights the
major challenge in WGS, the interpretation of the vast amounts of data. In addition
to the inclusion of non-exonic regions of the genome, WGS provide more complete
coverage of the exome, providing greater variant detection sensitivity[72]. Beyond merely
attaining sufficient coverage, WES sample processing leads to several other issues with
variant detection. These are discussed in detail in Chapter 4. Due to the rapidly moving
nature of the field, it is likely that there will be a move increasingly towards routine
WGS in the next couple of years.
17 Section 2.5
Genetic Research Technologies
2.5 Implementation of genomics in healthcare
As genomics moves to the fore, including in the context of routine healthcare provisions,
careful consideration must be given to potential uses arising issues to ensure that the
introduction is maximally beneficial, while avoiding potential public backlash in the
event of unexpected negative consequences, which could hinder the field.
2.5.1 Personalised medicine
Personalised medicine can be described as “an integrated, coordinated, and evidence-
based approach for individualising patient care across the continuum from health to
disease”[73]. Application of the tenets of personalised medicine requires identification
and evaluation of biomarkers within the patient prior to decision-making. Genetic
disease markers provide both the earliest indications of congenital disease-risk, as well
as the least information on the dynamic progression of said risk, due to the intrinsic
(mostly) stable nature of the genome (Figure 2.4)[73].
Figure 2.4: Potential roles for various biomarkers in disease risk prediction and diagnosis.
Genomic information about an individual provide the earliest identifiers of disease risk, including
even pre-fertilisation of the oocyte. However, genomic information alone will not provide
information on risk progression, as dynamic biomarkers such as mRNA expression profiles might,
(except where genetic instability is aetiological, as in oncogenesis). Interventions introduced
following disease initiation may be less able to reverse disease progression compared to prophylactic
interventions. Taken from Chan & Ginsburg, 2011[73].
For Mendelian disease traits, particularly those exhibiting dominant inheritance,
disease risk can be approximated via evaluation of a thorough family history. Following
this, where there is a perceived genetic risk, targeted genetic tests can be readily and
cost-effectively undertaken to confirm genotype where a strong candidate aetiological
locus for the disease of interest is known. Fulfilment of this caveat requires extensive
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prior investment in genetic research to identify the locus. More than 2,500 monogenic
diseases currently have available validated diagnostic genetic tests for clinical use[55].
Complex diseases pose a far greater challenge for both the elucidation of genetic risk
markers, as well as clinical application of these markers. Identification of associated
markers requires broadly-targeted genetic research, meaning ideally genome-wide meth-
odologies. Despite the challenges, the field of large-scale genetic research continues
to make huge advances in the identification of these markers[29,36,55,67,74–76]. Direct
clinical application of these markers however remains a challenge, due principally to
the relatively small increase in disease risk conferred by each variant identified[29,75].
In addition to the determination of personal risk for disease, genes and pathways
identified by genomic research can also identify novel drug targets for rational drug
design campaigns[77,78]. In addition to drug design, the identification of pharmacody-
namically relevant markers allows for pre-emptive adjustment of drug regimens prior to
administration, reducing the probabilities of adverse drug reactions[79]. Of particular
interest for this approach are genes which are involved in modifying the adsorption,
distribution, metabolism and excretion of the drug, such as transporters (e.g. ABCB1,
encoding P-glycoprotein, an important cellular eﬄux pump)[80], as well as enzymes
involved in metabolic processing, for both xenobiotic activation (e.g. TMPT, encoding
thiopurine S -methyltransferase, activating the pro-drug azathioprine)[81], and degrada-
tion (e.g. CYP3A4, encoding cytochrome P450 3A4, catabolising ciclosporine and many
others)[82].
2.5.2 Ethico-legal considerations
The unbiased nature of WES is also perceived as one of the major obstacles to
routine clinical application of the technology. In all likelihood, within many individuals
sequenced, healthy or otherwise, disease associated variants will be found, secondary
to the reason for referral for sequencing, termed incidental findings (IFs). In some
cases these may be low penetrance, entailing small increases in disease risk; in others
however, variants will be highly penetrant for significantly detrimental phenotypes, such
as certain BRCA1 /2 genotypes, associated mainly with breast and ovarian cancers[83,84].
There is a discrepancy in the attitudes towards disclosure of IFs between clinicians
and lay persons. Lay persons were significantly more likely in one study to support
the disclosure of IFs concerning themselves than the clinical geneticists who would be
performing the disclosure[85].
There is a correlation of the willingness of clinicians to report IFs to patients with types
of identified variant. For example, clinicians were more willing to report IFs which were
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linked, with high levels of certainty, to serious treatable disease, than for untreatable
serious disease or more dubious disease associations[85–87]. Resultant investigations
and counselling for IFs will impose a significant cost to health services, though in
some cases could also save costs thanks to avoidance of future acute interventions by
implementation of cheaper prophylactic interventions[88].
The American College of Medical Genetics and Genomics (ACMG) have issued
recommendations for the disclosure to patients undergoing medical sequencing, of all
putatively deleterious variants observed in a curated list of genes. This list is selected
so as to include genes in which deleterious variants predispose to serious, yet treatable
conditions[89]. These genes are recommended to be actively screened where there is data.
The apparent disregard for patient autonomy by not allowing patients to opt out of this
disclosure, as well as the requirement to disclose information regarding minors, has been
a source of much criticism, particularly in terms of the overly paternalistic nature of the
recommendations[90]. In light of this criticism, the ACMG issued a clarification article,
with no significant alteration to the stated position. More conservative recommendations
have since been published by the European Society of Human Genetics[91].
It is worth noting that the issue of IFs is by no means unique to NGS studies; IFs
are a major opposition to the utility of whole-body magnetic resonance imaging in
diagnostics[92]. IFs do not purely entail disease risk factors; it is possible that information
regarding false paternity and unknown consanguinity may be obtained. Some effort has
been put into creating informatics approaches to the categorisation of variants within
sequence data with pre-defined criteria[93]. This removes the human, time-consuming,
and highly subjective aspect of the case-by-case decision making, and therefore may
have a future role in the future simplification of the process for the end-user of the data.
While some have argued that the withholding of IFs pertaining to strong associations
with treatable disease is ethically unjustifiable, regardless of consent[85], it would appear
that thoroughly informed consent, detailing the patient’s wishes as regards IF disclosure
prior to data generation, and adherence to this agreement, would seem a reasonable
path to take, and more in line with existing practices in medicine[86,87].
Informed consent, by its very nature requires clear communication with patients/-
participants, which can be problematic. In a particularly extreme example of the issue
of miscommunication, during a public health project involving genetics with Yup’ik
Eskimos, researchers were unable to accurately convey the concept of genetics to some
participants:
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“The formulation of “things that are passed through the blood from parents
to children” can house real misunderstandings of the genetic basis of disease.
One young [Yup’ik] man offered an example: “Parents who have HIV
or AIDS will pass it on to their daughters or sons.” An elder male also
offered tuberculosis as such an example, as indeed it might appear to be,
if the sick person has contact only with his or her family members. Such
confusions highlight the need to clarify the differences between infectious
and genetic mechanisms in discussions of hereditary traits, especially if using
the “through the blood” descriptor.”
West et al., 2013[94]
It is clear that if the broad concept of genetics can pose such difficulties then communic-
ation of the more complex implications of genetic testing may also prove problematic.
The problem of dealing with non-diagnostically relevant findings is enhanced by the
availability of direct to consumer (DTC) testing. 23andMe, Inc. undertook a pilot
programme offering consumers raw exome data for $999 USD (∼£639 GBP as of 15th
August, 2013) per individual[95]. That 23andMe offer only raw reads for the consumer to
perform their own analyses, arguably absolves the company of responsibilities pertaining
to causal variant identification, as these variants will have been obtained by the end
consumer directly. The direct availability of WES data to the lay public will increase
demand on already stretched genetic counselling services[96]. The ambiguity in the
regulatory niche of DTC genetic testing has been clarified with the U.S. Food and Drug
Administration (FDA) instructing 23andMe and other providers to cease providing
medical interpretation of their DTC array genotyping results[97]. Regulatory vacuums
are not uncommon for rapidly advancing medical technologies, for example this is also
seen with some stem-cell treatments[98].
One of the intrinsic features of genetic information is that by definition, in most
cases, the information acquired does not pertain solely to the proband. Ownership of
information is a troublesome issue, requiring the balance of autonomy of the patient
with a duty to potentially affected relatives, particularly where there is a high risk of a
disease for which there are effective interventions[99]. The decisions by the patient in
these cases is highly influenced by societal factors, and the cohesiveness of the family[100].
The issue of ownership of genetic information has been highlighted recently with the
legal challenges of the family of Henrietta Lacks over the publication of the complete
haplotype-resolved genome sequence derived from the HeLa cell line[101–103]. IFs may
also directly affect relatives of the proband; in the case of IFs it increases the cost
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of providing potentially unnecessary counselling and tests, whilst also amplifying the
possible benefits of successful prophylactic intervention[88].
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Linkage Disequilibrium
3.1 Introduction
Many medical genetic approaches utilise the phenomenon of linkage disequilibrium
(LD, also known as allelic association). LD relies on the property of chromosomes as
continuous molecules; without further interference, alleles on the same chromosome
would always be inherited together. However, this LD is degraded along a chromosome
primarily through homologous recombination (HR; Figure 3.1)—the formation of chias-
mata and resultant reciprocal exchange of DNA between sister-chromatids—pertinently
during meiosis for these purposes, though HR is also important in DNA repair[104].
Figure 3.1: Early illustration of the concept of homologous recombination by Thomas Hunt
Morgan. It can be seen the the two sister chromatids crossover, forming a Holliday junction,
which, on resolution, may result in the switching of chromosome regions between the pair. Taken
from Morgan[105].
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Due to HR, we find that, on average, proximal markers are more likely to be co-
inherited than distal markers as HR is less likely to occur between closely spaced markers
through the generations. On a population level, LD patterns across the genome are
influenced by factors aside from recombination, though this is the primary architect.
In addition, regions with a higher mutation rate, such as that seen in the HLA region,
will show a greater breakdown in LD, and will also be more influenced by evolutionary
selection[106].
Figure 3.2: Degradation of LD from ancestral chromosome (yellow). A mutation arising on
the ancestral chromosome (red triangle) will remain associated with the surrounding genetic
background, with recombination events introducing new stretches (blue). Regions near the
mutation are less likely to be interrupted by recombination. Take from Ardlie et al.[107]. Reprinted
by permission from Nature Publishing Group, © 2002
3.2 Applications of LD
The principle of LD is exploited research such as linkage and GWAS studies, as well
as population genetics[108]. A few examples of the applications of LD are discussed here;
this list is not intended to be exhaustive, merely to illustrate the range of possibilities.
3.2.1 GWAS refinement
Arrays used for GWAS studies are optimised to provide as complete coverage of
the genome through tag SNPs as possible. These tag SNPs act as surrogate markers
for the encompassing haplotype (Figure 2.2)[35,46]. Where a tag SNP is identified as
significantly associated with a trait, further work must be performed in order to identify
the functional variation in LD with the tag SNP[36]. High resolution appreciation of LD
in the region of the tag SNP enables definition definition of a region of interest flanking
the tag SNP[109].
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Information regarding LD can also be used in the initial stages of an association study.
For instance, one approach implemented in CHROMSCAN [110] utilises an LD map[106]
in order to best incorporate LD information into association mapping. The authors
find that this algorithm provides a 5% improvement in statistical power; furthermore,
they report a 46% improvement in the accuracy of the localisation of the causal SNP
on the physical map compared to alternative methods. It is noteworthy that this
study was performed using data with ∼100,000 SNPs across the genome, it is therefore
reasonable to assume that further increases in resolution would be obtained with higher
marker densities[109,110]. Other groups have also had success using LD maps for GWAS
refinement[111].
3.2.2 Selection
A genomic region under purifying selection will have reduced haplotypic diversity
within a population, as variation arising through mutation will be removed from the
population over generations. As such, there will be significantly increased LD across
a region in a population where there is selection vs. a population where no selection
pressure is applied. Similarly, there are disctinctive patterns of LD where a locus is
under selection, without requiring differential selection between studied populations[112].
3.2.3 Recombination mapping
The predominant architect of LD patterns in the genome is meiotic recombina-
tion[104,109,113–115]. Because of this, patterns of LD can be used to identify recombination
hotspots, ∼2 kb regions with high recombination intensity. Using LD structure, Myers
et al.[114] identified a short motif underlying ∼40% of recombination hotspots, indentified
to be a binding site for PRDM9.
3.3 Visualisation of LD
LD patterns are shaped by multiple factors, namely recombination, mutation rates,
drift, selection and population history. As such, they are often highly complex; concep-
tualisation, particularly visually, therefore poses a real challenge for researchers utilising
LD. Many software packages are available to help tackle this problem, with a wide array
of approaches. One example of the methods for visualising LD is Haploview [116], which
is the most commonly used (based upon citations). However, there are many alternative
visualisation approaches, with diverse rationales; some examples of this are shown in
Figure 3.3. It can be seen that the pairwise visualisations (i.e. Figure 3.3a,c,d) become
cluttered and confusing with a large number of markers, whereas model based plots (i.e.
Figure 3.3b) facilitate the identification of the signal in the noise for clear display.
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Figure 3.3: Comparison of LD visualisation software. Software used: a) Haploview [116], a
triangular heat-map based visualisation; b) PHASE v2.1[117], a coalescent model based metric;
c) a Textile Plot[118] and d) Tulip[119], a latent forest based method. Common regions of LD
breakdown are indicated by vertical dashed lines. Figure taken from Mourad et al.[119] under the
Creative Commons V2 Attribution License.
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3.4 Measures of LD
Given the importance of LD in genetics, a plethora of measures are utilised by
researchers in order to quantify LD. A range of metrics used in LD utilising studies are
discussed below.
3.4.1 Pairwise metrics
Pairwise LD metrics are the most commonly used, being relatively free of biological
assumptions. For considering pairwise LD metrics, it is informative to first construct
a 2 × 2 contingency table for possible haplotypes (Table 3.1, adapted from Mueller,
2004[120]).
Table 3.1: 2× 2 contingency table for possible haplotypes of biallelic loci A and B.
B1 B2
A1 A1B1 A1B2
Actual pA1B1 pA1B2
Expected pA1pB1 pA1pB2 pA1
A2 A2B1 A2B2
Actual pA2B1 pA2B2
Expected pA2pB1 pA2pB2 pA2
pB1 pB2 1
There are many metrics available for the quantification of pairwise LD between
markers, which can be defing using the nomenclature in Table 3.1 (Table 3.2), each with
their own advantages and disadvantages[120]. The two most commonly used metrics
for pairwise LD are r2 and D′. r2 is the rate at which one allele successfully predicts
the other allele, rendering r2 metric sensitive to AF. D′ however utilises the Dmax
parameter to correct for AF, allowing for normalised comparison between marker pairs
with differing AF. The difference between these two commonly utilised pairwise metrics
is illustrated in Figure 3.4
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Table 3.2: Available metrics for pairwise LD quantification and their properties.
Metric Definition
D pA1B1 − pA1pB1
D′ D/Dmaxa
r D/(pA1pA2pB1pB2)
1
2
r2 D/pA1pA2pB1pB2
ρˆc |D′|
∆ pA1B1 + pA1/B1 − 2pA1B1b
aDmax =
min(pA1pB1, pA2pB2) when D < 0min(pA1pB2, pA2pB1) when D > 0
bpA1/pB1 is the frequency of alleles A1/B1 being inherited in trans.
cNote that ρˆ is termed ρ in the literature, we use this variant symbol herein to prevent confusion with
the Spearman’s correlation, ρ.
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Figure 3.4: Comparison of r2 and D′ for SNPs in the FCER1G gene. The Haploview display[116]
shows a triangular heatmap for 7 SNPs in the region, highlighting the differences in the two
metrics. Values for D′ between markers are consistently greater and more stable than r2, largely
due to compensation for marker AF though the Dmax component. Both metrics have utility
dependant upon the information desired.
3.4.2 Multi-locus measure of LD
While the pairwise measure of LD discussed are suitable for some purposes, where more
complex studies of LD are desired, particularly for downstream analyses, alternative
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methods are required. Two methods, the Male´cot-Morton and coalescent models for
quantifying LD will be discussed.
3.4.2.1 Male´cot-Morton model
The Male´cot-Morton model was developed by Newton Morton during his tenure
as the head of the Genetic Epidemiology group at the University of Southampton.
The model is based upon the Male´cot model of isolation by distance, itself initially
derived for application to separation of populations by geographic distance[121]. The
final Male´cot-Morton model is defined as:
ρˆ = (1− L)Me−d + L (3.1)
where ρˆ is the association between SNPs, the asymptote L is the ‘background’ association
between unlinked markers which is increased in small sample sizes and with residual
population structure, M reflects association at zero distance, with values of 1 consistent
with monophyletic origin and < 1 with polyphyletic inheritance,  is the rate of LD
decline, and d is the physical distance in kb between SNPs[122].
The variable ρˆ has been shown to be the most efficient representation of LD in a
region, as well as being highly insensitive to AF, and intuitive to interpret[123]. The
software LDMAP iteratively fits the Male´cot-Morton model for values of ρˆ between
multiple markers to identify the values of L, M and  which provide the closest fit for
the observed data. The software ultimately produces a map in linkage disequilibrium
units (LDU), which equal d (Figure 3.5).
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Figure 3.5: Illustration of LDMAP algorithm. Firstly, LDMAP calculates pairwise ρˆ between
markers, then using these to estimate , as well as M and L accross the region. Once  is
estimated, the final LD map is constructed in LDU (i.e. d). Taken from Tapper[124]. Reprinted
by permission from Springer, © 2007.
3.4.2.2 Coalescent models
The coalescent model of evolution is based upon the principle that evolutionary
processes in a population can be represented as a Markov chain of events[125]. These
approaches are utilised for the simulation of population genetic data, as illustrated in
Figure 3.6[126].
30 Section 3.4
Linkage Disequilibrium
Figure 3.6: Illustration of the coalescent model. After four mutations (denoted by mn) and
two recombination events [indicated on nodes], the sequence of the last common ancestor has
evolved into five (four distinct) present-day sequences. Figure taken from Yang et al.[126] under
the Creative Commons V2 Attribution License.
Software such as LDhat takes empirical genotype data from a population and derives
estimates of recombination. Specifically, the rhomap function implemented in LDhat
provides a value of ρ, defined here specifically as:
ρ = 4Ner (3.2)
where Ne is the effective population size and r is the sex averaged recombination rate
in the population[127]. In a comparison of LDMAP and LDhat, Tapper et al.[128] showed
that LDU maps have a greater correlation with empirical linkage maps than their
coalescent counterpart (R2 = 0.37 and 0.32 respectively).
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“On two occasions I have been asked,—“Pray, Mr. Babbage, if you put into
the machine wrong figures, will the right answers come out?”. . . I am not
able rightly to apprehend the confusion of ideas that could provoke such a
question.”
Charles Babbage, 1864 [129]
As discussed in Chapter 2, NGS and associated methods are a powerful approach for
clinical molecular diagnostics. Translation of NGS into clinical science however requires
improvement and validation of the quality of final data.
NGS has proven to be a disruptive technology in the field of genomics. The im-
provements in technologies have required a concomitant increase in our analytical
capabilities, not purely in terms of computing power and storage, but also in intelligent
methodologies for efficient analyses. In this section I will discuss the practical processes
for NGS analysis of DNA, from patient selection for sequencing through to aetiological
candidate identification in Mendelian disease.
4.1 Sample selection and acquisition
4.1.1 Patient selection
It is essential that appropriate selection of individuals is undertaken to ensure that
sufficient power is available for the identification of candidate aetiological variants.
Firstly, the pedigree should be formally recorded in as much detail as practicable to
allow for evaluation of the mode of inheritance of the disease (e.g. Figure 4.1). For the
purposes of this work, primarily focused on Mendelian disease, the pedigree should be
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evaluated to ensure that the disease is likely to have a strong genetic component, as
otherwise the standard methodologies of analysis utilised are unlikely to result in useful
conclusions.
I1 I2
II1 II2
P
III1
II3 II4
III2 III3
IV1
III4 III5
IV2 IV3
Figure 4.1: Illustrative pedigree showing inheritance of autosomal dominant disease across 4
generations. P indicates the pedigree proband (III1). Of the affected individuals sequencing the
proband and individual IV3 would provide the best segregation filtering power.
Where it is deemed suitable (and genetic material is available) to sequence multiple
members of a pedigree, it must be ensured that the affected members selected are
maximally informative by minimising the probability that alleles are shared by chance
between members, improving filtering power on variants based on segregation. Indi-
viduals selected from a pedigree for sequencing may vary dependent upon the presumed
mode of inheritance. A recessive condition will require more members of the pedigree
to be sequenced than a dominant condition. In severe autosomal dominant disease,
the causal variant is expected to be a strong outlier in terms of conservation at the
site whereas in recessive conditions it is possible that the aetiological variants circulate
within the population at an appreciable frequency, and are thus more problematic to
identify by comparison with databases.
Based upon Table 1.1 it can be seen that to minimise the IBD between sequenced
affected individuals, 1st cousins would be optimal out of the above options. Conversely,
to sequence an unaffected member of the proband’s family then a sibling or parent
is ideal. Caution must be used with distant relatives; it is possible that ‘affected’
individuals may possess a dissimilar phenotype or even an alternative aetiology for the
disease (dependent upon disease frequency). It must be ensured that the intervening
pedigree information is consistent with continuous carriage of the disease through
the pedigree. In Figure 4.1, between the proband and IV3 it is expected that there
is excellent segregation filtering power (Φ = 0.0625). At this stage also it cannot
be overly stressed the importance of accurate phenotyping; erroneous assignment of
affected/unaffected status can nullify the value of segregation filtering of variants. In
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consanguineous pedigrees, autozygosity mapping for regions of IBD that are homozygous
in affected individuals can be a powerful approach[130].
4.1.2 DNA isolation
Following selection of pedigree members to be sequenced, DNA must be appropriately
sourced. In some cases a specific source tissue may be used e.g where somatic mosaicism
is anticipated as in cancer. Where there is no anticipated tissue specificity then the
most commonly used sources of DNA are peripheral whole-blood and saliva where this
is not feasible. NGS of a large proportion of the genome requires a large amount of
high-quality gDNA (ideally in the order of μg, though smaller quantities are viable).
The quantity and quality of DNA required for NGS can be problematic for some studies,
particularly where non-fresh sources such as formalin-fixed, paraffin embedded (FFPE)
samples are used. FFPE fixation produces cross links between the protein and DNA
in the sample, and chemical modification and fragmentation of the DNA. However,
specific approaches can be undertaken in order to maximise the likelihood of obtaining
high-quality DNA from samples such as these[131,132].
4.2 In vitro technologies for NGS
4.2.1 NGS sequencing platforms
Since the advent of mainstream NGS with the release of the 454 sequencing platform
in 2005, several platforms have been made available, based upon diverse chemistries and
rationales. Comparisons of several NGS platform have been made (Table 4.1, adapted
from Liu et al., 2012[133]), in which the Illumina HiSeq 2000 system appears to be the
frontrunner, all factors considered[133,134]. These data were collated in 2012; given the
rapid progression of technologies in the field all platforms have been improved, the table
however still proves informative. This is reflected by the fact that Illumina is also the
clear market leader in NGS, with a market share of 56% in 2012[135]. Furthermore, in
Q4, 2013 Illumina, Inc. received approval from the FDA for its MiSeqDx diagnostic
sequencing system and associated targeted gene sequencing panels[136], the first such
NGS technology to receive FDA approval.
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Table 4.1: Comparison of considerations for 3 NGS platforms.
454 GS FLX HiSeq 2000 SOLiDv4
Methodology Pyrosequencing Synthesis Ligation
Read length (bp) 700 150 PE 50 PE
Runtime (Days) 1 7 14
Accuracy rate (%) 99.9 98a 99.94
Cost/Mbp ($) 10 0.07 0.13
PE - paired end reads
aAs quoted in Liu et al., 2012[133], 99.74% is the quoted accuracy in Quail et al., 2012[134], this large
discrepancy may be due to different metrics being used, as error rates will be dependant upon
sequence context and nature of the errors counted.
The Illumina sequencing by synthesis (SBS) technology published in 2008[137] could
produce 35 bp paired end (PE) reads, with the best cost-efficiency per Mbp of the 3
platforms compared. The maximum read-length is now far longer, with 300 bp PE
reads possible on the MiSeq platform due to process improvements. The rationale
of SBS is that of reversible chain termination, as opposed to the irreversible chain
termination utilised in Sanger sequencing. On each reagent-cycle within the microfluidic
flowcell, fluorescently labelled, terminated nucleotides are passed over immobilised
single-stranded, primed DNA, allowing the progression of the complementary strand
synthesis by a single base. Each base is terminated with a different fluorophore, with
non-overlapping emissions maxima; following removal of unbound nucleotides, the base
incorporated can be identified by imaging of the flowcell following laser excitation. The
cycle is ended by chemical cleavage of the terminating fluorophore, leaving the 3’-OH
open to nucleotide addition in the new cycle.
This process is repeated for a defined number of cycles, which may be followed by
equivalent sequencing from the opposing end of the template DNA fragment, which
is typically ∼300 bp in length[137]. This use of PE reads allows for more long-range
information to be gleaned from the data, particularly useful for alignment, as well
as investigating structural rearrangements (as discussed in subsection 4.3) and local
phasing. The length of the short reads however is limiting in their use for alignment in
certain regions of the genome, and can be problematic for de novo assembly of genomes
and transcriptomes[138].
In addition to the above platforms available for purchase, Complete Genomics, Inc.
specialise in providing service WGS, using their proprietary DNA nanoball sequencing
by ligation methodology[139]. The method has also been adapted to allow for long
range phasing of genotypes to produce haplotype contigs of N50 > 500 kbp[140], further
enhancing the utility of the technology.
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NGS technologies are constantly evolving, with regular updates to sequencing
chemistries and control software, improving sequencing and analysis accuracy, par-
ticularly for de novo assemblies. Also, new platforms and methodologies emerge, with
approaches providing long single-molecule reads becoming more mainstream[141–143].
4.2.2 Genomic subset enrichment
Due to the continued relative expense of WGS as a single test there are several
approaches available for the selection of regions of gDNA of interest, theoretically
enhancing the efficiency in terms of variants of interest observed per unit of sequence
data acquired. There are two major classes of enrichment: whole-exome sequencing
(WES) and more limited in scope targeted enrichment, which may be custom designed
to cover tens of genes. An increasing move toward more selective panels can be seen
recently, particularly as NGS diagnostics becomes more routine. This further increases
efficiency where the genomic regions of interest have been identified in previous studies,
while also greatly simplifying the analytical and ethical issues due to the narrower scope
of the investigations, resulting in less data to analyse per patient.
4.2.2.1 Whole-exome sequencing
The human exome (complement of protein-coding regions of the gDNA) is oft-quoted as
bearing 85% of aetiological variants, despite constituting 1–2% of the genome[144], though
the provenance of this statistic is unclear. The utility of WES was first demonstrated
by Ng et al. in 2009[145] on 12 individuals, and has since been demonstrated to be an
exceptionally useful tool in the geneticists toolbox[54,67,70,76,144,146–152]
Sample preparation in WES is more complex than WGS, due to the requirement for
this pre-enrichment of gDNA for exonic regions (Figure 4.2), with implicit additional
costs for this stage of processing. However, this additional preparation cost is offset
currently by savings in required sequence data for suitable data, as well as downstream
in silico processing. Sample preparation utilises sequence-specific hybridisation: ‘baits’
of oligonucleotides complementary to exomic regions of the genome are incubated with
fragmented gDNA. Subsequent retrieval of baits will provide a pool of enriched DNA for
downstream processing. As with NGS, there are several exome enrichment platforms
available, each with their own defined target regions[153].
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variants for monogenic diseases3. Second, most alleles 
that are known to underlie Mendelian disorders disrupt 
protein-coding sequences13. Third, a large fraction of 
rare, protein-altering variants, such as missense or 
nonsense single-base substitutions or small insertion– 
deletions (that is, indels), are predicted to have functional 
consequences and/or to be deleterious14. As such, the 
exome represents a highly enriched subset of the genome 
in which to search for variants with large effect sizes.
Defining the exome. One particular challenge for apply-
ing exome sequencing has been how best to define the 
set of targets that constitute the exome. Considerable 
uncertainty remains regarding which sequences of the 
human genome are truly protein coding. When sequence 
capacity was more limiting, initial efforts at exome 
sequencing erred on the conservative side (for exam-
ple, by targeting the high-confidence subset of genes 
identified by the Consensus Coding Sequence (CCDS) 
Project). Commercial kits now target, at a minimum, all 
of the RefSeq collection and an increasingly large num-
ber of hypothetical proteins. Nevertheless, all existing 
targets have limitations. First, our knowledge of all truly 
protein-coding exons in the genome is still incomplete, 
so current capture probes can only target exons that have 
been identified so far. Second, the efficiency of capture 
probes varies considerably, and some sequences fail to 
be targeted by capture probe design altogether (FIG. 1). 
Third, not all templates are sequenced with equal effi-
ciency, and not all sequences can be aligned to the ref-
erence genome so as to allow base calling. Indeed, the 
effective coverage (for example, 50×) of exons using 
currently available commercial kits varies substantially. 
Finally, there is also the issue of whether sequences other 
than exons should be targeted (for example, microRNAs 
(miRNAs), promoters and ultra-conserved elements). 
These caveats aside, exome sequencing is rapidly prov-
ing to be a powerful new strategy for finding the cause 
of known or suspected Mendelian disorders for which 
the genetic basis has yet to be discovered.
Identifying causal alleles
A key challenge of using exome sequencing to find 
novel disease genes for either Mendelian or complex 
traits is how to identify disease-related alleles among 
the background of non-pathogenic polymorphism 
and sequencing errors. On average, exome sequencing 
identifies ~24,000 single nucleotide variants (SNVs) in 
African American samples and ~20,000 in European 
American samples (TABLE 1). More than 95% of these 
variants are already known as polymorphisms in 
human populations. Strategies for finding causal alleles 
against this background vary, as they do for traditional 
approaches to gene discovery, depending on factors 
such as: the mode of inheritance of a trait; the pedigree 
or population structure; whether a phenotype arises 
owing to de novo or inherited variants; and the extent 
of locus heterogeneity for a trait. Such factors also influ-
ence both the sample size needed to provide adequate 
power to detect trait-associated alleles and the selection 
of the most successful analytical framework.
Box 1 | Workflow for exome sequencing
Since 2007, there has been tremendous progress in the development of diverse 
technologies for capturing arbitrary subsets of a mammalian genome at a scale 
commensurate with that of massively parallel sequencing8,10,72–79. To capture all 
protein-coding sequences, which constitute less than 2% of the human genome,  
the field has largely converged on the aqueous-phase, capture-by-hybridization 
approach described below.
The basic steps required for exome sequencing are shown in the figure. Genomic 
DNA is randomly sheared, and several micrograms are used to construct an in vitro 
shotgun library; the library fragments are flanked by adaptors (not shown). Next, the 
library is enriched for sequences corresponding to exons (dark blue fragments) by 
aqueous-phase hybridization capture: the fragments are hybridized to biotinylated 
DNA or RNA baits (orange fragments) in the presence of blocking oligonucleotides 
that are complementary to the adaptors (not shown). Recovery of the hybridized 
fragments by biotin–streptavidin-based pulldown is followed by amplification and 
massively parallel sequencing of the enriched, amplified library and the mapping  
and calling of candidate causal variants. Barcodes to allow sample indexing can 
potentially be introduced during the initial library construction or during 
post-capture amplification. Key performance parameters include the degree of 
enrichment, the uniformity with which targets are captured and the molecular 
complexity of the enriched library.
At least three vendors (Agilent, Illumina and Nimblegen) offer kitted reagents  
for exome capture. Although there are technical differences between them (for 
example, Agilent relies on RNA baits, whereas Illumina and Nimblegen use DNA baits 
— the kits vary in the definition of the exome), we find the performance of these kits 
to be largely equivalent, and each is generally scalable to 96-plex robotic 
automation. The fact that the costs of exome sequencing are not directly 
proportional to the fraction of the genome targeted is a consequence of several 
factors, including imperfect capture specificity, skewing in the uniformity of target 
coverage introduced by the capture step and the fixed or added costs that are 
associated with sample processing (for example, library construction and exome 
capture). This ratio will fall as the cost of whole-genome sequencing drops.
Although methods for calling single nucleotide substitutions are maturing80, there 
is considerable room for improvement in detecting small insertion–deletions and 
especially copy number changes from short-read exome sequence data81 (for 
example, detecting a heterozygous, single-exon deletion with breakpoints that fall 
within adjacent introns). Exome sequencing also needs improvements of a technical 
nature. First, input requirements (several micrograms of high-quality DNA) are such 
that many samples that have already been collected are inaccessible. Protocols using 
whole-genome amplification or transposase-based library construction offer a 
solution82, but additional work is required to fully integrate and validate these 
methods. Second, as the minimum ‘unit’ of sequencing of massively parallel 
sequencing continues to increase, sample indexing with minimal performance loss 
and minimal crosstalk between samples will be required to lower the costs of exome 
sequencing. Third, a substantial fraction of the exome (~5–10%, depending on the kit) 
is poorly covered or altogether missed, largely owing to factors that are not specific 
to exome capture itself.
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Figure 4.2: Workflow of exome sequencing sample processing. Extracted genomic DNA is
fragmented by ultra-sonication, which may be followed by ligation of identifying barcodes to
the fragmented DNA. DNA fragments are then hybridised to t rgeted baits (red) of an exome
capture kit such as Agilent SureSelect. These baits are designed to be complementary to protein
coding regions, thus the pulldown of the baits will provide a DNA sample enriched for exonic
DNA, ∼1% of the genome. This is then sequenced and analysed downstream in silico. Taken
from Bamshad et al., 2011[70]. Reprinted by permission from Nature Publishing Group, © 2011.
One of the main strengths of WES over targeted candidate gene sequencing lies
in the relatively unbiased nature of the data acquisition. Excessive masking of data
acquisition too early in the study would limit the answers to this initial subjective area
of interest[154]. This will limit the utility of the experiment in cases where the cause lies
within a non-candidate gene for the disorder, or where the disease is mischaracterised
or uncharacterisable. However, once the unbiased data are acquired, a initial tiered
interrogation of the data may still be performed to reduce the analytical burden where
strong candidate loci are known.
There are several weaknesses within the WES methodology. Due to the requirement
for sequence identity between the gDNA and WES capture kit, there can be biases in
capture of alleles. This may for example be caused by a deletion preventing correct
alignment of bases for the bait annealing stage[155]. Furthermore, the core principle of
WES in only sequencing exonic regions of the genome can result in the non-identification
of non-exonic variants or CNVs and large-scale structural rearrangements due to the
low level of information on 99% of the genome. These factors could result in the absence
of data on potentially clinically relevant alleles.
4.2.2.2 Targeted capture
While WES provides an attractive cost-effective alternative to WGS currently, for some
purposes a smaller genomic subset may be desired. In these cases, smaller panels of
gDNA enrichment are available, and are also amenable to custom design. There are two
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approaches used for this: hybridisation based, similarly to in WES pre-enrichment, and
amplicon based, where the enrichment is by means of multiplexed PCR amplification
of regions of interest[156]. The small proportion of the genome that can be captured
using these approaches allows for much larger throughput of samples than WES, and
also allows use of low-throughput sequencing platforms such as the Illumina MiSeq. A
further effect of the small region of enrichment is an increased depth of coverage for
the regions captured. This is particularly useful for cancer resequencing, where the
tumour DNA purity is likely to be low due to stromal contamination. High depth allows
for increased detection of somatically acquired variants[157], including developmental
mosaics; the cost of very high-depth sequencing for a whole-exome would be excessively
high for many purposes.
4.3 In silico analytical processing of NGS data
The nature of NGS data requires several processing stages for the gleaning of biologic-
ally interpretable data (Figure 4.3). The three phases will be discussed below, as well as
the quality control (QC) that should accompany analysis. The storage requirements for
NGS data and analysis files can be substantial, requiring ∼10 GB for WES data, as well
as additional capacity for working files and back-ups as required. This is unlikely to pose
a challenge for individual patients, however, as NGS becomes more commonplace, an
appropriate storage infrastructure will become essential. Computational power is also a
consideration, with WES alignment taking many hours on a modern desktop computer.
Again, single samples do not pose a challenge, but analysis parallelisation becomes
essential as throughput increases, ultimately requiring high-performance computing
facilities, either locally or cloud-based, though this poses additional challenges of data
security.
Alignment Aligned reads
Genotype callingNon-reference genotypes
Annotation
Raw NGS reads
Annotated 
variants for 
analysis
Figure 4.3: Generalised analysis workflow for NGS data analysis. The three major stages of
NGS analysis are shown, namely alignment, variant calling and annotation.
4.3.1 Alignment of NGS short-reads
Alignment of NGS short-reads is the first, and most computationally intensive stage
of the in silico analysis in resequencing following data generation. Alignment entails
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defining the position of each read in relation to the reference genome based upon finding
the position in the reference genome with which the read has least mismatches, be
they SNPs, indels or sequencing errors. A commonly utilised aligner for WES is BWA
(Burrows-Wheeler Aligner[158]). BWA applies the Burrows-Wheeler transformation[159]
to efficiently hold the reference genome in memory for comparison with read sequences,
outputting a sequence alignment/map (SAM) file containing read sequences along with
best alignment positions; following SAM file generation, data can be more efficiently
stored in binary alignment/map (BAM). The SAM/BAM formats are the de facto
standard for alternative alignment software. Other popular aligners such as Bowtie [160]
and Novoalign[161] are based on an alternative implementation of the same principle. For
PE reads, there is an extra layer of complexity. In BWA both reads are independently
mapped to the reference genome and viable positions are then compared to select the
pair most closely collocated in the correct orientation[158].
Certain aligners will be preferable in different circumstances. Bowtie for instance is
able to more rapidly process reads compared to BWA, but at the expense of tolerance to
errors in the reads[162]. Additionally, regions in which there is a high sequence diversity
require alternative approaches for accurate alignment, and thus downstream calling.
The HLA region is a region towards which considerable attention has been directed due
to the region’s biological import. As such tools are available for the specific alignment
to all known haplotypes and subsequent calling, e.g. Omixon Target [163].
4.3.2 Variant calling from aligned reads
There are many tools for the calling of genetic variants from aligned sequence data,
some of which are focused on calling of particular classes of variants; an illustrative
selection of tools is discussed below. The variant call file (VCF) has become the de
facto standard for genotype calls of all variant classes[164].
4.3.2.1 SNP calling
SNP genotypes are the most readily called class of genetic variation. The software
SAMtools is currently the most highly cited tool suitable for this purpose[165], followed
closely by GATK [166]. SAMtools initially produces a raw ‘pileup’ of sequence data at
a position from an alignment, then applying a Bayesian probabilistic framework to
determine the most likely genotype at the position, as well as assigning a phred-scaled
score to the genotype call indicating the quality of the call (see subsubsection 4.4.1).
As well as the calling of singleton samples, SAMtools and GATK can be used for
calling multiple samples in an analysis; here several pileups are analysed concurrently
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with prior probabilities for genotypes for each sample being dependant upon the allele
frequencies within the pool, improving calling of shared genotypes.
4.3.2.2 Indel calling
Short insertion/deletion variation (indels) can often be called using standard SNP
calling software such as SAMtools, however increased accuracy can be obtained with
dedicated software for various sizes of indel. Two types of read-level evidence can be
utilised for indel discovery (Figure 4.4). Firstly, split reads, where portions of a single
read map discontiguously to the chromosome, and split pairs, where a read pair maps
with an insert size between the pair significantly greater than that expected given
the distribution of insert sizes in the sample. Pindel takes advantage of both sources
of information, affording the ability to call medium–large indels of 10 kb from 36 bp
PE reads with base-pair precision[167]. Similarly, SoftSearch takes advantage of this
information, as well as ‘soft-clipping’ of aligned reads, where an end of the read has low
mapping quality due to a gap in the alignment that has not been opened, resulting in
multiple mis-matches which would normally be ignored in downstream analysis[168].
TGGAGGATCACCATCAACGGCGCCACCCACGAGAGCATCAGCATCA GCGCCATGGCCAGCAGCATCGTGGAGCCCGCCATCAACATCAACACCCACGAGGCCAGCAGCACCCACGAGTTCAACTTCG
Split read
Split pair
Figure 4.4: Informative features in NGS reads for the detection of indels. Reads (thick arrows)
may be split directly by a deletion as compared to the reference sequence (red sequence), allowing
for identification of the indel with base-pair resolution. PE reads may also have an increased
aligned insert size (thin joining line) where the insert spans the indel event. Multiple pieces of
such evidence will be required to confidently call the genotype.
4.3.2.3 Copy number variation calling
Copy number variations (CNVs) are a form of large-scale structural variation of the
genome which entails the duplication/deletion of a region. Here there are three main
forms of evidence for these events in NGS data. Since CNVs can be considered large
scale indels, the information described in Figure 4.4 still proves informative. In addition,
depth of coverage (DOC) of a region will be proportional to the genomic dosage of
that sequence, i.e. where a heterozygous deletion is present the expected DOC for that
region is halved.
CNV detection methods required vary between WGS and WES studies. In WGS
we expect a relatively uniform DOC in most regions, whilst in WES DOC is highly
heterogeneous due to variable capture efficiency at the exome enrichment stage. WGS
by definition has reads mapping to the majority of the genome, making read-level
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information of more utility than in WES, where this information is available for a
minority of the genome; off-target reads, where the region has some data despite not
being a target of the exome enrichment can prove informative in these situations (e.g.
see subsection 7.3.2). There is a plethora of CNV calling software available, particularly
for WES where more complex approaches are required, and can be broadly categorised
as split-read/pair based (such as Pindel [167]), DOC based (such as XHMM [169]), or a
hybrid methodology (such as SoftSearch [168])[170].
4.3.2.4 Somatic variants
Variants present at an individual’s conception will be present with an allelic dose of one
or two alleles in diploid cells, and will therefore be expected to be in a high proportion
of the reads from a sequencing experiment (see also subsubsection 4.4.4), allowing
detection with the software such as SAMtools [165] and GATK [166]. Variants may arise
during foetal development, resulting in mosaicism. Alternatively, variants may also
arise later in life, for example, though nor purely, as associated with cancer. In these
cases, we expect a lower proportion of reads to be derived from the variant DNA, as
well as greater variation dependant upon the exact DNA source; here more sensitive
methods of detection are required than for germline variation.The power of detection of
somatic variants in inexorably linked to the read depth of the sequencing experiment. If
a variant if present at an allelic proportion of 1%, it is highly unlikely that a sequencing
experiment delivering 20 X would detect this variant. Where low level variant detection
is a priority, read depths  1,000 X may be used.
To allow for greater variant detection sensitivity in silico, for example as required in
cancer genomics, there are two main approaches. The first is simply the lowering of
thresholds for variant calling when sequencing tumour derived DNA. This approach
however will perform poorly in terms of specificity. Alternatively, paired sequence derived
from both tumour and germline material allow for comparative calling between the
samples in order to discriminate between germline and somatically acquired genotypes,
including small variants and CNVs. Both of these approaches require alternative
software, such as VarScan 2 [157,171].
The properties of somatic variants in terms of allelic ratios presents opportunities as
well as challenges. Loss of heterozygosity (LOH) post-conception, such as that resulting
from a chromosome arm deletion, will result in a tract of variants exhibiting skewed
allelic ratios (as measured by the B allele frequency (BAF), i.e. the proportion of reads
harbouring the alternate allele). These regions can be identified using specialist tools
such as BAFsegmentation [172]. In this, the BAF is transformed to the mirrored BAF
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(mBAF) using:
mBAF = |BAF− 0.5|+ 0.5 (4.1)
Regions with recurrent deviation from mBAF = 0.5 beyond the pre-defined cutoff are
ultimately segmented using circular binary segmentation (CBS) to identify continuous
regions which are likely to have LOH[172,173].
4.3.3 Annotation of called variants in WES data
There are several annotations that are required for the downstream interrogation of
genotypic data. At the most basic, annotation as regards the genes and transcripts
in which the variant is situated, as well as resultant changes to the gene product are
essential. However, several other information sources of information are also required
for downstream analysis.
4.3.3.1 Allele frequencies
A key annotation type is the AF of a variant. These data are derived from the
large scale sequencing/genotyping consortia discussed in Chapter 2, such as the 1000
Genomes[12] and HapMap[35] Projects. Where Mendelian disease is being investigated,
particularly with a severe phenotype, a high AF for a variant will support its exclusion
as a aetiological candidate. AFs will vary between populations dependant upon the level
of historical isolation between populations. As such, it is essential that an ethnically
matched data-source is used for association analyses, for Mendelian disease however it
is worth having a broader panel of comparison. Similarly, some apparent genotypes,
particularly erroneous calls, may be sequencing/analysis/batch specific, and thus a
database of in-house samples will allow us to recognise systematic artefactual genotypes,
at both a platform and batch level.
4.3.3.2 Conservation metrics
As an extension of the AF in human populations, one can use conservation across
multiple species to investigate the possible deleteriousness of a variant, effectively
utilising information from a far longer evolutionary history, enhancing the power of
discrimination between variants. Many scores are available for this, including PhyloP[174]
and GERP++[175]. However, all of these tools are imperfect in their predictive capacity,
and a consensus approach is required for reliable prioritisation.
4.3.3.3 Physicochemical properties
A change of amino acid within a protein can have vastly differing consequences dependent
upon the nature of the change. For instance, the change from a glycine (R-group: -H)
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to a cysteine (R-group: -CH2SH) will be likely to have a far greater effect on protein
function compared than to an alanine (R-group: -CH3). Additionally, proline, with
its cyclic structure making it the only secondary amine amino acid, imposes severe
constraints on the φ bond angle at that position, affecting protein folding[176]. Scores
are available, based upon the physicochemical factors alone (such as the Grantham
score[177]) or integrating this with sequence conservation (such as the SIFT[178] and
PolyPhen-2[179] scores).
4.3.4 Filtering of genotypes for the identification of aetiolo-
gical candidates
There are many possible stages for the filtering of genotypes. Firstly, where multiple
related individuals have been sequenced, genotypes can be filtered based upon patterns
of segregation, where phenotyping is clear. In the majority of cases variants will be
expected to be present in all affected individuals, but not in the unaffected individuals.
Furthermore, variants known to be seen at an appreciable frequency in population
datasets will be excluded. For highly penetrant, severe, dominant Mendelian disease
variants would be expected to be present a rate of < 1% in a healthy population, though
this will also vary slightly with mode of inheritance. Prioritisation of variants by effect
type will be useful; a rare frameshift or stopgain variant is more likely to cause disease
than a synonymous variant. Finally, where candidate genes are known, these should
be interrogated first, reducing both the analytical burden if the causal variant is seen
within this subset, as well as reducing the likelihood of discovering clinical variation
unrelated to the primary diagnosis of referral.
4.4 Quality metrics & QC of NGS data
There are several key quality considerations in the use of NGS data. Two common
metrics (mean DOC and phred) are detailed below, as well as QC approaches that
should be undertaken in the processing of NGS data throughout all stages of the
analysis.
4.4.1 Phred
Within a read, bases will be of different qualities, due to various factors such as those
inherent in the sequencing chemistries and starting DNA quality. Downstream analyses
are required to consider this variable quality to allow for weighting in the determination
of a consensus between reads for instance. During the HGP, Phred became the standard
software for sequence determination from Sanger reads. On base calling, Phred assigns
a quality score to each base, based upon factors such as the amplitude and resolution
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of peaks in the electrophoretogram trace[180]. The quality score (itself termed phred)
directly relates to the probability of a base call being erroneous:
phred = −10× log10 (E) (4.2)
where E represents the probability of the base call being in error. Phred scores are
a standard method of reporting error probabilities; while the background method
for determining E will vary between platforms, the integer scores represent the same
concept. A phred score of > 20 is considered a standard for ‘good’ quality of a read,
corresponding to a 1% error rate (Table 4.2). It is worth noting that with NGS, one
hopes to have multiple reads covering the same position, and thus the confidence in
a consensus call for a position will be increased with increased coverage, allowing for
cumulative phred scores for a position  100.
Table 4.2: Error rates for a range of phred scores.
phred Error rate (%)
3 50
10 10
20 1
30 0.1
40 0.01
100 0.0000000001
4.4.2 Depth of coverage
NGS reads have a higher error rate than Sanger reads. Due to the massively parallel
nature, a multiplicity of reads spanning a region of interest can be readily produced. The
number of reads aligning to a site in the reference genome is a key consideration during
experimental design. Required DOC varies greatly dependent on the intended use of
the data. For example, the 1000 Genomes Project utilises low mean DOC (2–6 X) WGS
data in order to determine genotype calls for individuals by using a pooled approach
that considers external genotyping data from both genotyping arrays and WES for the
individual, as well as prior knowledge of AFs[12].
Due to the cumulative nature of the evidence for each read at the position, far
greater DOC is required when dealing with individuals, particularly where sequencing
is for clinical purposes, where accuracy is paramount[181]. Profiling of the mutational
spectrum of cancer can require extremely high DOC due to the heterogenous nature of
the polyclonal sample from which DNA would be sourced, including both cancerous cells
and stromal cells, in varying proportions depending on the cancer type and stage. Reads
will cover the various alleles present in sub-clones in proportion to the stoichiometry
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present in the DNA sample, high DOC is therefore required to ensure that the rarer
alleles at a position are observed, and distinguishable from sequencing errors[157].
Another related factor is the uniformity of coverage. Sequencing to a lower mean
DOC is more likely to be viable knowing that there is a narrow distribution of DOC
across the exome. This allows us confidence that the majority of regions of interest will
have sufficient DOC to provide useful data. As such, the proportion of the genome, or
defined subset of interest, that is covered to a certain threshold DOC is also often a
more useful metric than the mean.
4.4.3 Confirmation of identity
Prior to the interrogation of data, it must be validated that the correct data-set is
being interrogated for the correct individual. Approaches such as validation of gender
based upon X-chromosome calls—with a significant deficiency in heterozygous genotypes
in males due to their monosomy—and ethnicity utilising principal-components analysis,
allowing comparison with individuals of known ethnicity, are two low-resolution methods
that can prove informative[182]. Where multiple family members are sequenced, pairwise
IBS should be checked to ensure that it is consistent with the reported relationship (see
Table 1.1); this will also allow for the discovery of issues such as false-paternity, which
would hinder variant filtering by segregation.
The ultimate validation of identity will be by comparison of the NGS data with
external data such as SNP genotypes, and there are approaches available to do so[183,184].
A key advantage of this approach is that it allows comparison of samples at all stages
though processing due to the intrisic nature of the markers, and also allows comparison
with fresh blood from the individual in question to avoid all ambiguity if required (see
Chapter 6).
4.4.4 Contamination checks
Even where the identity of the sample has been successfully validated, the inclusion
of sequence data from exogenous DNA may affect the results. Possible sources may
include from cross contamination between concurrently processed samples, as well
as environmental contamination such as from bacterial DNA. Contamination can be
assessed through interrogation of the alternate allele read-counts across variant loci. We
would expect a trimodal distribution centred on 0%, 50% and 100% corresponding to
homozygous reference, heterozygous and homozygous alternate genotypes respectively.
Significant deviation from this pattern may indicate the presence of DNA from another
individual, or somatically acquired variants. For contamination with non-human
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sequence, exclusionary pre-alignments of raw data can be performed to remove reads
that map to non-human sequence and not the human reference[185].
Genomics, and particularly NGS has the capacity to be of great utility in genetic
research and clinical medicine. However, in reference to the quote from Wilhelm
Johannsen with which this part was started, it is clear that genetics is still in this
transition period. Where the stoichiometric balance of chemistry is now well defined
and understood, the problem of missing heritability is still a challenge to be met in
medical genetics, limiting the translational application currently. NGS should help meet
this challenge, allowing for the identification of novel causes of disease at a greater rate.
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The overarching purpose of the work detailed herein is to present examples of the
research utility of large scale genetic data. This is particularly relevant given the current
rapid advances in NGS technologies, affording even greater data resources in the very
near future. I will present a summary of the specific intentions of each primary research
chapter below.
5.1 Part II - Application of NGS to Diagnostics
5.1.1 Chapter 6 - Sample tracking in WES studies
In this chapter, a novel tool for the tracking of DNA samples from an individual
throughout an exome sequencing workflow is presented, given the need for increased
robustness in clinical WES. The major intended properties of this tool were that it
would be: robust, even with large numbers of samples sequenced; cost efficient and; be
effective across populations. This tool, in the format of a SNP fingerprinting panel,
also required stringent validation in both existing NGS data, as well as in theoretical
simulations to allow for the inevitable larger future number of samples sequenced.
This Chapter was predominantly my own work, with significant input from Gaia
Andreoletti, Chris Mattocks and Prof. Sarah Ennis.
5.1.2 Chapter 7 - Identification of cryptic variants
Chapter 7 is intended to illustrate a selection of cases, which were interrogated
in partnership with clinical colleagues, in which the identification of the aetiological
variants in patients has been particularly challenging. The hope is that these cases
illustrate broader paradigms in terms of the challenges facing those who wish to best
interrogate clinically applied exomes. The cases detailed will also highlight some of the
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current deficiencies in WES/NGS technologies which will need to be resolved in order
for NGS to have the best possible application to human samples.
For this work, my contribution was mainly data analysis and interpretation, with
clinical phenotyping, recruitment and interpretation performed by clinical colleagues,
including Dr. Ananth Ramakrishnan, Eleanor Seaby, Dr. Rodney Gilbert and Prof.
Ignacio Bricen˜o.
5.1.3 Chapter 8 - Cleft lip WES
Chapter 8 reports the application of WES to 10 families with cleft lip/palate pheno-
types from the Bogota´ region of Colombia. These patients display a mix of syndromic
and non-sydromic presentations. Evaluation of the WES data is with a view to identi-
fying the aetiology in the ten families, whilst also highlighting the genetic differences
between syndromic and non-syndromic presentations.
For this work, my contribution was mainly data analysis and interpretation, with
clinical phenotyping, recruitment and interpretation performed by clinical colleagues led
by Prof. Ignacio Bricen˜o, and Prof. Andrew Collins contributing to variant interpretation.
5.1.4 Chapter 9 - Gene panels in kidney disease
In Chapter 9, targeted NGS sequencing using a custom gene panel is applied to a
cohort of 83 patients in the Wessex region with focal segmental glomerulosclerosis. The
aim of this work was to evaluate the mutational spectrum in these patients, and further
interrogate the presence of genotype/phenotype correlations in subsets of the cohort.
For this work, my contribution was mainly data analysis and interpretation, with
clinical phenotyping, recruitment and interpretation performed by Dr. Christine Gast.
5.2 Part III - Mapping of Linkage Disequilibrium
5.2.1 Chapter 10 - Characterisation of WGS LD maps
Chapter 10 details the work done assessing the utility of WGS data for LD map
generation. The aim was to validate that WGS is a viable source of genotypic data
for LD map generation, as well as being computationally feasible. Furthermore, an
assessment of gains attributable to the increase in genotype density, and, the corollary
of this, the specific deficiencies of array-based genotyping data for LD map generation.
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This work was predominantly my own, with significant input from Prof. Andrew
Collins, Prof. Sarah Ennis and Dr. Rick Tearle.
5.2.2 Chapter 11 - LD in commercial chickens
The work in Chapter 11 details the generation of LD maps from array-based genotyp-
ing of several lines of commercial chickens. This was with a view to quantify the degree
of concordance in LD patterns between distinct populations, as well as investigating
the features underlying patterns of LD, i.e. primarily sequence features associated with
recombination hotspots.
This Chapter was predominantly my own work, with significant input from Prof.
Andrew Collins, Prof. Sarah Ennis, Dr. Almas Gheyas and Prof. David Burt.
5.3 A note on terminologies
As in all fields, geneticists utilise some terms with scant consistency, particularly
between specialities. A few cases will be discussed here briefly in order to ensure clarity
in the later chapters. Some situations require the use of less standard terminologies
to ensure that there is no ambiguity due to the broad scope of this work. Choice of
terminology in this work is not intended to suggest that these terms should be used
across genetics, it is merely a choice for clarity.
5.3.1 Allele frequencies
The minor allele frequency (MAF) of a variant is defined as the second most common
allele observed across the sample that the MAF is being defined in. In some situations,
this can lead to confusing and unintuitive presentation of results. For instance, for
some loci, the minor allele is the reference allele, as the reference genome does not
accurately represent the variation across populations, though advancements in this are
being made[186]. Further to this, the minor allele may be different for populations.
An alternative to the MAF metric is the alternate-allele frequency (AF)[164]. This
can be defined as the most common non-reference allele at a position. The advantage
of the AF is that the reference allele is constant between populations, removing some
ambiguity. It should be noted that the most common alternative allele may still be
different between populations, though this will mostly be the case in the case of highly
rare variants[12].
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For the purposes of this work, the term AF will be used in preference to MAF. The
exception to this is where it is truly the MAF that we require for analyses, for instance
in Part III. The verbose term allele frequency will be used when referring to a specific
alternative allele, which will be specified.
Another usage of allele frequencies is in describing the ratio of alleles within a sample
where technologies which sample multiple copies of DNA are used, such as NGS; this is
discussed in more detail in Chapter 4. For these situations, we will borrow the term B
allele frequency (BAF) from microarray analysis[172]. This will refer to the frequency
of the most common non-reference allele within the read data of an individual at a
position.
5.3.2 Genetic variants
In medical genetics particularly, there is a confusion of terms regarding the description
of deviations from the reference genome. In the medical literature, these are often
referred to as mutations, particularly where they are expected to cause disease. This is
at odds with population genetics, where the term variant is utilised. In this work we
will use the term variant in preference, aside from where the acquisition of the variant
by the process of mutation has been observed. In cases such as somatically acquired
and de novo variants, these will be referred to as mutations.
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Chapter 6
Post Hoc Sample Tracking in
Whole-exome Sequencing Studies
6.1 Background
The high start-up investment required for in-house WES is currently prohibitive to
many groups so sample preparation and/or sequencing is commonly outsourced. This
transference of sample custody, combined with the complex sample preparation workflow,
makes sample mix-ups possible, and difficult to detect. In both clinical and research
contexts, ensuring provenance of data is essential to allow the accurate assignment
of clinical details to sequence data. It is possible that samples may be misidentified
at any stage of the analytical process, both in vitro and in silico. Therefore, sample
tracking must be contiguous throughout both data generation and analysis. Consequent
to sample mix-ups in a research setting, erroneous data and sample matching may
result in a loss of power for identification of causal variants[187]. In a clinical setting,
these mix-ups may instead lead to delayed or inaccurate reporting of results to patients.
Whilst good practice in the handling of samples and increased laboratory automation
minimises potential for error, additional checkpoints are still required to support QC[188].
A method for the post hoc confirmation of sample identity is therefore highly desirable.
Genetic sample identification methods have an advantage over alternative sample
management systems in that the genetic ‘label’ is intrinsic to the biological sample
itself, removing the possibility of manual labelling errors. SNPs are increasingly utilised
for DNA-based identification of human samples, with several benefits compared to
standard forensic methods, such as amenability for highly degraded samples[189–191].
Existing SNP panels for human forensic identification and commercial SNP panels for
sample identification, such as the iPLEX Sample ID Plus panel (Sequenom, San Diego,
CA, USA), utilise pan-genome SNPs, the majority of which are non-exonic, and are
therefore not useful for WES studies, as the majority of markers will not lie within
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the enriched regions of the genome. In addition to existing SNP panels, short tandem
repeat markers, as used in standard forensic identification procedures, can be used for
genetic sample tracking. However markers applied are again frequently outside exomic
regions and, if captured, will be prone to erroneous NGS genotyping using standard
pipelines due to the repetitive nature of the markers[190,192].
Several methods for genetic tracking of human biological samples have been pre-
viously described, some of which are application specific, such as for transcriptome
microarray studies[187,193,194]. Although software for the validation of NGS (including
WES) sample identity, such as verifyBamID is available, for the detection of sample
misidentifications external array-based genotypes of the samples are required, without
which only contamination of the samples can be assessed[183].
Due to the lack of an existing tool for the identification of sample mix-ups without the
availability of array genotypes, we aimed to formulate a cost-effective panel of a small
number of SNPs. Here we describe an optimised panel of SNPs for which WES data are
typically informative, the genotypic profile of which can be utilised to extract intrinsic
identifiers from human genomic DNA. These SNP profiles have high discriminatory
power, even in large datasets. The profile derived from this panel can be compared to
an independently genotyped profile for the same individual, allowing accurate validation
of data and sample pairings, at a modest cost per sample.
6.2 Methods
6.2.1 Panel selection
6.2.1.1 Candidate SNP identification
Regions of overlap between three current commonly used whole-exome enrichment kits,
(namely Agilent SureSelect Human All Exon V4, Illumina TruSeq Exome Enrichment
and Nimblegen SeqCap EZ Human Exome Library V3.0 kits), and common SNPs
(as contained in dbSNP 137[65]), were established using BEDTools[195]. SNPs were
further filtered for inclusion based upon their presence in genes targeted by the Illumina
TruSight Exome kit, which targets only genes of clinical interest.
Primary candidate selection criteria required SNPs to:
1. Represent bi-allelic substitutions, excluding substitutions of complementary bases,
that is, A↔T and G↔C transversions;
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2. Be technically amenable to both accurate WES and orthogonal genotyping, that is,
not present in large-scale genomic repeats[196], or homopolymeric tracts of ≥ 5 bp,
GC content for the flanking 250 bp was restricted to a range of between 40% and
55% and no other variant within 50 bp with an AF ≥ 0.01 was permitted;
3. Conform to desirable HapMap Phase 3 AFs across several populations, explicitly
AFs of between 0.2 and 0.8 in: CEPH (Utah residents with ancestry from northern
and western Europe; CEU), Japanese in Tokyo, Japan (JPT), Han Chinese in
Beijing, China (CHB) and Yoruba in Ibidan, Nigeria (YRI)[35] and;
4. Not alter the primary sequence of the encoded protein or have an associated
OMIM record[17].
6.2.1.2 Candidate SNP selection
Following primary candidate identification steps, SNPs were further optimised by the
following requirements:
1. Be located at least 10 bp from intron–exon boundaries to minimise the likelihood
if involvement in splicing processes;
2. Not be situated in regions with a high sequence similarity to non-target regions,
that is, no non-target BLAT score > 100[197], as this could result in nonspecific
genotyping and;
3. Be outside of linkage disequilibrium with all other selected SNPs.
Finally, candidate SNPs were prioritised for inclusion in the panel by proximity of the
AFs to 0.5, across HapMap populations, in order to maximise discriminatory power.
6.2.2 Validation & application
6.2.2.1 WES coverage
A set of 91 in-house exome samples was evaluated for depth of sequence coverage
for the candidate SNPs, with a requirement that no samples had < 10 reads covering
the SNP. Exome capture was performed using Agilent SureSelect Human All Exon V3
(n = 22) and V4 (n = 55), Illumina TruSeq Exome Enrichment (n = 9) and Nimblegen
SeqCap EZ Human Exome Library V3.0 (n = 5). Exome enrichment, sequencing and
in silico analysis of samples was performed as previously described[146,198].
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6.2.2.2 Publicly available data
The power of sample resolution for the panel was validated using NGS derived
genotype data from phase 1 of the 1000 Genomes Project (n = 1,092 WES samples)[12]
and the UK10K project (n = 2,688; 256 of which are WES samples, the remaining
2,432 are low coverage imputed whole-genome data)[59]. Genotypes were extracted from
VCF files using custom scripts and Tabix [199]. Quantification of mismatches between
samples was performed using MEGA5 [200].
6.2.2.3 Simulated data
Estimates for the true probability of repeat profiles were determined using a Monte
Carlo simulation approach. Simulated datasets were generated by taking the individual
population AF for each SNP as input and defining numeric boundaries in accordance
with the expected proportions of genotypes under Hardy-Weinberg equilibrium. A
pseudo-random number generating function was then used to assign a genotypic state
for each SNP within these boundaries, outputting a concatenate of genotypes, and
repeating until the desired dataset size is populated. This was implemented in the
custom Perl script generate_fingerprint.pl (Appendix A.1), with the output passed
to a wrapping shell script, outputting a count of the unique genotype concatenates
within the dataset. We performed 20,000 bootstrapping pseudoreplicates of dataset
generation in all cases.
6.2.2.4 Calculation of power
Due to the computational intensity and non-empirical nature of the Monte Carlo
simulation, especially for large simulated datasets, a mathematical method for approx-
imation was attempted. To perform an approximation allowing for variable likelihoods
for each genotype profile, we used:
C ≈ qn
2
2
(6.1)
where C is the likelihood of a collision within the dataset, and n is the number of
samples within the dataset and q is the probability of a collision between two samples.
The value for q is calculated as:
q =
O∑
i=1
r2i (6.2)
where i refers to a possible profile, and O the number of possible profiles (324, equal
to 282,429,536,481 for the described panel), and r is the probability of a sample
being assigned profile i; the probability r can be readily calculated from the AF data.
Calculation of q is required once for each population for the panel, and can then be
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utilised for all sample sizes of interest. Implementation of the calculation of q was
attempted in custom Perl scripts.
6.2.2.5 Application of panel
We applied the panel to a batch of 48 samples exome sequenced by an external
service provider, for which orthogonal genotypes were obtained concurrently through an
independent genotyping provider using KASP genotyping (LGC Genomics, Hoddeston,
UK). Following plating of DNA samples for dispatch, a replica plate was made directly
from the primary plate, to be dispatched for the orthogonal genotyping. Genotypes
derived from exome data and orthogonal genotyping assays were compared using
PLINK v1.07[182] and custom Perl and shell scripts.
6.3 Results
6.3.1 Panel selection
In total, 26.2 Mbp of genome sequence was found to overlap all three commonly
applied whole exome capture kits, containing 9,493 common SNPs. Of these, 1,662
SNPs are additionally covered by the Illumina TruSight Exome kit. Within this subset,
following the filtering for all primary candidate criteria, 117 candidate SNPs were
identified (Figure 6.1; Table B.1).
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(c) Properties of 1,662 SNPs covered by all kits
Figure 6.1: Venn diagrams showing commonality of targeting between capture kits (a,b) and
properties of encompassed SNPs (c). Overlap between exome capture kits is presented in Mbp (a)
and number of SNPs with an AF ≥ 0.3 (b). Agilent - SureSelect Human All Exon V4; Illumina -
TruSeq Exome Enrichment; Nimblegen - SeqCap EZ Human Exome Library V3.0. For a subset of
SNPs present in both the intersection of the three kits shown, and the Illumina TruSight Exome
kit, a breakdown of fulfilment of the four classes of candidate filtering criteria is shown (c) (see
the main text for details of filtering criteria). 117 SNPs exhibited all desired characteristics; 74
SNPs exhibited none of the desired characteristics.
From the 117 available SNPs, an optimised panel of 24 SNPs was selected (Table 6.1).
Within the set of 91 in-house WES samples, all 24 SNPs were sequenced at sufficient
read-depth for accurate genotype calling, across all capture kits.
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Table 6.1: Optimised panel of identifying SNPs.
HapMap Phase 3 AF
Chr Positiona rsID Gene Alleles CEU CHB JPT YRI
1 179520506 rs1410592 NPHS2 A/G 0.59 0.62 0.54 0.53
1 67861520 rs2229546 IL12RB2 A/C 0.64 0.36 0.44 0.58
2 169789016 rs497692 ABCB11 A/Gb 0.55 0.65 0.51 0.22
2 227896976 rs10203363 COL4A4 C/T 0.46 0.44 0.36 0.57
3 4403767 rs2819561 SUMF1 C/Tb 0.56 0.73 0.73 0.72
4 5749904 rs4688963 EVC A/Gb 0.33 0.65 0.67 0.52
5 82834630 rs309557 VCAN A/Gb 0.49 0.34 0.52 0.50
6 146755140 rs2942 GRM1 A/G 0.54 0.49 0.55 0.47
7 48450157 rs17548783 ABCA13 C/T 0.46 0.72 0.53 0.48
8 94935937 rs4735258 PDP1 C/T 0.40 0.64 0.66 0.46
9 100190780 rs1381532 TDRD7 C/Tb 0.48 0.59 0.50 0.58
10 100219314 rs10883099 HPSE2 A/G 0.52 0.52 0.53 0.62
11 16133413 rs4617548 SOX6 A/G 0.52 0.65 0.61 0.51
12 993930 rs7300444 WNK1 C/T 0.46 0.55 0.48 0.28
13 39433606 rs9532292 FREM2 A/G 0.29 0.41 0.44 0.54
14 50769717 rs2297995 L2HGDH A/G 0.55 0.65 0.67 0.59
15 34528948 rs4577050 SLC12A6 A/G 0.68 0.75 0.63 0.32
16 70303580 rs2070203 AARS C/Tb 0.53 0.28 0.51 0.49
17 71197748 rs1037256 COG1 A/G 0.50 0.67 0.65 0.56
18 21413869 rs9962023 LAMA3 C/T 0.67 0.81c 0.75 0.51
19 10267077 rs2228611 DNMT1 A/Gb 0.47 0.73 0.56 0.48
20 6100088 rs10373 FERMT1 C/Tb 0.54 0.31 0.35 0.58
21 44323590 rs4148973 NDUFV3 G/T 0.65 0.33 0.38 0.73
22 21141300 rs4675 SERPIND1 C/T 0.46 0.62 0.51 0.57
aPosition as defined in genome reference assembly GRCh37 (hg19).
bSNP is defined on the negative strand.
cAF marginally outside target range for candidate selection. Selected due to paucity of candidates on
chromosome 18.
6.3.2 Validation & application
6.3.2.1 Publicly available data
1000 Genomes Project
The 24 biallelic SNPs afford 48 points of allelic comparison. Testing the optimised
panel in the 1000 Genomes Project data (n = 1,092)[12], an average of 18.0 (SD = 3.3)
allelic differences between all pairwise combinations was observed, with a range of 3–34.
As such, there will be, on average, 18 differential alleles between any two samples,
enabling discrimination.
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UK10K Project
On addition of the UK10K data (n = 2,688) to the 1000 Genomes Project data
(nΣ = 3,780), there remained an average of 17.8 allele mismatches across the profiles.
Eighteen UK10K sample pairs produced duplicate profiles. On investigation of these
pairs, they were found to share > 98% genotypic concordance across an extended panel
of 1,662 SNPs in all cases compared to an average of 42%, with a range of 27–77%
for all 18 sample pairs with unique SNP profiles (Figure 6.2). As such, these pairs
represent extreme outliers, and are presumed to be derived from genetically identical
biological samples, either from the same individual or monozygotic twins, and were
therefore excluded from the mismatch average. In several cases, sample data producing
concordant profiles bore consecutive sample designations.
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Figure 6.2: Distribution of pairwise genotype concordance between samples. Pairs resulting
in duplicate SNP profiles (n = 18; red) and pairs between samples with unique SNP profiles
(n = 7,142,293; blue) within the combined dataset of 3,780 samples are shown. Concordance
across the 1,662 SNPs detailed in Figure 6.1c was evaluated. All pairs resulting in duplicate
profiles have > 98% concordance, well separated from the distribution of samples with unique
profiles. Note the logarithmic scale.
6.3.2.2 Simulated data
The discriminatory power of the panel was evaluated by Monte Carlo simulation.
First, we evaluated the time taken for the analyses to run for a range of dataset sizes
to confirm that the approach was computationally feasible. 50 pseudoreplicates of
CEU 1000 Genomes Phase 1 AF data based simulation for a range of dataset sizes was
performed and the CPU run-time was recorded, allowing for extrapolation to estimate
the time required to obtain the desired 20,000 pseudoreplicates (Table 6.2). Monte
Carlo simulation runtime increases approximately linearly with increased simulated
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dataset size. Based upon these data we parallelised the simulations across multiple
CPUs, allowing for the large CPU-time required to be completed in real-time inversely
proportional to the number of CPUs applied. We also limited our simulated dataset
sizes to 102,400 to maintain reasonable computational run-times.
Table 6.2: Time taken for simulation of collision frequency for varying dataset sizes
Size 50 replicates (s) 20,000 replicates (m)
100 0.45 3.02
200 0.62 4.15
400 0.99 6.62
800 1.73 11.51
1,600 3.23 21.52
3,200 6.28 41.89
6,400 12.52 83.43
12,800 25.11 167.37
25,600 50.96 339.72
51,200 102.88 685.85
102,400 210.15 1,401.02
204,800 429.04 2,860.24
We simulated datasets of 10,000 individuals, that conformed to AF distributions for
investigated HapMap populations (CEU, CHB, JPT and YRI), 1000 Genomes Project
pilot average[58], as well as for a hypothetical perfect allele distribution (AF = 0.5 for all
SNPs) (Table 6.3). In all simulated populations, < 2.5% of simulated datasets of 10,000
contained any repeat SNP profiles (henceforth termed ‘collisions’). This translates
approximately into less than 1 in every 40 independent datasets of 10,000 individuals
containing a single matching pair of profiles.
Table 6.3: Profile collisions per simulated dataset of 10,000 individuals with population AFs.
AF Source Average collisions
per dataset (± SD)
1000 Genomes average 0.0039 (0.062)
HapMap Phase 3:
CEU 0.0064 (0.079)
CHB 0.0239 (0.154)
JPT 0.0082 (0.086)
YRI 0.0076 (0.086)
Theoretical perfecta 0.0031 (0.056)
aAll 24 SNPs assigned an AF of 0.5, which will give the most even trifurcation per SNP, and thus
discriminatory power.
The effect of dataset size on the frequency of collisions was investigated for populations
present in 1000 Genomes Project Phase 1 data[12]. An exponential increase in the
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frequency of collisions was observed with increasing dataset size, though the panel
continued to have high power for the discrimination of samples (Figure 6.3). For
instance, were we to have 85,000 unrelated Southern Han Chinese (CHS) samples, (the
worst performing 1000 Genomes population evaluated, due to the AF distribution for
SNPs within this panel), we would expect the dataset to contain, on average, a single
duplicate SNP profile.
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Figure 6.3: Relationship between sample size and incidence of repeat SNP profiles for 13
populations. Collision rate was simulated for multiple populations using custom scripts. An
exponential increase in the probability of non-unique SNP profiles is observed with increase in
sample sizes. In the case of the worst performing population, an average of 1 repeat profile
per dataset of 85,000 would be expected. Allele frequencies are based on samples from the
1000 Genomes Phase 1 dataset[12]. Additional populations are Americans of African ancestry in
Southwest USA (ASW), Columbians from Medellin, Colombia (CLM), Finnish in Finland (FIN),
British in England and Scotland (GBR), Luhya in Webuye, Kenya (LWK), Mexican ancestry
from Los Angeles, USA (MXL), Puerto Ricans from Puerto Rico (PUR) and Toscany in Italia
(TSI).
In addition, total SNP absence, for example through technical failure of orthogonal
genotyping, was modelled. For each SNP that entirely failed to provide data, a less
than three-fold drop in discriminatory power was observed in all cases (data not shown).
This suggests that our approach is robust against technical failure.
6.3.2.3 Calculation of power
Several Perl implementations for the calculation of q were attempted, in an effort
to attain computational feasibility. Provisional testing indicated that calculation of q
for a single population utilising a single 2 GHz CPU core would require ∼42 days of
continuous processing. Given the iterative nature of the calculation, parallelisation is
programmatically challenging, and without parallelisation calculation is not practicable
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within a reasonable time-frame. As such, attempts to empirically calculate C were
abandoned at this stage.
6.3.2.4 Application of panel
Application of the SNP panel to our batch of 48 samples revealed a discrepancy
between exome and orthogonal genotypes for two samples dispatched in adjacent wells,
suggesting a reciprocal transposition (Figure 6.4). The occurrence of this error in the
exome data was also supported by interrogation of X-chromosome heterozygosity to
confirm sample gender. In addition to the identification of the switch, the panel allowed
for expeditious resolution of the error, permitting the continued use of the data in
downstream analyses.
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Figure 6.4: Exome derived and orthogonal genotypes for four samples, showing a sample-switch
between 2 and 3. Informative markers for the resolution of this switch are highlighted in yellow.
6.4 Discussion
Validation of sample identity is essential in order to ensure data integrity and validity
of conclusions drawn from data. We have described a powerful tool for the identification
and validation of data provenance throughout the workflow of WES data collection and
analysis. The power of discrimination, that is, the precision with which samples can be
uniquely identifiable, is sufficient and robust for most projects on the current scale of up
to 10,000 samples, with inbuilt redundancy of SNPs to protect against technical failures.
In WES, the exome enrichment process provides the limiting step for the availability of
data on SNPs for use in sample identification. As such, this panel will also be of utility
for whole-genome sequencing data, where there is no such limitation on SNP coverage.
This will be beneficial where there are mixed datasets of both whole-genome sequence
and WES data.
NGS is now developing as the diagnostic methodology of choice across a range
of applications, including mutation scanning in targeted gene panels and WES for
congenital disorders, as well as high depth analysis for tumour profiling. Whilst the
service model for delivery of these tests is not fully resolved at this stage, there will
certainly be economic arguments for centralising certain tests. This will have the effect
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of increasing the throughput requirements as well as physically moving samples between
labs. Both of these factors will increase the opportunity for sample misidentification.
Even for testing within a single lab, the use of inherent sample and data identification
methods, as described in this study, seems a robust approach to fulfil the regulatory
requirement for providing a full audit trail and ensuring data provenance[181,201]. The
SNP panel presented here is immediately usable across all commonly used exome capture
kits, and would be equally applicable to any gene panel by incorporating, or ‘spiking’,
the SNP regions into the custom capture kit at the design stage.
We have shown our panel to have a high discriminatory power across a diverse range
of populations. The discriminatory power of the panel may be reduced for various
reasons, such as geographically localised variation in AFs, and degradation of DNA
samples, resulting in incomplete data. Additionally, the discriminatory power will
be marginally reduced where many relatives are sequenced. In the case of highly
consanguineous families, sample tracking methods such as barcoding will afford optimal
certainty in these particular cases. Should concerns over insufficient discriminatory
power arise, additional SNPs may be added to the panel from the existing list of
candidates, also allowing the tailoring of an enhanced panel to the population(s) of
interest, should this be desired. Nevertheless, we have demonstrated our panel to
be sufficiently robust to withstand power reductions without loss of utility for most
purposes. Simulation of panel power as implemented in generate_fingerprint.pl
relies on the Perl rand function for pseudo-random number generation; there are known
issues with this function providing poor randomisation performance[202], though this
is unlikely to have influenced these results due to the low resolution binning of the
random numbers, i.e. from 32-bit accuracy numbers to trinary genotype categories.
While more random alternatives to this algorithm exist, it was decided to utilise the
stock rand function due to its low computational intensity, a requirement to facilitate a
large number of pseudoreplicates.
We have also presented a recent case in which use of this panel has allowed us to
identify, confirm, and resolve a sample switch, highlighting the importance of using such
a tool. Monetary cost will vary with the technology used for orthogonal genotyping
and sample throughput. We have intentionally designed the panel to be platform
nonspecific, allowing for the establishment of in-house assays using preferred genotyping
methodology or outsourced where required. Our own chosen methodology has a list-
price of approximately £10 GBP per sample, representing a small fraction of the cost
of exome data generation; this will of course vary dependant upon chosen method and
throughput.
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Since the publication of our panel, there has been one further publication by Hu et
al. elucidating a similar method, and SNP panel[203]. Hu et al. utilised information
theory to identify the optimal set of SNPs for sample tagging. They also provide a tool,
SNPtagger, for the generation of custom SNP panels where specific requirements exist.
Ultimately, they describe their 30 SNP panel as having an average mismatch distance
between simulated samples of 18, comparable to the average observed mismatch distance
in our study of 17.8 across 3,780 actual samples.
The demand for the development of effective tools for bioinformatic analysis, data
compression, mutation effect prediction and quality control is high. As such, we have
formulated this panel of SNPs for the discrimination of human biological samples on
the basis of data intrinsic to WES data derived from samples processed using common
capture kits. Since the panels inception we have utilised it routinely in our routine
sample analysis pipeline.
Following publication of the described final panel, the panel is now offered as a
genotyping service by LGC Genomics, allowing for use of the panel by groups without
laboratory facilities, as well as a pre-validated genotyping kit, to allow for ready
incorporation into existing laboratory workflows, without the requirements of assay
design and validation[184,204].
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Lessons Learned in the
Identification of Cryptic
Aetiological Variants in Whole
Exome Sequencing
7.1 Background
Whole-exome sequencing (WES) has proven to be a powerful tool for the identification
of aetiological variance, providing a cost effective means of leveraging the clinical
diagnostic power of NGS[68–70]. As discussed in Chapter 4, WES involves the pre-
selection of coding regions of gDNA by hybridisation with complementary baits, followed
by NGS sequencing, providing a high, cost-efficient, diagnostic yield.
I have worked closely with several local clinicians, identifying patients for which WES
may prove useful, and performing data analysis. In many cases, this has resulted in
a successful molecular diagnosis for the patients in question, informing appropriate
treatment and allowing for genetic counselling where this is desired by the patient.
In some cases however, the apparent aetiological variants have been refractory to
identification.
A genetic variant may be refractory to identification using WES methodologies (i.e. a
‘cryptic variant’) for a multitude of reasons. In this chapter I discuss several cases where
variants which are thought to contribute to disease pathogenesis have been identified,
though requiring (sometimes extensive) further analysis than purely the default pipeline
detailed below. This chapter focusses on cryptic variants as other identified aetiological
variants, while their identification is of clear benefit to the patient and may further
understanding in the relevant clinical field, are nonetheless of limited interest from a
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bioinformatic data analysis perspective. Categorisation of cryptic variants however
should allow for the identification of weaknesses in standard analytical processes. Key
weaknesses in the local pipeline used are identified, and approaches to resolving these
issues are discussed in the conclusion. These represent key areas where continued
research and method development will facilitate a diagnostic uplift upon the routine
clinical application of NGS in healthcare.
7.2 Methods
7.2.1 In vitro sample processing
gDNA was isolated from either whole-blood by the salting-out method or spin-column
preparation, or from stabilised saliva according to manufacturer protocol (Oragene
Discover 250 kit, DNA Genotech, Ontario, Canada). Downstream sample processing
steps from this stage were outsourced to an external service provider as detailed herein.
In brief, isolated DNA was fragmented by ultrasonication and size selected to give a
mean fragment size of 200 bp; whole-exome enrichment was performed using either the
SureSelect Human All Exon V4 or V5 kit (Agilent, Santa Clara, CA, USA) according
to manufacturer instructions prior to sequencing for 100 bp PE reads on either the
HiSeq 2000 or 2500 platform (Illumina, San Diego, CA, USA). Where necessary, Sanger
sequencing was performed following PCR of gDNA with standard methods, using
the forward amplification primers for sequencing; primer design was performed using
Primer3Plus [205].
7.2.2 In silico data processing
Data was analysed using the in-house Soton Mendelian V3.0 or V3.1 pipeline (collect-
ively referred to as V3.x)[146,184,198,206]. Raw FASTQ reads were aligned to the reference
genome GRCh37 (hg19) using Novoalign MPI v2.08.02i[161] (see Figure 7.1 for pipeline
overview). Following primary alignment, duplicate reads—reads which align originating
at the same genomic position, and are thus presumed to be technical artefacts as
opposed to true independent reads—were flagged using Picard v1.108[207]. Variant sites
were called using the SAMtools v0.1.18 mpileup command on individual samplesii[165].
All standard statistical analyses were performed in R v3.0.1 unless otherwise stated.
Pedigrees were drawn using Madeline 2.0 [208].
iNon-default parameters used were a presumed mean fragment length of 200 bp, SD 30 bp, gap-
opening penalty of 65 and gap-extension penalty of 7 (these gap-penalties are the weighting against
the opening and extension of gapped alignments as compared to the reference genome assembly, as
seen in indels).
iiFor calling, non-default parameters were to: only consider reads with a mapping quality of ≥ 20;
perform extended base alignment quality computation; skip indel calling where DOC > 2000 and;
require ≥ 5% of reads to support an indel call.
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Where it was desired to investigate somatic LOH in samples, BAFsegmentation [172]
was applied to the exome data. BAFsegmentation assesses the deviation in the allelic
ratios in heterozygotic loci (assessed by the mBAF), with contiguous regions segmented
using CBS. VCF files were converted to BAFsegmentation input format using custom
scripts; only variants with a read depth of ≥ 20 (this depth required in both samples
for pairwise analysis) were considered in order to minimise stochastic noise in the BAF
at very low read depths. Regions consistently exhibiting an mBAF of ≥ 0.6 were
considered to be regions of LOH.
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Figure 7.1: Overview of the Soton Mendelian V3.x analysis pipeline. Flowchart embodies the
final section of Figure 4.2 as performed in-house. The analysis is aggregated into three major
segments, read alignment (beige), genotype calling (blue) and annotation (orange). Early stages
are computationally intensive, with hardware requirements and file sizes decreasing throughout
the process due to the aggregation and filtering of data. Rectangular objects represent output
files (file formats in parentheses), diamonds denote processes and ovoid objects, software used.
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7.2.3 Annotation of called variants
Called variants were annotated using ANNOVAR[209] with: the AF in the 1000
Genomes Project Phase 1 dataset[12]; 5,400 individuals from the NHLBI Exome Sequen-
cing Project (ESP)[210] and; ∼250 individuals WES analysed in-house with the Soton
Mendelian V3.x pipeline. Protein alterations were annotated based upon the RefSeq
transcript databases, and with predictions of deleteriousness including GERP++[175],
PolyPhen-2[179] and SIFT[178] where the variant is non-synonymous. Variants within
10 bp of intron–exon boundaries were annotated as having a putative involvement in
splicing processes, and assessed using MaxEntScan [211] as required. A ∆MaxEnt score
of ≥ 2.5 was considered indicative of a variant likely to alter splicing processes. All
chromosomal positions are defined as in GRCh37 (hg19), and all SNP rsIDs are as
contained in dbSNP build 139[65].
7.2.4 Filtering of annotated variants
Filtering of variants was informed by prior information, and as such is not consistent
across all cases. As a flexible framework, variants were filtered out using the following
exclusion criteria, specifically being:
1. Synonymous, with the exception of exonic variants located within 10 bp of an
intron–exon boundary;
2. Present outside of coding regions (aside from if within 10 bp of an exon) of defined
candidate genes, where this information was available;
3. Common in the ESP and/or 1000 Genomes Project datasets (AF ≥ 0.01 or ≥ 0.05
dependant upon disease frequency/severity/mode of inheritance);
4. Present at a zygosity inconsistent with the expected mode of inheritance, and;
5. Segregating inappropriately within family members, where multiple members have
WES data available.
Furthermore, remaining variants were prioritised for investigation if they were: known
clinical variants; novel; predicted to be protein truncating or missense and predicted to
be deleterious.
7.2.5 Quality control
Raw FASTQ reads were subjected to standard quality checks using FastQC v0.10[212].
Following alignment, DOC statistics were compiled using BEDTools v2.17[195] and
evaluated for mean DOC and the percentage of target regions covered to 1, 5, 10 and
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20 X. The proportion of reads mapping both to the genome, and to the exome target
was also calculated. Following genotype calling, the X-chromosome and autosomal het-
erozygosity was calculated, to confirm gender and check for evidence of contamination
(see subection 4.4). An aliquot of DNA was contemporaneously dispatched for ortho-
gonal genotyping for the validation of the identity of the final data (see Chapter 6)[184].
IBS was calculated between all samples dispatched together to validate relatedness of
samples where this is expected, and to highlight cross-contamination between samples.
VerifyBamID [183] was applied to the BAM files in order to assess whether the data har-
boured consistent deviations in BAF from the expectation, indicative of contamination
with exogenous DNA.
7.3 Indels
7.3.1 Family A - Nager syndrome
7.3.1.1 Clinical presentation
The female proband of Family A received a putative diagnosis of Nager syndrome
(MIM 154400) at age 9, with no remarkable family history known, though an extended
family history was not available (Figure 7.2). Presentation included micrognathia
(an undersized jaw), hypoplasia of the ear-canal and absent index fingers. Further
detail is given in subsubsection 8.3.1.1. Given the sporadic nature of the case, it is
likely that the aetiological variant arose de novo, though it is also possible that it is
recessive if distantly related parents have formed the union. Nager syndrome has been
previously reported to occur in similar sporadic cases, as well as in familial cases with
both dominant and recessive modes of inheritance—including resulting from compound
heterozygosity[213]. The cause of the majority of Nager syndrome cases has been recently
identified to be mutations in SF3B4 [214], with the aetiology of the non-SF3B4 cases
currently unresolved.
I1 I2
P
II1
Figure 7.2: Pedigree showing inheritance of Nager syndrome in Family A. WES analysed
individuals indicated by ‘+’.
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7.3.1.2 Genetic analysis
The singleton proband was chosen for WES; the trio was not sequenced due to
cost constraints. Returned WES data were of a good quality, passing standard checks
(Table B.2). A mean DOC of 56.9 X was attained, with 25,139 variants called by
our pipeline. Given the putative diagnosis of Nager syndrome, we first queried the
variant calls for the candidate gene SF3B4 [213,215]; no variants were called by our
Soton Mendelian v3.1 pipeline. Given the strong candidacy, raw read data mapping to
SF3B4 was manually investigated in IGV [216], identifying a c.1060 1061insC:p.R354fs
variant (transcript NM 005850, transcribed from the reverse strand). This variant was
supported by 8
19
reads at the position and was subsequently confirmed as de novo by
myself using Sanger sequencing. It appears the indel was not called by our pipeline
as only 1
8
variant reads were mapped to the forward strand (Figure 7.3), leading to
exclusion of the variant due to quality filtering at the variant calling stage. This effect
has also been observed by other members of the group in other cases.
T
C
T C C G A A T G G A G G C C C T C G G G G G G G C A T G C C C A T
G F P P G R P P M G M
SF3B4
(a) NGS alignment
(b) Sanger electrophoretogram
Figure 7.3: SF3B4 :p.R354fs as seen in alignment data (a) and Sanger electrophoretogram (b)
for the proband of Family A. In (a), reads mapping to the forward stand are coloured in red,
and mapping to the reverse strand in blue; mononucleotide insertions in reads are represented by
purple bars. Note the bias in reads harbouring insertions toward reads mapping to the reverse
strand. Colour coding in (b) is consistent with sequence colouring in (a), frameshift indicated
with arrow. Primers used for amplification were F: 5’-TTCTCTTTCAGCCCTTGCCC-3’ and
R: 5’-ATGCTAAACTTCCTCCCCGC-3’. Figure (a) produced using IGV [216].
7.3.1.3 Discussion
SF3B4 :p.R354fs has been previously reported to be a dominant cause of Nager syn-
drome, with patients testing positive for deleterious variants in this gene in 32 of 53 cases
across two WES studies[213,215]. The remaining patients negative for SF3B4 variants
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may comprise a subset of Nager syndrome with a distinct aetiology, or alternatively
testing may be negative due to limitations inherent in the WES approach[214]. The
negative cases may carry cryptic loss of function mutations for example in transcription
binding motifs or intronic splicing regulatory regions. SF3B4 encodes for a component
of the pre-mRNA splicing machinery; given the recent identification of aetiological
variants in the gene, the mechanism of pathogenesis is not yet known.
The Soton Mendelian pipeline should be optimised to call this variant and other similar
examples, as it would currently appear to be overly conservative in the calling of small
indels where there is a significant strand bias. Variants exhibiting a strong strand bias
are not called as these are more likely to result in false positive calls due to technical
artefacts. This is a particulat issue for indel variants, and thus SAMtools is more
stringent with these variants. This may be in the form of optimisation of parameters
for the SAMtools mpileup command currently used for the calling of SNPs and small
indels, or the incorporation of other more specialised software into the pipeline. Care
must be taken however to minimise the increase in false positives. A known limitation
of NGS data is a weakness in the calling of indels, with lower sensitivity than for the
detection of SNPs, as well as higher false positive rate and greater between-software
heterogeneity[217].
This case highlights the need for prior hypotheses in the interrogation of WES data.
The presence of a strong prior hypothesis will allow for appropriate expenditure of time
investigating genes, proportional to the perceived likelihood of that gene being clinically
relevant. Where interrogation efforts are evenly distributed across the entire WES
data-set, an increased type II error rate is likely to be seen; additionally, care must be
taken in efforts to improve exome-wide sensitivity, as an increase in type I errors which
may accompany this will hinder meaningful interrogation of the data. For a further
example of the necessity of a targeted curatorial approach, see subsection 7.3.2.
7.3.2 Family B - Severe combined immunodeficiency with me-
galoblastic anaemia
7.3.2.1 Clinical presentation
Primary immunodeficiencies (PIDs) are a diverse class of disorders which are charac-
terised by the lack of an effective immune response to pathogens, including opportunistic
pathogens. PIDs are further defined by the cause of this immunodeficiency being endo-
genous, as opposed to being exogenous causes such as infection and chemotherapy[218].
Individual II2 (see Figure 7.4) presented at 4 months with Pneumocystis jirovecii
pneumonia, and responded well to appropriate antifungal treatment. P. jirovecii, like
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most fungi, is an opportunistic pathogen, infection with which is indicative of underly-
ing immunodeficiency[219]. Haematological testing indicated significant lymphopoenia
across all sub-sets; as such, a putative diagnosis of severe combined immunodeficiency
(SCID) was made. Whilst further tests were ongoing, II2 was listed for a bone-marrow
transplant, though continued to respond well to prophylactic antifungals.
I1 I2
II1
P
II2 II3
Figure 7.4: Pedigree showing inheritance of severe combined immunodeficiency in Family B.
WES analysed individuals indicated by ‘+’. Note that the mother, I2, is of Asian descent.
Individual II3 was born following diagnosis of II2, and was therefore diagnosed at
birth with a similar condition on the basis of haematology, going on to suffer septic
arthritis of the hip at 9 months. Following the birth of II3, II2 developed megaloblastic
anaemia, initially thought to be treatment related. Supplementation with folinic acid (a
vitamer of folic acid, vitamin B9) was successful in treating the anaemia. On folinic acid
supplementation an increase in lymphocyte counts was observed, affording a partially
reconstituted immune system in the brothers, obtaining low-normal lymphocyte counts.
It became apparent that the megaloblastic anaemia was not treatment related, but
likely due to a congenital metabolic deficiency.
7.3.2.2 Genetic analysis
Prior to these WES investigations, Sanger sequencing for several SCID candidate
genes was carried out in a clinical genetics laboratory (namely IL2RG, IL7R, JAK3,
ADA, PNP, and RAG1 /2 ); results were negative for pathogenic variants in all cases. As
such, it was decided to utilise WES to broaden the search for an aetiological candidate.
The unaffected father and two affected brothers were exome sequenced. Returned WES
data were of a good quality, passing most standard checks (Table B.2). A mean DOC
of 70.6, 67.0 and 59.7 X was attained, with 23,488, 24,577 and 23,886 variants called by
our pipeline for I1, II2 and II3 respectively. Data for II2 and II3 did however exhibit a
significant excess of autosomal heterozygosity, as has been previously been observed with
substantial contamination. This excess was determined to be due to the mixed-ethnicity
of the brothers; no other evidence for contamination was observed. Given the strongly
positive response to folinic acid supplementation primary candidate genes interrogated
were those involved in the ‘folic acid metabolic process’ (GO:0046655[220]). 15 variants
were called in these 14 genes.
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Filtering of the 15 variants in folic acid metabolism genes, for those present in both
brothers, excluding synonymous variants and those present with an AF ≥ 0.05 in the
1000 Genomes Project dataset, resulted in a single candidate remaining, a heterozygous
novel MTHFD1 :c.T152C:p.L51P substitution (transcript NM 005956). Analysis of
segregation of p.L51P in Family B showed that the variant was inherited from the
mother, I2. MTHFD1 was clearly a strong aetiological candidate gene, though the single
p.L51P SNP, also present in the healthy mother, would be unlikely to be pathogenic in
isolation.
MTHFD1 was further investigated for variation in DOC across the gene, with a view
to identifying any exonic deletions. In order to do this, the number of reads mapping
to each exon of the gene was first enumerated for the three family members, as well as
13 unrelated controls sequenced contemporaneously. Given the maternally inherited
p.L51P variant, it was hypothesised that a paternally inherited deletion may be the trans
aetiological counterpart in the brothers. The raw count of reads was then normalised
for each sample based upon the total number of reads aligned to the MTHFD1 gene,
and subsequently this was normalised by the mean normalised read count across the
13 control samples. A large deletion spanning the entire gene could be ruled out due
to the heterozygous nature of the p.L51P call. A significant deficiency of coverage
(p = 0.00019) within Family B across exon 13 of MTHFD1 was observed (Figure 7.5),
being indicative of a deletion of the exon.
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Figure 7.5: Normalised coverage across the MTHFD1 gene in Family B (red) compared to
13 controls from the same sequencing batch (blue). A significant lack of coverage of exon 13
if observed for all WES analysed members of Family B (p = 0.00019, one-tailed t-test). In
addition exon 14 appears to have an excess of reads in Family B samples (p = 0.011), though
this significance level does not withstand Bonferroni correction.
As an aside, there is a clear inverse correlation between the standard deviation of the
normalised coverage and the average coverage of an exon (ρ = −0.90, p = 7.28× 10−7,
Spearman’s rank). This correlation highlights the requirement for high DOC data where
CNVs are to be interrogated as a priority, in order to improve the power of detection;
similarly, a greater number of reference samples is invaluable for maximal power of CNV
detection. Out of several CNV and indel calling software applied to these data (namely
Pindel, SoftSearch and XHMM [167–169]) with fully relaxed criteria, none have called this
variant. However, the ExomeDepth [221] TestCNV function was able to call the deletion,
with a Bayes factor of ∼9. The TestCNV differs from the other software applied in that
it allows the user to specify the region to test, limiting concerns overs false positives
due to the greater a priori probability of the region harbouring a deletion; the standard
exome-wide CallCNVs function stil fails to identify the deletion.
In addition to the reduced DOC for exon 13 in Family B, a split-pair of reads was
observed across the region in the data derived from I1 and II3 (Figure 7.6). This
pair was used to approximate breakpoint location, informing the primer design for
confirmation. PCR and sequencing primers were placed outside this read-pair, ensuring
that both primers would flank the deletion. Sanger sequencing confirmation successfully
identified a 1,745 bp deletion in all WES analysed members of Family B, and confirmed
segregation of the two MTHFD1 variants with disease (Table 7.1).
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Figure 7.6: Supporting evidence for deletion of exon 13 of MTHFD1 in Family B. DOC histograms are shown for a representative control (b) and case
(II3; c) sample under the chromosomal coordinates and exonic structure of the gene. The pileup of reads is also shown for II3 (d), with an anomalously
diverged read-pair evident (red). This is further indication of the exon 13 deletion (see Figure 4.4 for further explanation). Breakpoints of the deletion were
confirmed by Sanger sequencing (f), and are shown to lie within the anomalous read-pair. The breakpoints lie within homologous positions in two AluSg
repeats, suggesting a mutational mechanism (e). Figure modified from IGV [216] output.
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Table 7.1: Segregation of MTHFD1 variants with SCID in members of Family B.
MTHFD1
Individual SCID L51P Δ exon 13
I1 - - +
I2 - + -
II2 + + +
II3 + + +
7.3.2.3 Discussion
MTHFD1 encodes C-1-tetrahydrofolate synthase, cytoplasmic (C1-THF synthase).
C1-THF synthase is a trifunctional enzyme with dehydrogenase (EC 1.5.1.5) and
cyclohydrolase (EC 3.5.4.9) activities in one active site, and synthase activity (EC
6.3.4.3) in a second (Figure 7.7). These three activities occur in sequence and are
required for the shuttling of folate metabolites between several key metabolic cycles
in the mitochondria, nucleus and cytosol, including purine biosynthesis[222]. A review
of the literature revealed that a similar paediatric SCID case was reported in 2011,
also in an admixed pedigree, with compound heterozygosity for deleterious variants in
MTHFD1 and similar response to folate supplementation[150].
THF
10-fTHF
10-fTHF
CHF
CHF
CH2F
(a) Synthase
THF
10-fTHF
10-fTHF
CHF
CHF
CH2F
(b) Cyclohydrolase
THF
10-fTHF
10-fTHF
CHF
CHF
CH2F
(c) Dehydrogenase
Figure 7.7: Activities of the trifunctional C1-THF synthase enzyme. THF - tetrahydrofolate,
10-fTHF - 10-formylTHF, CHF - 5,10-methenylTHF, CH2F - 5,10-methyleneTHF. All reactions
are reversible, with the second and third reactions requiring NADP cofactor. Taken from Scotti
et al., 2013[222]. Reprinted by permission from Wiley Periodicals Inc., © 2013.
The substitution of c.T152C is assigned a GERP++ score of 3.2, indicating a high
level of phylogenetic sequence conservation, in agreement with the PolyPhen-2 score of
0.99. Due to the substitution of a proline residue within an α-helix, this is expected
to disrupt the helix, deforming the proximal region[176]. Leu-51 is located near to the
bifunctional active site of C1-THF synthase (Figure 7.8).
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(a) C1-THF synthase top view (b) C1-THF synthase end view
Figure 7.8: Structure of C1-THF synthase showing substrate binding and residues mutated in
Family B and previous case. Leu-51 (red), Pro-51 in our cases, can be seen to lie next to the
binding pocket in the bifunctional dehydrogenase/cyclohydrolase active site for the substrate
(teal). The previously reported p.R173C (pink) lies within the binding cleft for the NADP
cofactor[150]. Both of these variants would as such be expected to alter the kinetics of this enzyme,
most likely through the reduction of substrate/cofactor affinity. Data from 1.5 A˚ crystal structure,
PDB ID: 1DIA[223].
It appears likely, as the breakpoints of the indel lie within two nearby homologous
Alu repeats in equivalent positions (Figure 7.6), that the high sequence similarity led to
the excision of the indel. A similar Alu-mediated excision has been previously reported
as an aetiological mutational mechanism, possibly due to replication slippage[224]. The
excision of exon 13 from the MTHFD1 mRNA results in a premature stop codon due to
a frameshift. As such, it would be indicated to undergo nonsense-mediated decay; this
was confirmed to be the case using reverse-transcriptase PCR, revealing the prevalence
of the c.T152C allele in the mRNA population vs. the wild-type allele at this site
as present on the deletion allele. It is of note that the previously reported case also
carried a compound heterozygote comprising c.[C517T];[727+1G>A], with the splice
site variant again expected to induce nonsense-mediated decay of the transcript[150,225].
It must be noted that, despite the similarities in clinical phenotype between Family B
and the previously reported case, there are some discrepancies, with the reported case
having a more severe phenotype, including renal and neurological issues. The reported
intellectual disability and seizures were not respondent to folate supplementation, though
neurological issues are known in conditions where homocysteine (a metabolite that
requires the products of C1-THF synthase for further processing) levels are increased[226].
Family B exhibits no signs of neurological defects, and did not have abnormally increased
levels of homocysteine when off supplementation. There are two possible, non-mutually
exclusive reasons for this: the p.L51P may not abrogate enzymatic activity to the same
degree as p.R173C, and dietary levels of folate may have been higher in Family B than in
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the previous case report. In an Mthfd1+/− mouse model, where it is the monofunctional
synthase active site that is fully disrupted, a significant increase in homocysteine levels
vs. Mthfd1+/+ was only observed when the mice were given a folate deficient controlled
diet. Furthermore, Mthfd1−/− was developmentally lethal, making it highly likely that
these SNPs permit some residual activity[227,228].
Overall, it is clear, based on both a single previous case report and evidence from a
murine model that the MTHFD1 compound heterozygote is aetiological for the SCID
and megaloblastic anaemia phenotypes in Family B; confirmation of this allows for the
confident continued use of folinic acid supplementation in the affected brothers, with
consideration no longer being given to bone marrow transplantation.
7.4 Loss of heterozygosity
7.4.1 Family C - Juvenile myelomonocytic leukaemia
7.4.1.1 Clinical presentation
The patient first presented at four months with a stroke, secondary to moyamoya,
the constriction of arteries in the brain, and had no relevant family history (Figure 7.9).
The patient was also developmentally delayed, initially attributed to the stroke. Aged
two, he was referred to nephrology with marked thrombocytopaenia, proteinuria and
hypertension. Low serum complement 3 suggested a perturbation in the alternative
complement pathway consistent with atypical haemolytic uremic syndrome (aHUS).
Renal electron microscopy confirmed endothelial cell separation from the glomerular
basement membrane and he commenced eculizumab therapy for aHUS.
I1 I2
P
II1
Figure 7.9: Pedigree showing inheritance of apparent aHUS syndrome in Family C. WES
analysed individuals indicated by ‘+’.
Following the first tier genetic interrogation which is detailed below, it was not felt
that these variants sufficiently explained the patient’s phenotype so further phenotyping
was performed. At this point it was determined that the patient had splenomegaly,
dysmorphology (Figure 7.10) and continuing thromobocytopaenia, a symptom of aHUS
78 Section 7.4
Identification of Cryptic Variants
which would be expected to be resolved by eculizumab therapy. An additional 44 genes
identified based upon these features were therefore interrogated[229].
Figure 7.10: Facial dysmorphology apparent in the patient from Family C. The photo, taken
at age four shows low set ears, microcephaly and broad neck. The patient is in the bottom
percentile for height and weight, and is developmentally delayed.
7.4.1.2 Genetic analysis
WES was performed for the proband with the intention of resolving the cause of
the aHUS. Returned WES data were of a good quality, passing all standard checks
(Table B.2). A mean DOC of 58.5 X was attained, with 24,955 variants called by
our pipeline. 540 genes associated with aHUS in HGMD were interrogated as tier
one[229]. Two potentially pathogenic variants were identified at this point, CFH :p.Q950H
and VWF :p.R1339H. As it was not felt that these variants sufficiently explained
the patient’s phenotype, further phenotyping was performed. At this point it was
determined that the patient had splenomegaly, dysmorphology (Figure 7.10) and
continuing thromobocytopaenia, a symptom of aHUS which would be expected to be
resolved by eculizumab therapy. An additional 44 genes identified in HGMD based
upon these features were therefore interrogated[229].
In the second tier interrogation, a CBL:c.1096-1G>T was identified. CBL germline
mutations are known to cause Noonan-like syndrome, which includes moyamoya and
dysmorphology[230]. The CBL variant in the patient was determined to have arisen
de novo by Sanger sequencing of the parents. This CBL syndrome is also known to
commonly progress to juvenile myelomonocytic leukaemia (JMML)[230]. The progression
is known to be initiated by the acquisition of a somatic uniparental disomy (UPD) for
11q, within which the CBL gene is located, resulting in LOH, and absence of functional
CBL in the cell[231].
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In order to evaluate the potential progression to JMML in the patient, evidence
LOH genome-wide was investigated, applying BAFsegmentation [172]. The application of
BAFsegmentation to the WES data for the patient identified an 11q LOH (Figure 7.11).
There was no evidence of a reduction in the depth of coverage across this region,
indicating that this is a balanced UPD.
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Figure 7.11: BAFsegmentation output showing 11q LOH in the patient from Family C. The
mBAF of genotypes is shown in black points at the appropriate position on the karyogram,
green indicated the segmentation results; regions indicated in red are segmented regions with an
mBAF > 0.6. Note that the apparent LOH at p15.5 and p11.2 are likely due to alignment issues
in these small regions, no additional large regions were deemed to have LOH by the software.
7.4.1.3 Discussion
The identification of the 11q UPD indicated that the patient is progressing to
JMML[232]; however the patient has not yet shown clinical symptoms of the disease,
aside from splenomegaly. As such, this finding in the WES data allow for the monitoring
of the patient’s burden of leukocytes carrying the UPD, as well as clinical manifestations,
in order to respond with appropriate treatments if/when required. A small number
of CBL germline mutation carriers do not progress to clinical JMML, and thus the
treatment of a bone marrow transplant would be unnecessary[233].
Though the initial referring diagnosis of aHUS did not lead to resolution of the
case, the flexibility of WES allowed for the interrogation of further genes when new
information was available. Furthermore, it allowed new approaches to the data analysis
to be applied where allelic imbalance was of interest, as well as depth of coverage.
7.4.2 Patient D - Actinic keratosis
7.4.2.1 Clinical presentation
The Patient D, an 83 year old female, presented with an actinic keratosis lesion on
the left middle finger, which required surgical removal in 2013 (Figure 7.12). Actinic
keratoses form due to mutations arising though prolonged, repeated exposure to the
sun[234]. These lesions appear to share common UV-induced mutation profiles (including
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frequent TP53 mutations and acquired CNVs) with skin cancers, and there is a risk
of progression of a lesion diagnosed as actinic keratosis to carcinoma[235]. Extensive
genomic instability in even apparently benign lesions has been reported[236].
Figure 7.12: Histology of lesion from Patient D. Slide prepared using Haematoxylin and eosin
staining
7.4.2.2 Genetic Analysis
Archival FFPE embedded tissue was laser-capture microdissected to isolate the
lesion at a high purity and appropriate normal tissue to allow for paired analysis.
Returned WES data for both samples were of a good quality, passing all standard
checks (Table B.2). A mean DOC of 119.4 X and 63.6 X was attained for the lesion and
normal tissues respectively, with an intentional increased number of reads for the lesion.
As actinic keratosis is expected to harbour somatic mutations, an alternative somatic
pipeline was utilised for genotyping using a VarScan 2 [157] paired analysis approach
between the lesion and normal tissue in place of the SAMtools [165] based calling used in
the Mendelian pipeline. The Varscan 2 copycaller function was also used to identify
acquired CNVs. Comparative CNV calling using the copycaller function utilises the
log2 ratio for the read depth between two paired samples (normalised for total read
count), and applies CBS to identify regions of consistent deviation from log2R = 0
[173].
When the copycaller function was applied to the paired samples, several regions
of whole chromosome amplification were identified (Figure 7.13b), as well as many
deletions. In order to evaluate if these were likely to be true amplifications, BAFseg-
mentation [172] was applied to assess evidence for allelic imbalance (Figure 7.13a); this
was paradoxically not the case for the apparently amplified chromosomes, but was for
all other chromosomes.
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It was at this stage noted that it appeared that the majority of chromosomes
showed LOH, consistent with acquired CNVs (Figure 7.13a), and that this may skew
the normalisation procedure, given that appropriate normalisation relies upon the
majority of the genome remaining euploid in both samples; if the average scenario
for a chromosome is a deletion, then this explains the apparent amplification of the
minority of chromosomes. As such, a normalisation using only reads aligning to the
chromosomes exhibiting minimal evidence of LOH was applied (Figure 7.13c). Using
this curated normalisation approach, chromosomes exhibiting minimal evidence of LOH
also have log2R ≈ 0, consistent with sustained euploidy between the two samples for
these chromosomes, this is consistent with initial expectations.
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Figure 7.13: Genome-wide comparison of normalisation approaches for detecting copy number
changes. Shown is the mBAF plot for the sample (a), with 14 chromosomes (e.g. chr2) showing
significant deviation from the expected value of 0.5, and nine chromosomes (e.g. chr1) appearing
to be have negligible deviation.
Where read-count normalisation for log2R sample comparison is performed on a genome-wide level
(b), it can be seen that chromosomes without LOH also appear to have undergone amplification
compared to the normal samples, a result which is clearly counter intuitive.
However, where read-count normalisation only utilises the nine chromosomes without mBAF
deviations (c), the more expected pattern of log2R ≈ 0 for chromosomes without apparent LOH,
and log2R < 0 for those showing LOH is seen. Figure generated using BAFsegmentation
[172].
On assessment of the mBAF plot for the whole genome (Figure 7.13a), it was noted
that the greatest sustained deviation in mBAF, with mBAF ≈ 0.9, was observed in 17q.
As 17q UPD is a recurrent mutation in cancers, it was decided to investigate this in
greater detail (Figure 7.14).
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Figure 7.14: LOH and apparent copy-number change across chr17. Shown is the mBAF
plot for the chromosome (a), and the log2R where read-count normalisation for log2R sample
comparison is performed on chromosome without apparent LOH (see Figure 7.13) (b). Whilst the
entire chromosome exhibits LOH, this is most pronounced downstream of 17q22. Interestingly,
there is also a corresponding change in the log2R in this region, being ≈ 0.5 upstream and ≈ 0
downstream. Figure generated using BAFsegmentation [172].
Given that the region upstream of 17q22 exhibits the greatest mBAF deviation, this
would indicate that this 17q LOH was an early event in the progression of the lesion, and
has therefore is present in the greater number of cells compared to the other mutations,
with the 17p LOH occurring later in the progression of the lesion. 17q LOH is very
common in cancers[237], and as such it is reasonable to assume that this is a common
driver mutation. It is interesting to note that 17q appears to be a copy-neutral LOH as
log2R ≈ 0, whereas the 17p LOH is accompanied by a marked reduction in read depth
(log2R ≈ −0.5), indicating that this is the result of a later deletion, as opposed to the
isodisomy seen in 17q. However, this leads us to a highly unintuitive conclusion. Given
the high degree of skewing of the BAF (mBAF > 0.8 across the chromosome), it would
appear that the majority of cells harbour LOH for the two segments of the chromosome.
However, as the 17p deletion spans the centromere, it would be impossible for the 17q
region to remain diploid during successive cell divisions. Further investigation would
be required to elucidate the mechanism by which these mutations occurred, requiring
alternative approaches such as single cell for phasing or WGS for breakpoint detection
to resolve this apparent paradox.
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7.4.2.3 Discussion
If paired copy number calling was applied in this case only using the total count of
aligned reads, then incorrect conclusions could be drawn from the CNV calls produced.
Whilst it would naively appear reasonable to presume that the majority of the genome
remains euploid, with acquired CNVs being the exception, this is clearly not the case
in this sample. Using a combination of the BAF and read depth information, it is
possible to elucidate a more complete picture of the progression of successive structural
alterations. To generalise the lessons learned while analysing this exome, it is clear
that appropriate choice of controls and normalisation procedures is essential in order to
generate meaningful results.
7.5 Clinical phenotyping
7.5.1 Family E - Activated PI3K-δ syndrome
7.5.1.1 Clinical presentation
Proband II1 (see Figure 7.15) presented with disseminated pneumonococcal infection
at age 5 years, pneumonia and non-clonal lymphoproliferation leading to splenomegaly
requiring surgical intervention, and haemolytic anaemia. In addition there was a
deficiency in polysaccharide targeting antibodies and lymphopoenia of mature CD4+
T-cells, as well as further perturbation in immunoglobulin levels. II1 responded well to
immunoglobulin infusion. Parents had no apparent PID conditions, though the father
had been treated some years prior for leukaemia, with no reported PID phenotypes in
the extended family. It was noted by the clinical team that the phenotype resembled
autoimmune lymphoproliferative syndrome, though without the expected increase in
CD4-CD8- T-cells.
I1 I2
P
II1
Figure 7.15: Pedigree showing inheritance of activated PI3K-δ syndrome in Family E. WES
analysed individuals indicated by ‘+’.
7.5.1.2 Genetic analysis
The simplex trio of proband and parents was sequenced. Returned WES data were of
a good quality, passing all standard checks (Table B.2). A mean DOC of 63.9, 68.0 and
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61.6 X was attained, with 23,055, 23,797 and 23,297 variants called by our pipeline for
I1, I2 and II1 respectively. Given the apparent recessive/de novo mode of inheritance,
variants were filtered for being discordant between the proband and parents, with a
higher allelic dosage in the proband. Initially, genes known to be involved in apoptosis
were interrogated[238]. No discordant variants with 1000 Genomes Project AF ≤ 0.01
were called in the 63 apoptosis genes queried. As such, 248 genes known to be involved
in PID disorders were interrogated[239]. No variants with an AF ≤ 0.01 were present
within these genes with increased dosage in II1.
In November 2013, a report of 35 patients with a common PID phenotype was
published, and highlighted by our clinical colleagues due to the comparable phenotype
to Family E[240]. This case series identified a recurrent PIK3CD :c.G3061A:p.E1021K
substitution in a high proportion of the cases. Given the phenotypic similarities, the
PIK3CD gene was interrogated, identifying the p.E1021K variant in the affected proband
and father. As such, II1 is affected with the newly described activated PI3K-δ syndrome
(APDS; MIM 615513)[240].
7.5.1.3 Discussion
Given the phenotypic similarities, it is clear that the PIK3CD :p.E1021K is pathogenic
in II1. However, what is not apparent is the reason for the lack of a PID phenotype
in the father, I1. PIK3CD encodes phosphatidylinositol-4,5-biphosphate 3-kinase,
catalytic subunit δ (PI3K-δ; EC 2.7.1.153). PI3K is a plasmalemma-bound complex
which catalyses the phosphorylation of plasmalemma-bound phosphatidylinositol-4,5-
biphosphate (PIP2) to phosphatidylinositol-3,4,5-triphosphate (PIP3); PIP3 is an active
signalling molecule, for which ∼200 proteins contain complementary binding sites.
Specifically, the PI3K-AKT-BAD signalling pathway is involved in the suppression of
apoptosis[6]. The PI3K-δ subunit is leukocyte specific[241].
The p.E1021K substitution was shown to be activating, leading to increased PIP3
levels and thus increased AKT activity and activation of BAD, and thus inhibition of
apoptosis[240]. This inhibition of apoptosis would explain the lymphoproliferative phen-
otype, additionally, this substitution has been observed in B-cell lymphoma. As such,
this germline variant may be contributory to the development of malignancies, as has
been reported in a case of a female developing B-cell lymphoma at age 19[242,243]. Given
this overlap with haematological malignancies, it was suggested that chemotherapeutic
inhibitors of PI3K-δ may be clinically useful in the treatment of APDS[240]. Rapamycin
(an inhibitor of mTOR, itself a coactivator of AKT) has already shown some clinical
utility[241].
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The segregation of p.E1021K in Family E highlights the importance of accurate
phenotyping and presumption of mode of inheritance and penetrance when filtering
based on phenotypic segregation is desired. PIK3CD was in the secondary list of
PID candidate genes, however the p.E1021K was excluded due to its presence in the
non-PID affected father. Immunology research is particularly susceptible to apparent
incomplete penetrance, as in this case, due to the complexity of the immune system,
it is challenging to phenotype the required characteristics where the characteristic of
interest is not known.
7.6 Discussion
In this chapter, five cases have been discussed, wherein the identified aetiology was
refractory to identification. In some of these cases, the identification of variant(s)
is hindered due to deficiencies in current software tools and sequencing technologies.
Particularly, the indels in Families A & B could not be identified due to limitations
self imposed by software for the minimisation of false positives. This is challenge to
be partly overcome statistically and programmatically, but improvements in long-read
technologies and greater uniformity in genome coverage will both support these efforts.
For the proband of Family C, the lessons are twofold. Firstly, purely focussing on the
subjective referral phenotype may result in the missing of important findings in a patient.
A holistic approach to data interrogation is therefore required, on a multidisciplinary
interface between diverse clinicians and informaticians. Furthermore, LOH detection
proved to be informative in data for which only constitutional mutations were initially
considered relevant. This highlights the malleability of NGS data, to be leveraged to
answer an evolving question without additional data generation. In Family D, the
necessity for appropriate curated controls was highlighted, beyond merely selecting
appropriate individuals.
Finally, in Family E, experience in the challenges associated with incomplete pen-
etrance and diverse presenting phenotypes were discussed. This can present a massive
challenge when utilising segregation information for filtering. It is noteworthy that the
PIK3CD :p.E1021K would likely have been identified sooner had familial data been
unavailable.
Analysis has revealed some specific weaknesses in the Soton V3.x pipelines, particularly
with regards to indel detection. SAMtools is known to be comparably weak for the
detection of indels, and therefore an alternative should be sought. Callers such as
GATK [166] and Platypus [244] use more encompassing approaches to variant calling,
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with features such as local realignment around indels greatly improving sensitivity.
Active pipeline development for the Soton V4.0 pipeline is currently underway, and
will utilise control DNA for comparison to a gold standard. Specifically, NA12878
(NIST RM8398) has been sequenced, and is compared to genotype data produced by
the Genome in a Bottle Consortium[245]. As a provisional assessment, the use of the
GATK [166] HaplotypeCaller provided an uplift in indel sensitivity of 17.7% compared
to SAMtools [165] (96.8% vs. 79.1% respectively) when applied to 200 X data captured
using the Agilent SureSelect Focused Exome.
Overall, it is clear that WES will prove to be clinically valuable, particularly as large
cohorts of data are amassed, allowing greater power to detect more subtle aetiological
signals. However, targeted approaches will also play a valuable role, particularly in
disorders where much of the heredity is understood. It is clear from the cases presented
here that a proportion of the ∼75% of WES investigations that remain unresolved
will require a more targeted, customised interrogation approach[68,69]. The routine
interrogation of WES data will likely become a relatively ‘push-button’ approach in
the near future, requiring minimal human involvement in the data interrogation stages,
this will allow bioinformaticians more time to better interrogate cryptic exomes, and
develop novel analytical tools.
As exome sequencing rapidly approaches clinical practice, the increasing amounts of
data will facilitate bioinformatic method development, as well as more powerful large
cohort studies allowing the identification of further novel aetiological genes, possibly
also genes with smaller pathogenic contributions.
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Chapter 8
Application of Whole-exome
sequencing to Cleft lip/palate
phenotypes in Colombia
8.1 Background
Correct establishment of growth patterning during foetal development is key to ensure
correct morphogenesis, including that of craniofacial features. This growth patterning
can be perturbed by many factors, including environmental and genetic. Isolated, single
feature disorders, such as a cleft lip/palate tend to be caused by the interaction between
genetic predispositions and environmental factors, such as excessive consumption of
alcohol, smoking and other teratogens, as well as prolonged developmental exposure
to altitude. In contrast, familial syndromic phenotypes are more likely to have an
underlying Mendelian genetic aetiology[206,246,247]. Our group have investigated several
affected families in collaboration with Prof. Ignacio Bricen˜o, based at the University of
La Sabana, Bogota´, Colombia.
8.2 Methods
Ascertainment of the individuals detailed herein was at the Operation Smile Mul-
tidisciplinary Centre in the Bogota´ region of Colombia, established for the treatment
of individuals affected by orofacial clefting. Exome sequencing and data analysis was
performed as described in Chapter 7. Given the diversity of cases analysed, these will
be analysed in two sub-cohorts of non-syndromic (designated as sample IDs beginning
NSCLP) and syndromic, (designated with SCLP).
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For filtering of identified variants, we established a comprehensive list of genes
previously implicated in any form of CLP phenotype including search terms related to
the clinical diagnoses made for the patients. First, we queried the Human Gene Mutation
Database (HGMD professional)[229] in July 2014, using the following search terms: cleft
lip, cleft palate, cleft, syndactyly, brachydactyly, Pierre Robin, incontinentia pigmenti,
Nager syndrome, hyperpigmentation, craniofacial, clubbing, dysmorphic, dysmorphia
and micrognathia. This list comprised 363 genes. Additional genes were included after
a corresponding interrogation of OMIM (accessed July 2014)[17], and a small number of
additional CLP-related genes from the review were also included by Collins et al.[247].
The complete list of 865 genes considered in variant filtering is given in Table S2. We
filtered the lists of called variants to identify all novel non-synonymous (NS), stopgain,
stoploss, splicing and indel variants in these genes as well as known rare variants with
an allele frequency of less than 1% in the 1000 Genomes Project database[12]. More
frequent variants were excluded from further consideration as unlikely causes of rare
syndromic disease.
For NS variants, we used the scaled predictive scores from dbNSFP v2[248] and only
considered NS variants classed as deleterious or damaging by any of: PhyloP (larger
positive scores represent conserved sites while negative scores indicate non-conserved
sites)[174]; SIFT (scores < 0.05 are predicted to affect protein function)[178]; PolyPhen-2
HumVar (scores ≤ 0.446 considered ‘benign’; scores between 0.447 and 0.908 considered
‘possibly damaging’; scores ≤ 0.909 considered ‘probably damaging’)[179,249]; LRT for
which variants are predicted deleterious if they are: (i) from a codon considered to
be significantly constrained, (ii) from a site with alignments in at least 10 eutherian
mammal species, and (iii) the alternative amino acid is not observed in any other
eutherian mammal species with other variants classified as neutral or unknown[250];
MutationTaster (variants with scores > 0.95 considered damaging)[251] and GERP++
(scores range from < 0 to 6.17, with higher scores indicating stronger constraint, a score
of 6.17 indicates perfect conservation across all sequenced mammals)[175]. Grantham
scores were also assigned to all NS substitutions (50 or below for conservative amino
acid changes, scores for moderate changes 51–100, and radical changes > 100)[177]. All
variants were also annotated with combined scores for deleteriousness: PHRED-scaled
CADD (higher scores indicate that a variant is more likely to be deleterious)[252]; Logit
(the conditional probability that a variant is Mendelian disease-causing given prediction
scores from 13 programs, including SIFT, PolyPhen-2, LRT, MutationTaster, PhyloP,
GERP++ and CADD, under a logistic regression model)[253]. We also produced a
combined rank for variants with PhylopP, GERP++, CADD and Logit scores based on
the summed ranks across all four scores.
90 Section 8.2
Cleft Lip WES
We excluded variants found in homopolymer/repeat regions that can arise through
miss-alignment between the sequenced reads and reference sequence. Any variants
with read depth of < 10 or in genes considered to consistently harbour erroneous NGS
genotype calls, were removed from further consideration[254]. All identified variants were
cross-referenced with an in-house database of exome-sequenced samples and variants
present in any of these exomes. The families display distinct phenotypes, and we
considered it unlikely that causal variants would be common to more than one family.
We therefore excluded variants present in more than one of the three families as likely to
reflect local population variation or artefacts from the sequencing batch. Finally, where
multiple members of a pedigree were sequenced, a variant was required to be observed
in all affected and be absent in all unaffected members in segregation analysis. 10
families were analysed in total, three syndromic (Figure 8.1) and seven non-syndromic
(Figure 8.2), with a total of 15 individuals sequenced.
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Figure 8.1: Pedigrees of families effected with syndromic CLP. Family SCLP1 is not shown as the proband has no relevant family history; the proband has
history of swallowing disorder due to retrognathia; bilateral dacryostenosis; micrognathia; atresia of the right external auditory canal; agenesis of 1st finger
(bilateral); normal external genitalia.
Phenotypes for affected members of SCLP2 (a): II5, II6, II7 facial clefting, cause of death uncertain; II10 (half-uncle of proband) facial clefting, syndactyly,
proximal thumbs, brachydactyly (exome sequenced) ; III2, III3, III4, II5 (males) postnatal death at 8–15 days and facial clefting; III6 (female) postnatal death
at 8 days and cleft lip and palate; IV1 prenatal death and facial clefting; III10 (proband, exome sequenced), unilateral (left side) cleft lip and palate, clubbing,
nail hyperpigmentation, cutaneous syndactyly.
Phenotypes of affected members of SCLP3 (b): II5 and III1 unilateral cleft lip and palate; III2 bilateral cleft lip and palate (exome sequenced); II9 cleft palate
(exome sequenced); III4 (proband, exome sequenced) cleft palate, micrognathia.
Exome sequenced individuals are indicated with a ‘+’
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Figure 8.2: Pedigrees of families effected with non-syndromic CLP. All individuals have an
isolated CLP phenotype. In family NSCLP3 the mother has submucous cleft palate and the
child has global developmental delay, suggesting the possibility of an undiagnosed syndromic
condition; the presentation is however not recognisable as a known CLP syndrome, and thus
these comorbidities may be incidental.
Exome sequenced individuals are indicated with a ‘+’
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8.3 Results
8.3.1 Syndromic CLP
WES data of a good quality was returned, with > 50 X coverage for all samples
(Table B.3). Table 8.1 lists 35 variants which met the filtering criteria across the six
exome-sequenced individuals, of which 30 are nonsynonymous SNPs, 3 are splicing
variants and there are single stop gain and frameshift insertions. Analysis on each
family suggests causal variation in each case, as described below.
8.3.1.1 Family SCLP1
The proband was diagnosed as a potential Nager syndrome patient. Nager syndrome
is extremely rare, and fewer than 100 cases have been reported[213–215]. Nager syndrome
belongs to a group of conditions displaying acrofacial dysostosis, characterized by
association between craniofacial and limb malformations[213]. The patient phenotype
(Figure 8.1) shows features associated with this condition including micrognathia,
auditory canal defects and malformed fingers. The patient represents a sporadic isolated
case with no known cases among relatives.
Exome sequencing of the proband identified novel heterozygous NS variants in the
IFT172 (rank 4, Table 8.1), ERCC2 (rank 7) and PROKR2 genes (rank 10). More
significantly, sequencing also identified the known c.1060 1061insC:p.R354fs frameshift
mutation in exon 5 of the SF3B4 gene. This variant was confirmed as present by
Sanger sequencing. Exome sequencing has previously established mutations in the
SF3B4 gene (splicing factor 3B, subunit 4) as responsible for autosomal dominant Nager
syndrome[213]. SF3B4 encodes a highly conserved protein involved in mRNA splicing
and bone morphogenic protein (BMP) signalling. The latter presumably contributes
largely to the skeletal phenotype in this syndrome. However, SF3B4 testing is negative
in approximately one-third of Nager cases, for example, in 16 of 41 individuals[213]; 5
of 14 families tested[214] and 5 of 12 families[215]. Most patients who are negative for
SF3B4 mutations are phenotypically identical, indicating genetic heterogeneity.
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Table 8.1: Deleterious variants in syndromic CLP cases
SCLP: 1 2 3
Gene Nucleotide Protein AF SIFT PP-2 LRT MT GS PhyloP GERP CADD Logit Rank 1 III10 II10 III2 II9 III4
SF3B4 1060 1061insC R354fs . . . . . . . . . . . 
TFR2 1483-7A>C . . . . . . . . . . . . 
TNNT3 82+7C>T . 0.001 . . . . . . . . . . 
COG1 743-10C>G . 0.001 . . . . . . . . . . 
IFT140 G2569A G857S . 0.07 0.995 0 1 56 7.661 5.22 34 0.275 1 
RPGRIP1L G724T E242X . 0.14 . 0 1 . 4.463 5.87 36 0.164 2  
IRF6 G604A V202I . . 0.916 0 1 29 7.311 6.17 27.1 0.119 3   
IFT172 G3604T V1202L . . . . 1 32 4.362 5.7 28.3 0.148 4 
IDUA T965A V322E 0.002 0 0.999 0 1 121 5.962 5.15 23.3 0.151 5 
SH3PXD2B C2288T P763L . . 0.997 0 1 98 7.565 5.29 19.54 0.116 6 
ERCC2 A1900G K634E . 0 0.925 0 1 56 5.182 5.13 28.3 0.123 7 
IKBKG G169A E57K . 0.16 0.997 0 0.99 56 5.105 5.6 21.9 0.094 8 
NKX3-2 G493C D165H . 0.17 0.419 0.022 1 81 3.045 5.31 21.4 0.212 9  
PROKR2 C719T T240I . 0.23 0.841 0 1 89 5.246 5.16 23.1 0.096 10 
COL1A2 C3226T P1076S . 0.02 0.063 0 1 74 3.858 5.32 16.87 0.147 11 
PGM1 C143T A48V . 0.13 0.025 0 1 64 7.651 5.13 19.05 0.072 12 
PKLR C92T A31V . 0.03 0.935 0 0.74 64 1.654 4.74 26.1 0.962 13  
NOTCH2 T7223A L2408H 0.001 0 0.969 0.006 0.74 99 2.431 5.35 15.05 0.1 14 
SEC23A A2116G I706V . 0.55 0.042 0 1 29 5.022 5.75 12.73 0.043 15 
GRIN2A A662G K221R 0.001 . 0.027 0 1 26 6.107 5.09 12.59 0.057 16 
TUBB2B C743T A248V . 0 0.082 1 64 9.506 4.18 7.09 0.098 17 
ECEL1 A1516G M506V . 0.01 0.76 0 1 21 3.251 5.36 14.54 0.048 18 
SRCAP A3859G T1287A . 0.47 0.091 . 1 58 2.494 5.17 8.04 0.062 19 
IFT122 C496T R166W 0.001 0.02 0.88 0.001 1 101 3.254 4.8 15.93 0.041 20 
UBE3B C136T R46W . 0 1 0 1 101 1.832 4.43 16.02 0.05 21 
ABCA3 G3052A G1018S 0.001 0.45 0.064 0 1 56 2.165 4.65 12.09 0.062 22 
ABCC6 C1963A Q655K . 1 0.004 0.061 1 53 3.499 4.97 4.84 0.017 23 
MCPH1 A775C K259Q . 0.43 0.506 0.164 1 53 -1.592 -1.78 18.37 0.053 24 
KMT2A G10327A A3443T . 0.23 0.001 0.016 1 58 3.393 1.73 8.28 0.04 25 
TRPS1 C2000T S667L . 0.01 0.024 0.418 1 145 1.658 4.9 7.06 0.044 26 
PALB2 G265C D89H . 0.04 0.063 0.084 1 81 0.699 0.034 7.76 0.066 27 
COL6A2 G316A E106K 0.002 0.3 0.437 0.088 0.99 56 1.335 4.34 12.22 0.04 28 
SZT2 G9611A R3204Q 0.003 0.57 0.001 0.002 1 43 2.405 3.49 7.06 0.014 29 
GJB6 A476G N159S 0.002 0.76 0.038 0.007 0.91 46 1.71 3.95 6.08 0.015 30 
MCPH1 T1273A Y425N . 0.75 0.001 0.096 1 143 0.073 -1.86 5.58 0.006 31 
AF - AF in 1000 Genomes Project; PP-2 - PolyPhen-2; MT - MutationTaster; GS - Grantham score. Rank is based on sum of ranks for variants with PhyloP, GERP++, CADD and Logit
scores and range from (predicted) most to least deleterious.  indicates a heterozygous variant.
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The variant identified in this patient corresponds to the same frameshift mutation
identified as de novo in family ‘I’ by Bernier et al.[213] and Petit et al.[214] in their ‘case
13’. The identification of the same mutation in three independent studies suggests that
this may be one of the more frequent mutations in Nager syndrome; however, causal
mutations have been identified in all six exons of the gene. Phenotypic differences
between patients with and without SF3B4 mutations are poorly defined. Czeschik et
al.[215] noted that a cleft palate occurs more frequently in SF3B4 mutation-positive
patients (86% vs. 20%). Larger patient cohorts will be required to better establish the
phenotype–genotype relationships.
8.3.1.2 Family SCLP2
The female proband presented with bilateral CLP together with a catalogue of other
syndromic features (Figure 8.1), including abnormal nail pigmentation and cutaneous
syndactyly. The family pedigree suggests an X-linked disorder associated with lethality
at a post-natal stage in males, but also in one female. Interestingly, the half-uncle
of the proband (II10) shows some shared phenotypic features, including syndactyly.
Incontinentia pigmenti (IP) was the clinical diagnosis for the proband, but this is usually
lethal prenatally in males[17,255,256], whereas in this family affected males are known
to have survived for 8–15 days. Facial clefting is a feature of the family phenotype,
although a case of IP associated with bilateral CLP was described as ‘unique’[255].
Familial IP is a rare condition arising approximately in 1 of 50,000 newborns[255], and
the most conspicuous phenotypic feature is a progressive skin pigmentation abnormality
resulting in linear or hypopigmented patches. However, the phenotypic expression is
highly variable. Hadj-Rabia et al.[257] studied the phenotypes of 40 IP cases of which 7
had been misdiagnosed because of similarity to other pigmentation disorders. IP is an
X-linked dominant disorder that causes skewed X-inactivation in female patients but
affected male IP conceptuses typically fail to survive the second trimester.
Exome sequencing of the proband (III10) reveals 15 rare and novel variants in different
genes that include IFT140 (combined score rank 1), RPGRIP1L (rank 2), IDUA (rank
5) and IKBKG (rank 8). Both variants in IFT140 and IDUA are known in dbSNP
and have not previously been linked to clinical phenotypes. The second ranked variant
is a heterozygous stop gain in the RPGRIP1L gene on chromosome 16. This variant
is classed as damaging by most predictive metrics, including a very high GERP++
score of 5.87 suggesting a highly deleterious variant. Homozygous and compound
heterozygous mutations in RPGRIP1L are associated with Joubert syndrome and
Meckel syndrome[258]. However, there is no evidence thus far that heterozygous variants
in this gene are pathogenic and the patient’s phenotype does not overlap characteristic
features of these syndromes. However, the patient also carries the E57K missense
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mutation in exon 2 of the IKBKG gene on chromosome X. Smahi et al.[259] showed that
cells of IP patients lack NF-κB function due to mutations in the IKBKG gene (NF-κB
essential modulator).
Aradhya et al.[255] identified 277 patients with IKBKG mutations from a sample of
357 unrelated patients. A total of 248 of the 277 patients (90%) exhibited an identical
deletion that eliminates exons 4–10. Their study also revealed that 29 of 357 patients
had smaller mutations including microdeletions, substitutions and duplications. The
E57K mutation found here is a substitution also reported by Aradhya et al. as only
one of the two (of 29) small mutations that changed the amino acid identity. They
also identified IKBKG polymorphisms in unaffected members of IP pedigrees but
all were in untranslated or intronic regions suggesting that an undisrupted IKBKG
sequence is usually essential for normal function. Conte et al.[260] point out that IP
is most frequently a sporadic condition with 65% of IKBKG mutations occurring de
novo. However, the missense mutation identified here was also reported in a familial
case by Aradhya et al.[255], Conte et al. consider genotype and phenotype correlations
in IP and recognize that the clinical phenotype is highly variable, and there is an
expectation that some missense mutations might only slightly affect IKBKG function.
The missense p.E57K mutation we have identified here is described as presenting a
‘milder’ IP phenotype[255,260], although Aradhya et al. indicate there is no evidence that
it is compatible with male survival.
The family presented here establishes that this missense mutation is compatible
with male survival but only just beyond full term whereas the majority of IKBKG
mutations do not permit survival beyond the second trimester. The pedigree also
features a phenotypically normal transmitting mother (II3) and a female post-natal
death at 8 days (III6). Differences in X-inactivation are known to produce variation
in the degree of clinical expression and this variability may explain the diversity of
female phenotypes in this pedigree. We exome-sequenced the half-uncle of the proband
(II10), who also shows a facial clefting and a syndactyly phenotype. As expected, he
does not carry the IKBKG mutation that is associated with male death. Assuming the
shared syndactyly features have a common genetic basis, the heterozygous stop gain in
the RPGRIP1L gene (shared by both individuals) is a possible cause. However, this is
speculative in the absence of evidence for clinical phenotypes arising from heterozygous
mutations in this gene and functional assays may be required to establish causality.
8.3.1.3 Family SCLP3
The family (Figure 8.1) shows a complex pattern with very variable penetrance
(including unaffected presumed transmitting relatives) with unilateral and bilateral CLP
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and cleft palate. Unlike other members of the pedigree the proband shows micrognathia
and, as a result, needed ventilator support in the ICU at birth and was treated with
oral surgery (mandibuloplasty). Pierre Robin syndrome (PRS) was diagnosed based
on paediatric clinical history of respiratory failure as a consequence of micrognathia.
Physical examination did not reveal congenital heart abnormalities or developmental
delay to suggest 22q11 deletion. PRS is characterized by cleft palate and micrognathia
resulting in glossoptosis arising when the tongue obstructs the airway causing feeding
and respiratory problems in the early post-natal period[261]. It represents a causally
heterogeneous series of events (micrognathia causing glossoptosis preventing palatal
shelves to fuse) and is often referred to as the PRS. Tan et al.[262] describe the highly
heterogeneous nature of genetic factors that underlie the PRS phenotype. Mutations in
the SOX9 gene are known to explain a proportion of PRS cases but a number of other
genes have been implicated[262].
Exome analysis (Table 8.1) identifies a novel p.V202I missense mutation in the IRF6
gene (c.G604A) in exon 5 shared by all three affected relatives tested. This variant is
damaging by most predictive metrics (including the highest GERP++ score of 6.17)
and has the third highest rank in the table for the combined scores. IRF6 mutations
underlie Van de Woude syndrome (VWS) and 80% of the causal mutations are found in
exons 3, 4, 7 and 9, whereas mutations underlying popliteal pteringeum syndrome are
more frequent in exon 4[247]. Wu-Chou et al.[263] found exon 5 mutations in 2 of 13 VWS
cases. However, the SCLP3 family exhibits variable PRS features and lacks lip pits that
are characteristic of VWS. Nikopensius et al.[264] were able to show that mutations in
IRF6 also underlie susceptibility to some nonsyndromic CLP cases, so mutations in this
gene are associated with considerable phenotypic heterogeneity. Vieira[265] describes
positive associations of clefting with hypodontia with IRF6, although the role of this
gene in PRS has not been previously described. Sanger sequencing confirmed carrier
status for unaffected (transmitting) relatives II14 and III1.
8.3.2 Non-syndromic CLP
Table 8.3 lists 28 novel missense variants, each of which segregates within an individual
family and is classed as deleterious by at least one predictive score, with Table 8.2
showing likely protein truncating and indel variants in the families. Table entries are
ordered using combined ranks from most to least deleterious by predictive score. Four
of the genes listed (WNT7A, MSX1, CLPTM1 and EVC2, ranked 9, 10, 11 and 23
respectively) have previously been identified as containing variants implicated in NSCLP
phenotypes. Family NSCLP1 has the 9th ranked variant in the WNT7A gene. Members
of the WNT gene family have previously been associated with NSCLP phenotypes[266].
Specifically, a number of WNT signalling pathway genes including WNT3A, WNT5A,
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WNT9B, and WNT11 have been established as candidates[266] and mouse expression
studies have shown roles for WNT genes in mid-facial formation and lip and palate
development[267]. Chiquet et al.[266] tested 38 SNPs in seven WNT family genes within
a large NSCLP cohort. Nominally significant associations within WNT7A were found
but the strongest association were in WNT3A, WNT5A and WNT11.
Table 8.2: Novel protein truncating and indel variants in non-syndromic CLP cases
NSCLP:
Gene Nucleotide Protein ΔMaxEnt 1 2 3 4 5 6 7
DLG1 923 925del 308 309del . 
FRAS1 G7354T E2452X . 
WDR11 2660 2662del 887 888del . 
IGF1R 3940 3941insCGTCCTCCC L1314delinsPSSL . 
FBLN1 485-5C>- 22.14 
The 10th ranked variant, found in family NSCLP4, is in the MSX1 gene, and
considered damaging by SIFT, PolyPhen-2 and MutationTaster, and has high GERP++
and CADD scores. Variants in this gene have been strongly implicated in NSCLP in
several studies. Jezewski et al.[268] found mutations in 2% of cases and indicated that
this has genetic counselling implications where autosomal dominant inheritance patterns
are found. Exon 2 of MSX1, in which the p.P260T is located, has been found to be
highly conserved with significantly fewer sequence variants compared with exon 1[268].
Functional validation of MSX1 as a candidate is established through a cleft palate and
foreshortened maxilla phenotype in knockout mice[269]. A number of association studies
have also indicated involvement of MSX1 in NSCLP.
In a study of 94 patients and 93 controls from Operation Smile, Colombia, four MSX1
microsatellite alleles were analysed and a positive disease association was observed
with CA polymorphisms in the gene[270]. An autosomal dominant MSX1 mutation in
a family with clefting and tooth agenesis indicates a familial pattern of segregating
MSX1 mutations. Jezewski et al.[268] sequenced the MSX1 gene in 917 individuals with
NSCLP and found potentially aetiological variation in 16 individuals including coding
and non-coding variants. Diverse evidence establishes that MSX1 promotes growth
and inhibits differentiation. Mutations in MSX1 can cause primary or secondary facial
clefting within mouse models[269].
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Table 8.3: Novel deleterious non-synonymous variants in non-syndromic CLP cases
NSCLP:
Gene Nucleotide Protein SIFT PP-2 MT GS PhyloP GERP CADD Logit Rank 1 2 3 4 5 6 7
WDR35 C2161T R721C 0 0.92 1 180 9.81 5.04 27.7 0.13 1 
PTHLH G71A G24E 0 1 0.99 98 5.75 5.13 32 0.39 2 
GPC6 T599A F200Y 0 0.98 0.95 22 7.65 5.48 31 0.06 3 
INPPL1 G349A V117I 0 0.95 0.04 29 8.18 3.9 22.8 0.11 4 
MYH3 G3869A R1290H 0 0.1 0.94 29 4.95 4.84 21.3 0.13 5 
AHDC1 C1996G R666G 0 1 0.06 125 8.73 5.08 22.8 0.04 6 
ABCA12 C254T T85I 0.99 0.73 0 89 4.18 5.3 15.26 0.1 7 
DEAF1 C1532G A511G 0 0.59 1 60 9.01 3.03 17.71 0.08 8 
WNT7A G1019A S340N 0 0.94 0.99 46 6.07 4.11 23.6 0.06 9 
MSX1 C778A P260T 0 0.61 0.99 38 5.96 4.76 27.6 0.04 10 
CLPTM1 A1058G N353S 0.04 0.6 0.99 46 6.6 3.01 17.19 0.09 11 
IGF1R C4030G Q1344E 0 0.01 0.99 29 4.78 5.24 13.05 0.04 12 
CFDP1 A535T T179S 0 0.02 0.99 58 2.66 5.54 15.68 0.04 13 
NBAS G784A G262S 0.01 0.09 0.86 56 4.26 4.15 13.81 0.07 14 
COL17A1 T3434C I1145T 0 0.15 0.31 89 5.46 4.39 12.18 0.06 15 
CDON A860G N287S 0 0.34 0.64 46 3.1 5.01 15.32 0.04 16 
SNAP29 A427G N143D 0.02 0.34 0.17 23 8.77 3.7 11.41 0.04 17 
NOTCH2 G1465T V489L 0 0.08 0.34 32 0.87 5.38 12.51 0.05 18 
MASP1 G2087A G696E 0.05 0.09 0.37 98 1.65 3.75 14.53 0.06 19 
FREM2 A2512G T838A 0 0 1 58 2.49 4.44 7.38 0.07 20 
SPRY4 C856T R286C 0 0.88 0.97 180 2.44 4.7 13.49 0.04 21 
ZBTB24 A367G K123E 0 0.05 0.32 56 1.52 4.16 14.67 0.03 22 
EVC2 G2536A E846K 0.1 0.67 0.27 56 1.14 2.85 16.13 0.03 23 
SCN2A T2204C M735T 0.04 0 0.06 81 0.47 2.35 2.95 0.04 24 
RYR1 G5459T R1820L 0.04 0.01 0.71 102 0.93 1.71 8.87 0.03 25 
WT1 C137T A46V 0.02 0 0 64 0.33 0.81 12.21 0.02 26 
INPPL1 T3563G L1188R 0.1 . 0.01 102 0.44 1.47 10.2 0.01 27 
COL6A2 G2470A V824M 0 . 1 21 . 3.62 . . - 
PP-2 - PolyPhen-2; MT - MutationTaster; GS - Grantham score. Rank is based on sum of ranks for variants with PhyloP, GERP++, CADD and Logit scores and range from (predicted)
most to least deleterious.  indicates a heterozygous variant.
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The 11th ranked variant (from family NSCLP1) is in the CLPTM1 gene (Cleft lip-and
palate-associated transmembrane protein-1) which is situated at 19q13.3. A balanced
translocation is this region was found in a multi-case CLP family[271] and this region
is implicated in NSCLP by linkage at linkage and transmission disequilibrium test
association studies[272]. However a de novo deletion of 0.8 Mb in this region associated
with CLP, but not encompassing CLPTM1, has been reported[273]. As Kohli & Kohli[274]
indicate the role of CLPTM1 or other genes in this locus is uncertain and there is a
need for further studies to elucidate the precise role of this region in NSCLP.
The 23rd ranked variant is in the EVC2 gene (family NSCLP2) and belongs to the
same two megabase chromosomal region as MSX1 (4p16). Ingersoll et al.[275] found
linkage and association signals in genes in this region by examining CLP cases and
trios from a number of populations. They found suggestive evidence for linkage and
association amongst cleft palate trios to EVC2. Mutations in EVC2 can lead to Ellis-
Van Creveld syndrome or Weyers acrofacial dysostosis[276]. The former is autosomal
recessive and not usually associated with oral clefts but cases with ‘partial hare-lip’,
and tooth anomalies have been reported[275].
8.4 Discussion
Linkage, candidate gene association and GWAS have been applied to investigate
numerous multifactorial diseases, including NSCLP. As a result of these studies more
than 11 genes and gene regions are now known or likely to have a role in NSCLP[46,247].
However, there is increasing evidence that NSCLP is a heterogeneous condition com-
prising a substantial multifactorial component but also a much smaller proportion of
cases showing more Mendelian patterns of inheritance. The Gajdos et al.[277] segrega-
tion analysis indicated that the complex familial patterns observed in NSCLP is best
explained as a mixture of monogenic cases, probably dominantly inherited, combined
with others which have a multifactorial aetiology. The conclusions favour analyses of
multiple-case pedigrees to reduce heterogeneity and help identify Mendelian sub-forms.
We have investigated 10 families, prioritising those with an extensive family history. In
all three syndromic families, a monogenic cause of the disease was identified, consistent
with their previous clinical diagnosis. Furthermore, in the seven non-syndromic families,
we have identified novel, deleterious variants, in genes previously associated with CLP.
It is possible that some of these variants have contributed to the high-penetrance
non-syndromic CLP in these families; it is however impossible to confirm the precise
role of these variants without functional evidence. In the case of the MSX1 :p.P260T
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variant however, the extensive evidence regarding the high penetrance pathogenicity of
this gene makes it highly likely that this is aetiological in NSCLP4.
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Chapter 9
Diagnostic Utility of Targeted Gene
Panels in Kidney Disease
9.1 Background
9.1.1 Gene panels
Targeted gene panels are an option for clinical diagnostics, providing a middle ground
between traditional Sanger-based single gene sequencing and WES/WGS approaches.
These more focused gene panels allow for the reduction in the required sequencing,
facilitating the use of lower throughput sequencers, such as the Illumina MiSeq, as well
as reducing the data analysis burden. However, sequencing only the a priori candidate
genes for a patient limits options for the extension of the interrogation if required for
the patient, possibly requiring further sequencing[278].
There is an increased availability of NGS based gene panels for clinical use. According
to the UK Genetic Testing Network (UKGTN), there are 25 NGS gene panels currently
approved for NHS testing (sequencing an average of 26 genes), with a further 60 panels
recommended for approval as of April 2015[279]. Each panel is required to undergo a
rigorous validation process prior to UKGTN approval. Due to this, alternatives such as
clinical exomes, including ∼5,000 clinically relevant genes, provide an umbrella panel,
which may streamline the laboratory and validation workflow.
In this chapter I will describe the use of a custom NGS gene panel for focal segmental
glomerulosclerosis (FSGS). This panel was designed based upon extensive curation of
the literature and medical genetic databases and evaluated for its clinical utility when
applied to heterogeneous, representative patient cohorts.
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9.1.2 Focal segmental glomerulosclerosis
FSGS is a clinico-pathological diagnosis, which encompasses a spectrum of underlying
disorders. Clinically, FSGS (as well as the similar diagnosis of steroid resistant nephrotic
syndrome (SRNS)) presents with protein in the urine, and often progressive renal
impairment, with characteristic eponymous findings on biopsy (Figure 9.1). The
aetiology of FSGS often remains unknown, and these cases are classed as primary.
There are several forms of secondary FSGS due to various causes, such as obesity,
diabetes mellitus and hypertension with similar biopsy findings. A number of genes are
also implicated in cases of hereditary FSGS. FSGS accounts for approximately 40% of
nephrotic syndrome in adults in the U.S.[280].
(a) Healthy (b) FSGS
Figure 9.1: Comparison of healthy and sclerotic glomeruli. The glomeruli are the point of
filtration of the kidneys. In FSGS, the glomeruli are scarred, reducing filtration capacity. Tissue
is stained with periodic acid-Schiff stain, staining the basement membrane. The sclerosis is
apparent in the bottom right setion of the glomerulus shown in b. Images used under Creative
Commons Attribution licences, provided by Ed Uthman and Wikipedia user ‘Nephron’ for images
a and b respectively.
Given the non-specific findings in FSGS, the diagnosis is sometimes given in error to
other renal diseases presenting in a similar way. For instance, Gibson et al.[281] applied
exome sequencing in a family diagnosed with FSGS, identifying a collagen variant (in
COL4A5 ), changing the diagnosis to Alport disease (AD). AD has addition features
such as hearing loss, as well as differing prognostic implications[281]. Following this case,
it was decided to investigate the distribution of pathogenic variants in a large cohort of
adults with a clinical diagnosis of FSGS.
9.2 Methods
83 patients with primary FSGS or SRNS registered with the Wessex Kidney Centre
(catchment population two million) were recruited, after prioritizing those within the
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registry with a family history (FHx) of renal disease. Clinical data were recorded from
patient interviews and clinical records.
A gene panel containing 39 genes was designed on the Illumina TruSeq Custom
Amplicon (TSCA) platform using the vendor DesignStudio software for an amplicon
length of 250. Gene coverage was optimized by the manual adjustment of thresholds in
problematic regions, as well as division of the panel into two kits to avoid unfavourable
amplicon–amplicon interactions. The genes for inclusion on the panel (Table 9.1) were
chosen based on a comprehensive literature review and information from the Human
Gene Mutation Database (HGMD) Professional 2013.1 and 2013.3[229]. 22 additional
SNPs were targeted to cover all 24 SNPs in the exome sample tracking panel[184] as
two SNPs in COL4A4 and NPHS2 were already targeted. The final designed panel
comprised two TSCA kits of 1,093 and 381 amplicons covering 137.2 and 45.9 kb
respectively.
Sample processing was performed similarly to as described in Chapter 7 except where
noted. gDNA was captured using the TSCA kits independently and pooled prior to
sequencing on two lanes of the Illumina MiSeq, with a read length of 150 bp paired
end. Per-base coverage of genes was calculated using BEDTools[195] and collated using
custom scripts. All variants deemed potentially pathogenic with a read depth of < 80
were validated by Sanger sequencing. Putative splice variants within 10 bp of the
intron–exon boundary were evaluated using MaxEntScan [211]; variants with a differential
score of | ≥ 3| were deemed to be likely to disrupt splicing.
Recommendations by the American College of Medical Genetics (ACMG)[282] were
followed to allocate variants into the categories ‘definitely pathogenic’, ‘probably patho-
genic’, and ‘possibly pathogenic’. Definitely pathogenic variants were listed in HGMD,
consistent with the phenotype, and individually assessed to establish the strength of
evidence for pathogenicity in the literature. Probably pathogenic variants included
novel splice site, frame shift and nonsense variants, and variants listed as disease-causing
in HGMD with insufficient or conflicting evidence in the literature to determine their
definite pathogencity. Possibly pathogenic variants consisted of nonsynonymous variants
with an AF < 0.05. Variant zygosity had to match its known pattern of inheritance,
and be present in all affected relatives in the panel to be considered disease-causing.
Clinico-pathological parameters were compared between patients with pathogenic
collagen variants and the remaining cohort. Statistical significance was determined by
the χ2, Fisher’s exact test, or Mann-Whitney U test as appropriate, using SPSS v21
(IBM, Armonk, NY).
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9.3 Results
82 patients with FSGS and one with SRNS were recruited into the study, with a
median age at presentation of 37 (range 0–84); 61% male; all but 12 patients presented
in adulthood. 75% of the cohort had progressed to end-stage renal disease, requiring
renal replacement therapies (RRT) such as dialysis and transplantation. The cohort
included nine individuals from within the region belonging to four families. To the best
of our knowledge, the remaining individuals were unrelated, resulting in 76 independent
families. All but two patients were Caucasian (one Black African and one Asian).
The diagnosis of FSGS was based on eponymous biopsy findings in combination with
proteinuria; except in five patients, where no biopsies were taken, and two patients with
minimal change disease on biopsy. Their diagnosis of FSGS was supported by biopsies
in similarly affected relatives and/or the clinical picture. A diagnosis of ‘familial FSGS’,
requiring the diagnosis of FSGS in at least one relative, was established in 12 individuals
from eight families.
98.9% of the coding region was targeted successfully across 39 genes (Table 9.1).
Following sequencing and alignment, > 94% of the targeted region was covered to a
depth of at least 10X, with a mean depth of > 300X (Table 9.1).
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Table 9.1: Genes included in panel design and proportion successfully targeted
% covered to median depth
Gene Chr Exons Size (bp) % Targeted 20X 30X 50X 100X
ACSL4 X 15 2364 99.6 93.1 93.1 78.7 68.8
ACTN4 19 21 2736 99.5 91.5 86.4 72.2 48.3
ALG1 16 13 1395 91.2 98.2 97.8 95.5 94.7
APOE 19 3 954 99.9 96.4 96.4 87.9 77.8
APOL1 22 7 1289 99.8 67.0 66.7 66.7 48.5
ARHGAP24 4 12 2478 99.2 99.5 98.2 91.4 71.8
ARHGDIA 17 6 683 100.0 100.0 100.0 100.0 95.9
CD2AP 6 18 1920 99.2 92.4 92.4 92.2 58.2
CFH 1 23 3710 94.1 96.2 95.8 88.4 68.1
COL4A3 2 52 5013 99.1 98.5 95.6 93.9 90.0
COL4A4 2 47 5073 99.1 98.4 97.2 82.5 56.2
COL4A5 X 53 5383 99.2 83.4 74.1 64.6 34.4
COQ2 4 7 1266 99.5 100.0 99.2 90.8 68.2
COQ6 14 13 1495 99.5 99.7 94.9 90.0 80.3
INF2 14 23 3817 99.7 87.4 87.4 86.8 78.3
ITGB4 17 40 5628 99.6 97.0 97.0 95.0 92.0
LAMA5 20 80 11088 99.8 87.6 82.4 70.9 44.4
LAMB2 3 32 5397 99.9 99.0 99.0 95.8 81.6
LMNA 1 18 2452 91.4 94.6 94.6 94.6 94.6
LMX1B 9 10 1453 99.8 71.9 71.9 66.7 53.5
MYH9 22 40 5883 99.5 95.9 93.6 85.3 64.6
MYO1E 15 28 3327 99.2 98.2 95.9 90.9 66.2
NEIL1 15 11 1865 87.1 76.5 73.1 73.1 64.1
NPHP4 1 31 4505 99.4 92.0 86.9 77.9 53.9
NPHS1 19 29 3726 99.7 98.8 98.8 98.2 92.5
NPHS2 1 8 1152 99.5 84.5 80.4 80.4 73.9
NXF5 X 14 1098 99.5 83.9 83.5 75.2 64.6
PDSS2 6 8 1200 99.4 97.5 97.5 94.0 80.2
PLCE1 10 33 7300 99.6 97.6 97.6 97.1 86.0
PMM2 16 8 741 99.2 83.7 81.2 74.8 65.0
PODXL 7 9 1677 94.0 98.6 98.6 98.6 87.9
PTPRO 12 27 3655 99.3 100.0 100.0 93.1 79.6
SCARB2 4 12 1437 99.2 100.0 100.0 98.5 84.4
SMARCAL1 2 16 2865 99.5 99.6 99.2 94.8 86.2
SYNPO 5 5 7560 100.0 94.6 94.6 94.3 84.6
TRPC6 11 13 2796 99.6 97.2 95.6 95.6 86.1
WT1 11 12 1648 99.5 71.1 68.1 55.9 49.8
ZEB1 10 11 3445 99.8 98.3 96.7 93.1 87.8
ZMPSTE24 1 10 1428 99.4 100.0 100.0 100.0 85.6
562 on-target variants across the 39 genes were identified in the 83 patients. After
filtering for functional effects and AF, 266 variants remained (Figure 9.2). 17 definitely
pathogenic variants, five probably pathogenic variants, and 242 possibly pathogenic
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variants were identified. The participant-centric Table 9.2 shows only those definitely
or probably pathogenic variants which occurred in the zygosity reported to be disease-
causing.
19 
Total number of on-target variants 
n=562
199 synonymous variants removed 
unlikely to have functional consequences
n=363
51 common population polymorphisms removed 
>5% in NGS databases (1KG and ESP)*
n=312
29 common local population 
polymorphisms removed        
n>10 in Soton non-disease database** 
n=283 
17 variants removed 
to exclude batch effects 
>5% MAF in cohort# 
n=266
Definitely Pathogenic
• 17 Variants
Probably Pathogenic
• 5 Variants
Possibly Pathogenic
• 242 Variants
Figure 9.2: Variant attrition throughout filtering in FSGS cohort. *The 1000 Genomes Project
(1KG) and Exome Server Project (ESP) are large genomic databases including populations with
European ancestry. Variants with AF of > 5% in these databases were excluded from further
study as they are likely to be common population polymorphisms with no significant functional
consequences. **Variants found to be common in our own genetic non-disease database of
unrelated whole-exome sequenced individuals (n = 292). #Variants with AF in the cohort of
> 5% were excluded as they were likely to represent common local population polymorphisms or
batch effects (artefacts).
Definitely pathogenic variants were found in 14 patients from 12 of the 78 families
(Table 9.2). In order to establish diagnostic rates for a pure adult FSGS/SRNS cohort,
we excluded a family with previously suspected AD, and patients with nail patella
syndrome and congenital nephrotic syndrome from the statistics, leaving 75 families.
Thus we achieved molecular diagnoses in 12% of families and 13% of the case series.
Definitely and probably pathogenic variants combined were identified in 16 patients
from 15 families, giving a diagnostic rate of 20%. Diagnostic rates for patients with
and without FHx, and according to the age of disease onset are shown in Table 9.3.
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Table 9.2: Aetiological variants identified in FSGS cohort
Participant Path Chr Gene Variant(s) Inheritance Sex FHxc Clinical Diagnosis Age RRT Age enrolled
F1 mother def X COL4A5 p.G1170Sb X-linked F 2.5 FSGSd 39 64
F1 son def X COL4A5 p.G1170Sb X-linked M 2.5 FSGSd 35 45
F2 brothera def 2 COL4A3 p.[G818R;L1474P] Recessive M 1 likely ADd - 33
F2 sistera def 2 COL4A3 p.[G818R;L1474P] Recessive F 1 likely hereditary nephritisd - 42
I1 def X COL4A5 p.G325Rb X-linked M 3.75 FSGSd 36 49
I2a def 9 LMX1B p.W266C Dominant F 2.5 FSGS with NPSd 46 47
I3a def 1 NPHS2 p.[R138Q;R138Q] Recessive F 2 FSGSd 6 48
I4 def 2 COL4A4 p.S969X Recessive F 2 FSGSd - 43
I5 def X COL4A5 p.G1170S X-linked F 1.5 FSGS 64 66
I6 def 14 INF2 p.R218Q Dominant F 1 FSGSd - 36
I7 def 2 COL4A3 p.L1474P Recessive M 0 FSGSd 57 66
I8 def 1 NPHP4 p.[R1192Wb;R848W] Recessive M 0 FSGSd - 28
I9 def 6 CD2AP p.K301Mb Dominant F 0 FSGSd 30 34
I10 def 22 MYH9 p.M1651T Dominant M 0 FSGSd 60 66
I11 prob 20 LAMA5 p.G3685Rb Dominant M 0.5 FSGSd - 28
I12 prob 20 LAMA5 p.G3685R Dominant M 0 FSGSd 59 66
I13 prob 19 ACTN4 p.V801M Dominant F 0 FSGSd 30 47
I14 prob 11 WT1 c.1432+1G>C Dominant F 0 SRNS 16 44
I15 prob 14 INF2 c.1735+2T>G Dominant M 0 FSGSd 40 52
I16 prob X NXF5 c.860+2T>Cb X-linked F 0 FSGSd 67 67
aExcluded from statistics due to prior clinical diagnosis.
bConfirmed by Sanger sequencing.
cFHx score is defined as 2
∑
Φ for all relatives with a similar clinical diagnosis
dBiopsy proven.
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Table 9.3: Diagnostic rates in sub-cohorts
Definitely
pathogenic
Probably & definitely
pathogenic
Total (unrelated) 975 (12%)
15
75 (20%)
Total 1079 (13%)
16
79 (20%)
With FHx 523 (12%)
6
23 (26%)
Without FHx 552 (10%)
10
52 (19%)
Adult onset 669 (13%)
14
69 (20%)
Infantile onset 11 (100%)
1
1 (100%)
Childhood onset 13 (33%)
1
3 (33%)
Adolescent onset 07 (0%)
1
7 (14%)
9.3.1 Patients with collagen variants
Eight participants from six families with disease-causing COL4A variants were identi-
fied (Table 9.3), including one family with previously suspected AD (F2). Excluding
this family, collagen variants represented 56% of all definitely pathogenic variants in the
pure FSGS/SRNS cohort. The discovered COL4 variants confirmed the diagnosis of AD
in two patients (F2 brother and sister), changed it to AD in four (F1 mother and son, I1
and I5), and TBMN in two patients (I4 and I8). All participants had heavy proteinuria,
resulting in nephrotic syndrome in I1.There was no documented microscopic haematuria
in F1 mother, I1 (male) and I5 (female). Only one participant presented with hearing
loss (F2 brother). In two others, hearing loss developed post-transplantation and was
attributed to external factors.
Ophthalmic tests are only documented in I1 and were normal. Light microscopy
showed FSGS in all biopsied participants, with the exception of F2 sister (normal
light microscopy). As shown in table 6, F1 mother’s first EM was normal, the second
revealed glomerular basement membrane (GBM) lamellation possibly compatible with
AD, but she had no associated clinical features or FHx at the time. The EM in F1 son
was not diagnostic, but showed widespread podocyte foot process fusion, lamellation
and splitting of the GBM. Clinical testing for AD was arranged at the time, but not
completed. The two participants with single COL4A3 /4 variants (I4 and I8) had
microscopic haematuria (with a FHx in I4), nephrotic range proteinuria, and FSGS on
light microscopy. EM in I4 was normal.
9.3.2 Patients with non-collagen aetiological variants
Pathogenic variants in CD2AP and INF2 causing autosomal dominant disease were
found in patients I6, and I9; both had biopsy-proven FSGS. I2’s LMX1B variant causes
FSGS and congenital nail patella syndrome, matching her diagnosis. I3’s homozygous
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podocin (NPHS2 ) variant p.R138Q was responsible for FSGS in infanthood and the
death of two siblings from SRNS (parents unaffected). Compound heterozygosity for
two NPHP4 variants in I8 with sporadic biopsy-proven FSGS and nephrotic range
proteinuria changed his diagnosis to nephronophtisis. The MYH9 variant p.M1651T
in I10 with sporadic FSGS and intermittent macroscopic haematuria at presentation
causes May Hegglin anomaly, characterized by platelet anomalies with the possible
development of renal failure. No platelet abnormalities were noted in I10, but the
clinical picture was confused by recurrent bleeding on anticoagulants, requiring multiple
blood transfusions.
9.3.3 Patients with probably pathogenic variants
Probably pathogenic splice-site variants in INF2, NXF5 and WT1 were discovered in
three individuals (I14, I15 & I16), all with biopsy-proven FSGS. We took the conservative
approach of classifying the nonsynonymous variants in LAMA5 in I11 and I12, and
in ACTN4 in I13 as probably pathogenic, instead of pathogenic despite their listing
in HGMD, due to either conflicting or insufficient evidence in the literature regarding
their pathogenicity.
9.3.4 Variants in families
No reported pathogenic variants were identified in two of the four families on the
panel. F4 sisters 1 and 2 both have the novel LAMB2 variant p.D181N, which would
be expected to be recessive. No common variants were found for F3 father, daughter 1
and daughter 2. Apart from two pathogenic COL4A3 variants, F2 brother and sister
also share the ACTN4 variant p.R310Q and the APOL1 variant p.S324G.
9.3.5 Clinical characteristics associated with pathogenic vari-
ants
Clinical and histological features were analyzed for patients with pathogenic colla-
gen variants, compared to the remaining patients (Table 9.4). Differences in gender,
proteinuria, age at RRT, RRT requirement, renal transplantation, and biopsy findings
were not significant. COL4 variant patients were more likely to have FHx, haematuria,
GBM abnormalities, and younger age at presentation.
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Table 9.4: Clinical feature comparison between patients with identified variants
COL4A Non-COL4A No variant identified Significance level
Definitely pathogenic Probably pathogenic
n = 8 n = 6 n = 4 n = 57
Male Gender 4/8 4/6 1/4 39/57 p = 0.448
Age presentation 5–56, median 23 23–53, median 27 15–54, median 30 2–81, median 41 p = 0.029
Age at RRT 35–64, median 39 30–60, median 59 16–67, median 35 10–85, median 52.5 p = 0.744
Protein:creatinine ratio 300–900, median 500 53–1,352, median 329 212–2,000, median 434.5 13–2,740, median 730.5 p = 0.867
Nephrotic syndrome 1/8 2/6 1/4 29/57 p = 0.071
Haematuria 5/8 2/6 0/4 9/57 p = 0.009
Hearing deficit age < 40 2/8 1/6 0/4 1/57 p = 0.054
Biopsy shows FSGS 6/7 6/6 3/3 54/54 p = 0.1
GBM abnormalities 3/4 1/2 0/2 5/26 p = 0.041
ESRD 5/8 3/6 4/4 43/57 p = 0.433
Transplant 4/8 2/6 4/4 30/57 p = 1
Transplant recurrence 0/4 0/2 0/4 5/30 p = 1
FHx 7/8 2/6 0/4 17/57 p = 0.001
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9.4 Discussion
We designed a customized NGS panel for the investigation of FSGS/SRNS, which is
the first comprehensive FSGS gene panel in an adult cohort. Targeted panels have been
recognized as a promising approach in the investigation of FSGS[283]. We have shown
that this technique works well with excellent coverage of the targeted genes after manual
optimization, and a high diagnostic rate. We resolved 12–20% of all FSGS/SRNS cases.
This represents 22–26% of families with family history and 10–19% of those without.
We solved 13–20% of adult onset cases, which is higher than the previously reported
8–14%, and explained by our use of NGS allowing the testing of a comprehensive gene
panel.
Of strong clinical relevance is the frequency with which COL4 mutations were found
to underlie FSGS. Pathogenic COL4 mutations were discovered in five of nine families
(56%) with a definitely pathogenic gene mutation, and 7% of families in the cohort,
representing the highest prevalence of any mutation. They were found in 38% of families
with familial FSGS (3/8), and 3% of sporadic FSGS/SRNS (2/67). AD or TBMN had
only been suspected in one family (F2) not included in the statistics.
Our prevalence of COL4 mutations in familial FSGS is higher than the recently
reported 10–12.5%[284], which is likely explained by our inclusion of COL4A5, where
over half of our COL4 mutations occurred. This is more consistent with the mutation
distribution in AD[285]. Our cohort included more patients with sporadic than familial
FSGS, thus also giving an estimated prevalence of COL4 mutations in sporadic FSGS.
The simultaneous sequencing of 36 podocyte genes allowed us to rule out potential
modifier mutations in NPHS1 /2. The ACTN4 variant p.R310Q in F2 brother and sister
is thought to predispose to FSGS[286,287] and may have acted as a modifier. Theoretically
others could have been missed by less than complete coverage and the unknown effect
of novel variants.
We established six new diagnoses of AD in our FSGS cohort. AD can be difficult to
diagnose due to variations in diagnostic features, both clinical and histological[288,289].
Diagnostic criteria for AD have been published recently[290]. They rely on the presence
of (familial) haematuria with or without renal impairment, in combination with either
characteristic EM biopsy changes, or specified COL4 mutations—which established the
diagnosis in all patients in our cohort. FSGS has been found to be the most common
misdiagnosis in female patients with X-linked AD[289]. In these cases it can be difficult
to distinguish biopsy changes of AD mimicking FSGS from a development of FSGS.
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There is evidence that FSGS occurring in our patients with AD is more likely to
represent FSGS phenocopy than merely the late development of FSGS. The first biopsy
per family was taken 0–3 years after presentation when the excretory renal function was
still (near) normal. GBM thickness was largely within normal limits in all four, with
normal GBM appearance on F1 mother’s first biopsy and FSGS on light microscopy.
Relevantly, the clinical features of the patients with COL4 mutations were atypical for
AD. Three patients (one male, two female) with COL4A5 mutations had no documented
haematuria. The absence of haematuria is reported in 5% of females, but 0% of males
with X-linked AD[288]. It is possible that haematuria was present intermittently in male
I1, but missed at clinical sampling, with his clinical records being incomplete following
transfer from another unit. Hearing loss developed late in two of three males, and was
not present in any female. This is compatible with 90% of males and 10% of females
developing hearing loss before the age of 40[288]. The severe phenotype in F1 mother
and female I5 with progression to ESRD occurs in 15% of female carriers[288], and is
likely due to skewed X-inactivation[291].
Several pathogenic mutations were encountered in other patients in CD2AP, INF2,
LAMA5 and ACTN4 reported to cause autosomal dominant FSGS of adult onset.
We are only the second group to describe mutations in LAMA5 in FSGS[292], with
mouse models demonstrating LAMA5 ’s role in the formation and maintenance of the
glomerular filtration barrier[293]. The mutation p.G6358R found in two of our patients
was also identified by a previous targeted NGS panel[292]. Further work is needed to
confirm the exact role of LAMA5 in FSGS.
The discovery of two NPHP4 mutations changed the diagnosis of I6 from FSGS to
nephronophthisis, also known to be associated with biopsy findings of FSGS[294]. MYH9
mutations causing May Hegglin anomaly can present with features similar to AD, as
was the case in I8[295].
Assigning variants to the category “probably pathogenic” is fraught with difficulty[282].
The probably pathogenic splice-site mutations we identified in INF2, NXF5 and WT1
have a high ΔMaxEnt score, which indicates a high probability of disrupting canonical
splicing. One variant in female I12 occurred in the same position as a published splicing
change in WT1[296], known to cause isolated SRNS in females, and Frasier syndrome in
males[297]. Without extensive functional studies, we cannot prove if all altered splice
products are definitely pathogenic. The absence of a family history in some patients
with presumed dominant pathogenic mutations may be explained by de novo mutations,
incomplete penetrance, or a false negative family history.
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We have performed confirmatory Sanger sequencing for all pathogenic variants with
read depths below 80, confirming the accuracy of our NGS genotype calls, since targeted
NGS has been shown to be equally reliable as conventional sequencing for read depths
above 30[298]. Before any variants are reported back to participants, fresh blood samples
will be sent to an approved National Health Service (NHS) laboratory for confirmatory
sequencing to meet current diagnostic standards.
By comparing patient and biopsy characteristics between participants with and
without pathogenic or collagen mutations, we demonstrated that these features poorly
predict the underlying pathology. As could be expected, the presence of a positive
FHx and younger age at presentation make a genetic aetiology more likely. When
haematuria, hearing and GBM abnormalities are present, this can suggest an underlying
COL4 mutation. Our case histories confirm that EM can raise suspicion and guide
genetic testing, and should become routine practice in all cases of FSGS[299]. A normal
EM, however, should not give false reassurance as the typical changes have been found
in only approximately 60% of AD[300].
The discovery of gene defects can have significant benefits for patients and their
relatives, including genetic counseling, screening, avoiding unnecessary immunosuppres-
sion, and slowing the progression of renal disease through early treatment, with known
benefits of early renin-angiotensin system blockade in AD[301,302]. The risk of graft loss
in renal transplantation can be predicted as very low, due to disease recurrence for
patients with podocyte mutations[303] or anti-GBM disease in AD[304].
Our targeted NGS panel produces fast, affordable and reliable results, verified by
confirmatory sequencing. The cost was approximately e250 EUR per participant for
all 39 genes, compared to conventional sequencing costs of e1,000 for a single collagen
gene. Limitations of the technique are the intentionally absent coverage of intronic
regions (also missed by conventional sequencing) unless these are actively included in
the panel design, and being restricted to genes previously associated with the disease.
Furthermore, the interpretation of novel variants remains challenging. We have chosen
a conservative approach likely to under-diagnose pathogenic variants, rather than risk
over-diagnosis. The identified 242 possibly pathogenic variants are likely to contain
further disease-causing mutations and non-functional polymorphisms. This distinction
cannot be clarified without extensive functional studies. The above reasons combined
can explain why we did not identify pathogenic mutations in all of the investigated
cases with family history.
In summary, NGS, as a targeted panel or whole exome sequencing, is an ideal
approach for the genetic testing of FSGS with multiple possible underlying aetiologies.
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We have demonstrated that not only COL4A3 /4, but also COL4A5 mutations should
be considered in patients with FSGS, especially in the presence of a positive FHx, even
if clinical and biopsy features are atypical.
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Chapter 10
Characterisation of LD Maps
Generated from Whole-genome
Sequencing Data
10.1 Background
Detailed analysis of the linkage disequilibrium (LD) structure of human populations
has been vital for the successful mapping of many human disease genes, understanding
mechanisms underlying genetic recombination and elucidating patterns of selection and
population structure[32]. The development of array-based genotyping (ABG) panels
of single nucleotide polymorphisms (SNPs) enabled genome-wide association studies
(GWAS) to localise numerous genetic variants with roles in human disease. Recognition
that the genome contains ‘blocks’ of low haplotype diversity[305] facilitated the selection
of ‘tagging’ SNPs to enable cost-effective genotyping using panels of 500,000 to one
million SNPs[306]. Extensive SNP genotyping enabled the International HapMap Project
to characterise the LD structure of diverse human populations[32]. The first LD maps of
human chromosomes showed a haplotype block structure punctuated by ’steps’ aligning
with recombination hotspots[122,307]. The strong alignment of linkage and LD maps
confirms historical recombination as the major determinant of LD structure[106,122,308].
Array-based LD maps of human chromosomes contain regions with negligible apparent
LD between adjacent markers, seemingly reflecting high regional recombination, which
are not well defined in the maps. Service et al.[308] assessed the impact of increasing
marker density in a number of these regions using ABG data and found that some,
though not all, regions were resolved with increasing marker density. For chromosome
22, 53% of these regions were resolved using 27,060 vs. 9,658 SNPs. Differences between
populations were apparent, with LD maps from isolated populations (therefore having
more extensive LD) containing substantially fewer such regions. Tapper et al.[106]
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constructed genome-wide LD maps using ∼500,000 SNP genotypes from 60 HapMap
samples with European ethnicity, identifying 3,144 poorly resolved regions genome-wide
and estimated that ∼40,000 markers per Morgan would be needed to fully characterise
LD structure. Assuming the autosomal linkage map length is ∼33 Morgans[309] this
suggests that 1.3 million SNPs genome-wide would be sufficient to resolve these regions
in this population. However, this assumes uniform marker spacing and LD intensity,
whilst in reality much higher local marker density may be required for some of these
regions. A particular difficulty exists for populations which have reduced LD due
to extended population history, such as those from Sub-Saharan Africa, for which
considerably higher marker coverage is required for complete coverage.
Given that whole-genome next generation sequencing (WGS) provides maximal
genotype density, we consider the advantages of WGS-derived SNP genotypes for the
characterisation of LD structure in different populations. We construct LD maps
according to the Male´cot-Morton model, using the program LDMAP [106,310]. This model
is defined as:
ρˆ = (1− L)Me−d + L (10.1)
where ρˆ is the association between SNPs, the asymptote L is the ‘background’ association
between unlinked markers which is increased in small sample sizes and with residual
population structure, M reflects association at zero distance, with values of 1 consistent
with monophyletic origin and < 1 with polyphyletic inheritance,  is the rate of LD
decline, and d is the physical distance in kb between SNPs[122].
LDMAP constructs maps in linkage disequilibrium units (LDU, equal to d) such that
one LDU corresponds to the (highly variable) physical distance over which LD declines
to background levels. LDU plotted against the chromosome location forms step-like
patterns with intense breakdown in LD, canonically due to recombination hotspots,
and plateaus for broader regions of low haplotype diversity (blocks). Overall LDU map
lengths are proportional to time since an effective population bottleneck[308,311]. Hence,
populations with shorter LDU maps have been founded more recently, experienced a
more recent selective sweep, or have a smaller effective population size (such as some
population isolates) compared to those with longer maps (such as Sub-Saharan African
populations).
The close correspondence between LD patterns and the linkage map reflects the
dominant role of recombination in LD structure. In contrast to linkage maps, which are
derived from family data and describe recombination over recent generations, LD maps
are constructed from population data and reflect the historical impacts of recombination,
mutation, selection and population history. Our findings show that WGS based LD
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maps provide greatly increased resolution of LD structure in both populations and
indicate some genome regions in ABG-derived maps are incompletely covered. The
findings have implications for interpretation in genome-wide association studies (GWAS)
and support the use of WGS for association mapping and for establishing LD structure
for studies of mechanisms underlying recombination and for identifying genomic regions
subject to selection.
10.2 Methods
Publicly available 1000 Genomes Project[12] data derived from the Complete Genomics
high depth whole-genome sequencing platform was used for WGS map generation[139].
WGS data for two population cohorts were used, namely the Utah Residents (CEPH)
with Northern and Western European ancestry (CEU; 96 individuals), and Yoruba in
Ibadan, Nigeria (YRI; 80 individuals). For comparison, array-derived HapMap Phase
3 release 3 data were also used[35]. ABG cohorts used were CEU (112 individuals),
and YRI (147 individuals) samples. All individuals utilised for map generation were
founders, and physical positions were defined according to GRCh37 (hg19) coordinates.
We consider here the region Chr22:20,000,000–51,304,566. The centromeric hetero-
chromatin was excluded as these regions show very low density of polymorphic makers
and complete LD, as well as a tendency for erroneous genotyping due to the repetitive
nature of the sequences. Genotype data were filtered prior to map generation using
PLINK [182] or VCFtools [164] to remove non-biallelic SNPs, SNPs with MAF within the
dataset < 0.05, SNPs with Hardy-Weinberg equilibrium deviation p-value < 0.001[312]
and SNPs with > 5% missing data. All statistical analyses were performed using R[313].
LD map generation was performed using the LDMAP program, with default para-
meters[106,310]. For sample size reproducibility investigations, random subsets of the full
cohort were generated and LD maps generated from the resulting dataset for three re-
gions (Chr22:20,000,000–25,000,000, Chr22:30,000,000–35,000,000 and Chr22:45,000,000–
47,000,000; 12 Mb total size) with 20 pseudoreplicates generated for each region. We
restricted these analyses to 12 Mb of the chromosome due to the computational intensity
of LD map generation. Following subsampling, filtering and LD map generation with a
range of sample sizes, a negative exponential cumulative model was fitted to the marker
density data for each population and extrapolated to estimate sample sizes required for
effective map saturation. We defined map saturation as the sample size at which an
additional 10 individuals provides less than 1% increase in marker density.
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We investigated regions of intense LD decline, which are canonically the product of
high levels of historical recombination. Recombination hotspots are known to span just
1-2 kb[113,114]. For comparison of LDU maps we defined a hotspot as a region of maximum
size 5 kb in which there was at least a one LDU change between two encompassed
SNPs, as observed in previous studies[314]. Hotspots were deemed concordant between
datasets if there was any physical overlap; these liberal definitions were required due to
the differing marker composition and density of datasets.
10.3 Results
To investigate the impact of using WGS data for defining patterns of LD, we utilised
publicly available WGS genotype data for chromosome 22 within the 1000 Genomes
Project (henceforth referred to as the WGS dataset), and array-based genotype data
from the International HapMap Project Phase 3 (henceforth the ABG dataset)[12,35].
Due to its small size, chromosome 22 exhibits the highest recombination intensity in
the genome[106] whereby LD declines sharply with distance and the LD maps are thus
particularly sensitive for demonstrating the impact of the increased marker density in
WGS data. We analysed LD maps constructed from CEU (Utah Residents (CEPH)
with Northern and Western European ancestry) and YRI (Yoruba in Ibadan, Nigeria)
populations. These are representative of populations which have developed since the
effective ‘out of Africa’ bottleneck (CEU) and Sub-Saharan Africans (YRI). SNP markers
within these datasets were filtered as described in Methods; final marker counts for
each are given in Table 10.1. A detailed breakdown of marker attrition through filtering
is presented in Table 10.2.
Table 10.1: Number of individuals, component marker counts and LD map length using ABG
and WGS data
Individuals Markers Map Length (LDU)
ABG
CEU 112 15359 850.07
YRI 147 16083 993.80
WGS
CEU 96 66704 (4.34) 1021.07 (1.20)
YRI 80 91320 (5.68) 1569.46 (1.56)
Fold change vs. ABG data in parentheses.
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Table 10.2: Marker counts throughout filtering for all datasets
ABG WGS
CEU YRI CEU YRI
Count FCd Count FC Count FC Count FC
Raw count 17938 - 18906 - 214399 - 279848 -
MAFa 15420 0.86 16142 0.85 74946 0.35 106910 0.38
HWEb 17923 1.00 18887 1.00 211048 0.98 275780 0.99
Missingnessc 17872 1.00 18906 1.00 198911 0.93 258517 0.92
Final count 15359 0.86 16083 0.85 66704 0.31 91320 0.33
aMarkers with minor allele frequency < 0.05 within the cohort excluded.
bMarkers with a Hardy-Weinberg equilibrium deviation p-value < 0.001 within the cohort.
cMarkers with > 5% data missing excluded.
dFold change in comparison to the raw count for each filtering criterion in isolation.
10.3.1 LD map topography
LD maps produced using the ABG and WGS CEU datasets appear topographically
highly similar when plotted, though with differing overall map lengths (Figure 10.1).
Regions of concordant strong LD are apparent, seen as low gradient regions in the plot,
as well as regions of weak LD, appearing as a steep gradient. In addition, both maps
appear to have similar contours to the linkage map produced from European samples,
with broad areas reflecting strong and weak LD/recombination[315]. It is noteworthy
that there is an increased overall map length for the CEU WGS map compared to the
ABG map (1.2 fold, Table 10.1). The change in map length is concurrent with much
greater increases in marker density (4.3 fold) from ABG to WGS datasets.
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Figure 10.1: Comparison of WGS (red) and ABG (blue) CEU LD maps (left ordinate axis
scale) and linkage map (black; right ordinate axis scale) for chromosome 22. Linkage map shown
is from the June 2012 release of the Rutgers Map v3, interpolated using the Kosambi function
(available at http://compgen.rutgers.edu/download_maps.shtml)[315].
LD maps for the two WGS populations also show close alignment in LD structure with
broad shared regions of stronger and weaker LD. When the LDU maps are represented
as a rate (LDU/kb) in 100 kb windows (Figure 10.2) the positions of the peaks, where
LD declines rapidly, align closely between the two populations, as do regions with
strong LD (low LDU/kb) . The much longer LDU map for the YRI population reflects
population history with increased time to erode LD through recombination, mutation
and other processes[311]. There is a particularly marked increase in length for the YRI
map of 1.6 fold from ABG to WGS data sets (Table 10.1).
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Figure 10.2: Comparison of regional rates of LD breakdown for CEU (green) and YRI (purple)
populations using the WGS dataset for chromosome 22 for 100 kb windows. A very strong
correlation between the LDU/kb for the two populations can be seen (ρ = 0.91, p < 2.2× 10−16).
10.3.2 Marker density and frequency
The WGS data provides up to a 5.7 fold increase in number of markers compared to
ABG data (Table 10.1 & 10.2). This increase in marker density allows greatly improved
resolution of the LD maps in many regions. Although whole-chromosome LD map
contours of ABG and WGS derived maps look very similar, noteworthy differences exist
at higher resolution. Figure 10.3 shows an expanded view of a 250 kb region of the YRI
population maps. The map of this region generated from the lower density ABG data
failed to resolve 13 hotspots which are discernible in the WGS-based map. Many such
narrow regions of high recombination can be far more accurately located using WGS
maps.
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Figure 10.3: Fine detail comparison of WGS (red) and ABG (blue) LD maps for a 250 kb
region of YRI chromosome 22. All markers are plotted individually; hotspots are highlighted in
grey. Whilst 13 hotspots are identified within the WGS map for this region, the ABG map shows
no hotspots.
As well as increased marker density in the WGS data, there is also a shift in the
minor allele frequency (MAF) spectrum of the component markers (Figure 10.4). The
WGS dataset shows a significant reduction in the median MAF compared to the ABG
data (p < 2.2 × 10−16 for each population), with a far greater magnitude change in
the YRI population compared to the CEU population (with a 35 and 18% reduction
in median MAF respectively). These data illustrate that: 1) markers at the lower
frequency end of the range are particularly underrepresented in the arrays used to
genotype the HapMap samples; and 2) this underrepresentation is most pronounced for
the YRI population.
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Figure 10.4: Histogram showing MAF distributions within ABG (left panel) and WGS (right
panel) datasets for CEU (green) and YRI (purple) populations. A MAF bin width of 0.05 has
been used. The median MAF for CEU is 0.25 and 0.21 for the ABG and WGS data respectively;
the same metrics for the YRI are 0.23 and 0.15 respectively.
10.3.3 Effect of population size
We investigated the extent to which population sample size within the WGS datasets
impacts the marker density available for map generation, as well as the length of
the final LD maps. For 12 Mb of the chromosome we generated random subsets of
the full datasets with varying sample size, and then performed marker filtering and
map generation as described. With an increased sample size, a higher marker density
is achieved for map generation, with diminishing returns with larger sample sizes
(Figure 10.5a). From these data, we extrapolated the sample size for which the addition
of 10 individuals increases marker density by < 1%; this marker saturation is achieved
with 90 and 110 individuals for the CEU and YRI populations respectively.
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Figure 10.5: Correlation between number of individuals sampled and number of markers (a) and
LDU length (b) for a 12 Mb region, in the WGS data for CEU and YRI populations. For marker
density, a negative cumulative exponential regression has been fitted (r2 > 0.94, p < 2.2× 10−16
in both populations. For LDU length, a linear regression has been fitted (r2 = 0.04, p = 0.0087
for CEU, gradient is not significantly different from zero for YRI (p = 0.69). Shaded regions
indicate 95% confidence intervals).
For maps from these data subsets, there is a weak, but significant, correlation between
sample size and LDU length of the resultant CEU maps (Figure 10.5b); the YRI maps
show no significant correlation. This indicates that overall map lengths are largely
robust to variations in sample size. Due to the increased marker diversity of the YRI
cohort compared to the CEU, a greater number of individuals need to be sampled for
complete marker saturation. At smaller sample sizes however, the deviation of map
lengths from average is much broader, reflecting increased sensitivity to heterogeneity
within the dataset (Figure 10.6). Despite the increased map variability, the WGS map
remains consistently longer than the corresponding ABG map. Even where maximal
marker densities have been attained, larger sample sizes are likely to improve the
population representativeness of the map.
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Figure 10.6: LD maps for a 2 Mb region constructed following random subsampling of WGS
data for varying sample sizes (red to white with increasing sample size, range 10 to 90, with
increments of 10 individuals) of both populations. For comparison, the ABG map is included
(blue). Increasing variability in the WGS map can be seen in lower sample sizes, with the maps
converging at larger sample sizes. Despite the increased variability at the smallest sample size of
10, the ABG map remains consistently shorter.
10.3.4 Fine map structure comparison between ABG and WGS
To compare LD structure between ABG and WGS maps we segmented the LD maps
into non-overlapping 100 kb regions (Table 10.3). All LD maps show a very strong
correlation with all other maps (ρ > 0.87), with stronger correlations within population.
Table 10.3: Spearman’s rank correlations between LDU map lengths of 100 kb segments
CEU-ABG CEU-WGS YRI-ABG YRI-WGS Linkage
1 0.92 0.88 0.87 0.56 CEU-ABG
1 0.89 0.91 0.58 CEU-WGS
1 0.94 0.60 YRI-ABG
1 0.59 YRI-WGS
1 Linkage
p < 2.2× 10−16 for each correlation.
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In all cases, the correlation with the linkage map is also strong (ρ = 0.56− 0.60); this
correlation is likely lower due to the lower resolution of the linkage map and components
of the LD structure that are not due to recombination. We find a particularly strong
correlation (ρ = 0.94, p < 2.2×10−16) in the lengths of these segments in LDUs between
the two YRI data sources. The increase in LD map length for the WGS YRI map might
be partly attributed to the greatly increased marker density, however there is only a
relatively weak, though strongly significant, correlation between increase in marker
density and increase in LDU length in these 100kb regions (r2 = 0.19, p < 2.2× 10−16;
Figure 10.7). A total of 37.5% of 100 kb regions show negligible change in LDU length
(< |1|) despite greatly increased marker density, suggesting a large proportion of the
chromosome is approaching complete marker saturation in the ABG data. However,
other regions show substantially increased LDU length (with many regions increased
by over 5 LDU) with the higher marker density, suggesting they are poorly resolved in
array-based maps.
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Figure 10.7: Scatter plot showing change in LDU vs. change in marker density for 100 kb
regions between ABG and WGS map from YRI datasets. The 20 regions selected for further
analysis as regions of largest magnitude change (red) and those with minimal length change (blue)
are shown. Note that two of the selected regions span 23,000–23,200 kb, shown in Figure 10.3. A
total of 312 regions were assessed in total.
The 100 kb regions in the YRI data which exhibit the largest and smallest magnitude
LDU length change (10 of each; Figure 10.7) between ABG and WGS maps were further
investigated. Regions with large LDU increase in the WGS data contain SNPs with a
significantly higher MAF than regions with a small change (p = 5.7 × 10−7, median
of 0.18 and 0.13 for the large and small magnitude change regions respectively), no
significant difference between the MAF distributions of these regions was observed in
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the ABG data (p = 0.39). This indicates that while there is particular enrichment of
lower frequency markers using the WGS data, it is the inclusion of common variation
absent from array panels which has the largest effect on the resulting LD map. The
exclusion of highly LD informative common variation in array-based panels may reflect
the ascertainment of tagging SNPs which is not optimised for all populations.
10.3.5 Hotspot identification
The LD landscape is known to comprise long regions of low haplotype diversity
punctuated by very narrow regions of LD breakdown which align with recombination
hotspots. WGS-based maps allow for more complete resolution of recombination
hotspots compared to ABG-based maps (Figure 10.3). We therefore systematically
evaluated hotspots identified in the four LDU maps. We defined hotspots as five kb
regions containing SNPs which were separated by at least 1 LDU. In both populations,
the WGS derived maps delimit a substantially increased number of hotspots (Table 10.4).
The CEU maps show a 1.7 fold increase in resolved hotspots, compared to 2.8 fold
increase in the YRI maps. This indicates that array-based genotyping only partially
resolves the LD structure in both populations and resolution is particularly incomplete
for the YRI population.
Table 10.4: Counts of hotspots in each dataset with corresponding hotspots identified in all
other datasets
ABG WGS
CEU YRI CEU YRI
ABG
CEU 170 86 (0.51) 137 (0.81) 119 (0.70)
YRI 88 (0.50) 176 115 (0.65) 152 (0.86)
WGS
CEU 157 (0.53) 126 (0.43) 296 224 (0.76)
YRI 149 (0.30) 187 (0.38) 244 (0.50) 491
Values shown indicate the number of hotspots in the dataset indicated with the row label with a
corresponding hotspot(s) in the dataset indicated with the column label. Proportion of total hotspots
recapitulated is shown in parentheses.
We also assessed concordance between hotspots identified in the datasets (Figure 10.8).
The majority of hotspots identified in ABG data were also identified in the corresponding
WGS maps (81 and 86% for CEU and YRI maps respectively). However, for YRI only
38% of hotspots identified in the WGS map were also represented in the corresponding
ABG map. Furthermore, only 13% of identified hotspots showed concordance across
the four datasets, with 29% of all hotspots only observed in the YRI WGS map. Of the
170 CEU hotspots identified in the ABG map the YRI ABG map identifies only 50%
while, in contrast, the YRI WGS map detects 70%. This indicates that relatively poor
resolution of the LD structure in the YRI array-based map suggests misleadingly low
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concordance between hotspot locations across the two populations. Leveraging WGS
data will therefore enable more effective characterisation of LD structure for YRI, and
other populations with an extended population history, for disease gene mapping and
the functional analysis of genomes.
CEU - ABG
YRI - ABG
YRI - WGS
CEU - WGS
Figure 10.8: Euler diagram showing overlap between hotspots identified in each dataset. The
area of all regions is proportional to the number of hotspots which are present in those sets; total
area represents 629 independent hotspots across all datasets.
10.4 Discussion
We have shown that WGS-derived data enables superior resolution of LD structure
in two populations with distinct histories. The increased marker density provides
much improved delineation of regions of high and low recombination. Although some
chromosome regions are well represented in array-based maps, population specific
increases in map lengths of ∼20-60% reflect improved WGS resolution of the LD
structure in other regions. These seem likely to include regions highlighted as poorly
characterised in earlier array-based maps[106,308]. Similarly, Lau et al.[316] observed a
∼3% increase in map length when comparing maps generated from HapMap phases 1
and 2, with the associated increase in marker density.
We have shown that the YRI maps are improved by the greatest margin due to the
inclusion of common variation excluded from the array-based genotyping panel. Array
genotyping necessarily has a data acquisition bias; variants must be identified prior to
array design, limiting the array capture to known variation which may be optimally
informative for only the populations used for variant discovery. This ascertainment
bias can cause issues in population genetic studies particularly where array data of a
population not included in variation discovery is being investigated[317,318]. Recently
developed arrays which include data from the three HapMap phases, along with variants
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identified in the 1000 Genomes Project, achieve coverage of common variation of 92–93%
for CEU but only 76% for YRI[319].
The evidence presented here indicates that the YRI LD structure is particularly
poorly represented using array-based data, reflecting these unresolved biases in marker
selection. While improvements in representativeness have been made, achieving good
representation of all populations using ABG methodologies is intrinsically impracticable
given technological and cost limitations on genotyping density. In contrast, using WGS
there is negligible acquisition bias for variant discovery, though there can be bias where
a population is highly divergent from the reference genome assembly; improvements
in assembly and analytical tools should hopefully further reduce this bias in the near
future[186]. Some regions are still however refractory to WGS analysis, such as repetitive
regions, again, advances will continue to reduce these issues[320].
The total LD map length is relatively independent of number of samples. This
indicates that although an increase in the number of homogenous individuals used
in map generation improves accuracy, resolution and population representativeness,
the underlying LDMAP algorithm provides robust maps with even small population
samples as previously noted[310,311]. This may prove invaluable where the ascertainment
of large data samples is impractical.
The high diversity of African populations, which reflects a much longer effective
population bottleneck time, offers a rich resource for analysis of LD structure. Increased
historical recombination makes sub-Saharan African populations ideal for GWAS studies,
particularly for post-GWAS refinement, as well as for basic research into recombination
biology and selection. Poor representation of African LD structure is considered likely
to impact reproducibility of GWAS results. Marigorta & Navarro[321] investigated
GWAS-derived disease variant reproducibility across 28 diseases. While most loci and
SNPs discovered in Europeans have been extensively replicated in European and East
Asian populations, replication in African populations is much less frequent. At least
a proportion of these failed replications reflect heterogeneity in LD between causal
variants and the tag SNPs used in GWAS panels so selection of alternative tags specific
to the population used may improve reproducibility.
The incomplete resolution of LD structure in array-based LD maps which is evident
even for the CEU population may have impacted the detection of disease variation
in genome-wide association studies. With decreasing sequencing costs, WGS-based
GWAS are becoming viable, with some successes reported[322]. These studies have the
advantages of avoiding the marker ascertainment bias, and enable rare and common
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variation to be interrogated contemporaneously. Such studies may improve GWAS
reproducibility, as well as identification of additional disease variation underlying some
of the ‘missing heritability’[323].
LD maps have been used successfully in GWAS for refinement of candidate re-
gions[111,324]. Sabatti et al.[324] defined regions of interest around nine newly identified
disease genes underlying metabolic traits using a liberal four LDU window. Improve-
ments in LD map resolution through the use of WGS data will substantially reduce the
size of regions for targeted follow-up. To investigate the potential gains of using WGS-
derived LD maps for fine mapping, we assessed the physical window size corresponding
to four LDU for 172 GWAS association signals identified in European populations
on chromosome 22[46]. We considered the physical distance between the two nearest
markers up and downstream which are at least two LDU away from the GWAS signal
SNP. For the CEU population map WGS-based four LDU windows were, on average,
17% smaller compared to the ABG map (262 vs. 316 kb respectively). Furthermore, if
we presume these GWAS signals are reproducible in Sub-Saharan African populations,
the average four LDU window is just 152 kb in the WGS YRI map, a further 42%
reduction in candidate region size compared to the CEU WGS map.
Considerably greater resolution can be achieved in fine-mapping using a population
with African ancestry by exploiting the weaker LD as has been recently demonstrated
in African American populations[325]. African populations have been historically under-
represented in population genetic studies but the African Genome Variation Project[326]
is focussed on using whole-genome sequencing and other methods to refine the detection
of disease variation in these populations. Construction of fully saturated whole genome
LD maps from diverse African samples will undoubtedly improve efforts to map disease
variants and help distinguish true population differences in genetic disease variation
from those which have failed to replicate due to incomplete marker coverage in African
samples.
We have herein discussed several improvements to LD mapping attained using WGS
data. Firstly, WGS data allows complete resolution of LD structure, given the maximal
marker density. Secondly, as there is no ascertainment bias in genotypes, the data are
also far more representative of the population under study, particularly notable for
Sub-Saharan African populations. Thirdly, data from a larger number of individuals is
required to best interrogate LD patterns in diverse populations, particularly those with
long population history. We have shown that array-based SNP panels incompletely
represent the LD structure in both populations studied and this may have impacted the
success of genome-wide association studies for detecting disease variation. Genome-wide
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association studies using whole genome sequences may offer a route to capturing some
of this additional variation.
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Evaluation of LD patterns between
commercial chicken lines
11.1 Background
A detailed understanding of LD structure is essential for designing SNP genotyping
arrays, successful association mapping of the genetic factors underlying traits of interest,
establishing mechanisms underlying genetic recombination and elucidating patterns of
selection and population structure. This is particularly true for commercial chicken
(Gallus gallus) lines where LD analysis has the potential to establish the genetic mech-
anisms underlying selection and therefore contribute to further commercial development
of lines.
The chicken genome comprises many chromosomes of varying properties, categorised
primarily by size. The macrochromosomes (GGA1–5) span 50–200 Mb, intermediate
chromosomes (GGA6–10) range from 20–40 Mb and 28 microchromosomes (GGA11–38)
which average ∼12 Mb[327,328]. The microchromosomes are characterised as having
higher GC content, gene density and much higher recombination rates compared to
macrochromosomes (∼50–100 kb/cM versus ∼300 kb/cM in macrochromosomes). The
latter may reflect the requirement for a minimum of at least one chiasma for each
chromosome per meiosis and a higher density of cohesin binding sites[329].
Previous studies of LD in the chicken have established that the micro chromosomes
show reduced LD compared to macro chromosomes and these differences are almost
completely explained by differences in the recombination rate[328]. Studies of egg laying
chickens indicate higher levels of LD compared to broilers[330,331]. Despite relatively low
levels of LD in broilers, Andreescu et al.[330] determined that there is significant overlap
in LD for marker pairs across nine different commercial broiler lines.
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Linkage disequilibrium maps constitute the LD analogue of the genetic linkage map
and have been extensively utilised for human data[106,122]. LD maps are constructed
from population data and reflect the historical impacts of recombination, mutation,
selection and population history[109,311,314]. This approach to LD mapping has been
previously successfully applied to other agricultural species, namely cattle[332]. Thus
LDU maps of commercial chicken lines have the potential to provide new insights into
patterns of recombination and selection.
Previous studies have begun to describe differences in recombination across Gallus
genomes based on linkage and LD structure[328] and genome-wide LD maps have the
potential to yield further insights. Here, we construct genome-wide LDU maps for
three chicken lines types (broilers (BRO), white egg layers (WEL) and brown egg layers
(BEL)) and contrast the LD structure across the three lines considering recombination
hot spots, differences between chromosome types and motifs underlying major features
of the maps.
Birds lack the zinc-finger protein PRDM9, required for recombination hotspot loc-
alisation in humans and other mammals[333]. Despite this, recent work by Singhal et
al.[334] has shown that hotspots are highly concordant between wild populations of finch,
due largely to the localisation of recombination to functional elements of the genome,
namely CpG islands and transcription start sites (TSS).
Here, we construct genome-wide LDU maps for three chicken lines breeds (broilers
(BRO), white egg layers (WEL) and brown egg layers (BEL)) and contrast the LD
structure across the three lines considering recombination hot spots, differences between
chromosome types and motifs underlying major features of the maps. High resolution
mapping of LD in these commercial lines will facilitate array design to best capture
the breed diversity with minimal data generation, which is of interest to commercial
genome-led breeding operations.
11.2 Methods
Genotypic data used in this work are as reported in the validation populations of
Kranis et al.[335], with all genomic coordinates based on the galGal4 reference assembly;
1,050,975 SNPs were genotyped passing initial QC in total. Only data from independent
founders were included in these analyses. All pairwise samples were compared and
wherever one individual of any pair showed > 80% genome-wide identity by similarity
they were excluded. Individuals with < 95% genotyping completeness were also
excluded. Filtering was performed using a modified version of PLINK v1.07[182] in
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order to acomodate the additional chromosomes seen in the chicken. Multi-dimensional
scaling (MDS), as implemented in PLINK, was undertaken using all autosomal markers
in order to evaluate the population structure of the samples.
Once the three breed cohorts were defined, SNP marker filtering was undertaken
independently for each population. Markers with < 95% genotyping completeness,
MAF < 0.05 or Hardy-Weinberg equilibrium (HWE) deviation p-value of < 0.001 were
removed to leave a dataset containing only common, high quality markers[312]. Within
each breed the inbreeding coefficient (F ) was calculated as detailed by Wright[336].
LD maps were generated for the assembled autosomes GGA1–28 on filtered data
according to the Male´cot-Morton model using LDMAP [122,123,310]. Where necessary,
filtered genotype data were split into ∼25,000 marker segments (with 200 marker overlap)
to allow for parallelised processing. Overlapping map segments were then trimmed of
the terminal 25 markers, and merged to form complete, contiguous whole-chromosome
LD maps for the assembled autosomes. The order of markers in linkage maps from
Elferink et al.[337] was revised in line with galGal4 from the native chicken assembly
based upon SNP positions on this assembly within dbSNP 144. Following transition
to the galGal4 marker order, a small number of markers in the linkage map were no
longer sequential in the cumulative linkage map, and as such were manually removed.
To compare map structure between breeds, we focussed on the macrochromosomes
GGA1–5, which were chosen to avoid confounding factors such as potentially incomplete
reference assemblies, as well as varying recombination rates for the microchromo-
somes[327,329,337]. The Spearman’s rank correlation of LDU lengths for all 40 kb regions
between the three breeds was calculated (after Rubin et al.[338]).
For fine-scale interrogation of the LDU length of 5 kb regions, the concordance seen
for the longest LDU regions, defined according to the top percentiles in order to allow
for the differing extents of global LD for the breeds, was calculated. This analysis
gives an indication of the extent to which narrow regions of intense LD breakdown are
shared between pairs of samples. A large degree of concordance between long LDU
segments would suggest there is a high proportion of shared recombination hotspots
between the samples considered. As a final control, a randomised dataset was used for
which an equal number of 5 kb regions were randomly selected independently for each
dataset, and the concordance calculated; 100 pseudo-replicates were performed for each
percentile cutoff.
For comparing LDU decline rates with genome features we focused on the BRO
dataset due to the largest sample size. GC content was calculated directly from the
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reference sequence for the 5 kb regions, CpG islands were defined according the UCSC
genome browser, and Ensembl annotations were used to define TSS. BEDTools was
used to calculate the distance between elements and regions[195].
11.3 Results
11.3.1 Input data
MDS of all samples shows distinct clustering of breeds, though with three distinct
population clusters within each breed, corresponding to distinct commercial lines, and
thus isolated populations (Figure 11.1)[335]. For LDU map construction population
clusters were initially pooled within each breed. Counts of chickens and marker SNPs
passing quality and frequency filtering are detailed in Table 11.1.
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Figure 11.1: MDS for whole-genome genotype data for commercial chicken lines. Analysis
includes 219 founder chickens. Chickens coarsely cluster within breeds, with three population
clusters for each breed apparent, consistent with the three commercial lines genotyped for each
breed. Population cluster designations are labelled on the plot.
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Table 11.1: Number of individuals and component marker counts for analysed populations
BRO BRO3 BRO2d BRO3a BRO3b BEL WEL
Founders
Males 58 50 - 26 24 12 8
Females 17 9 - 4 5 40 38
Total 123d 59 48 30 29 52 46
SNPs
Raw count 966355 789359 790531 692467 778135 891200 691954
MAFa 833639 638947 658548 631449 645713 796430 627294
HWEb 760893 788284 789450 691625 777771 763931 420130
Missingnessc 966346 787732 788594 690038 776114 888903 690298
Final count 630435 636535 655905 628382 643554 667605 354737
aMarkers with minor allele frequency < 0.05 within the cohort excluded.
bMarkers with a Hardy-Weinberg equilibrium deviation p-value < 0.001 within the cohort.
cMarkers with > 5% data missing excluded.
dSex data unavailable for BRO2 line.
11.3.2 Global map properties
LD maps were generated for all autosomal chromosomes for the three breeds (Fig-
ure 11.2). The physical map of the chromosome is represented on the x-axis, while the
y-axis shows the LDU maps for each breed and and the linkage map in cM from Elferink
et al.[337]. As found in human LDU and cM maps there is a large region showing little
change in LD or cM, consistent with the location of the submetacentric centromere where
recombination is suppressed and there is therefore intense linkage disequilibrium[106,339].
Summary length statistics for all autosomes are shown in Table 11.2.
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Figure 11.2: LD and linkage map plots for 28 autosomes of G. gallus. The broadly analogous structure of the linkage map and LD maps for the three
populations can be seen. All maps contain a large plateau around 10,000 kb, corresponding to the centromere. Overall length of the LD maps is inversely
related to the strength of LD within a breed. Broilers show the lowest LD overall reflecting relatively high haplotype diversity while white egg layers show
strongest LD and lowest population haplotype diversity.
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Table 11.2: Map lengths for autosomes of G. gallus
BRO BEL WEL
Chr Mb span cM LDU LDU/cM LDU LDU/cM LDU LDU/cM
1 195.2 413.5 713.7 1.7 612.4 1.5 363.8 0.9
2 148.8 281.3 452.1 1.6 462.8 1.6 207.8 0.7
3 110.4 236.9 439.2 1.9 359.4 1.5 186.3 0.8
4 90.2 195.2 309.8 1.6 277.1 1.4 164.1 0.8
5 59.5 154.4 198.6 1.3 207.1 1.3 126.3 0.8
6 34.9 93.8 171.9 1.8 114.7 1.2 81.4 0.9
7 36.2 103.1 150.3 1.5 153.1 1.5 76.3 0.7
8 28.7 96.6 134.5 1.4 112.2 1.2 57.0 0.6
9 23.4 88.1 123.4 1.4 101.4 1.2 61.0 0.7
10 19.9 80.6 97.4 1.2 77.0 1.0 65.3 0.8
11 19.3 64.0 73.9 1.2 85.4 1.3 34.5 0.5
12 19.9 69.1 101.4 1.5 88.4 1.3 51.6 0.7
13 17.7 62.7 76.3 1.2 85.7 1.4 38.5 0.6
14 15.1 67.4 65.9 1.0 68.1 1.0 46.2 0.7
15 12.6 53.6 61.6 1.1 54.6 1.0 24.8 0.5
16 0.5 59.1 2.0 0.0 2.3 0.0 1.1 0.0
17 10.3 50.9 65.7 1.3 52.6 1.0 24.5 0.5
18 11.2 51.7 56.4 1.1 53.9 1.0 31.1 0.6
19 10 52.3 67.9 1.3 57.6 1.1 31.3 0.6
20 14.2 55.1 61.5 1.1 58.6 1.1 31.1 0.6
21 6.8 56.9 56.8 1.0 51.1 0.9 29.8 0.5
22 4.1 56.4 21.9 0.4 21.7 0.4 9.5 0.2
23 5.7 52.3 46.6 0.9 39.2 0.7 27.6 0.5
24 6.2 53.2 57.6 1.1 47.6 0.9 33.0 0.6
25 2.1 57.1 17.8 0.3 23.8 0.4 6.8 0.1
26 4.9 52.3 37.4 0.7 39.5 0.8 21.9 0.4
27 5.2 51.0 32.6 0.6 34.3 0.7 28.2 0.6
28 4.7 53.6 30.4 0.6 37.1 0.7 20.9 0.4
Σ 917.7 2762.2 3724.6 1.3 3378.7 1.2 1881.7 0.7
LDU map lengths reflect haplotypic diversity within that population and can be
compared with independent measures of population diversity such as F inbreeding
coefficients[109,308,336]. The mean F inbreeding coefficients are 0.21, 0.26 and 0.51 for
the BRO, BEL and WEL populations respectively, with the greater value for WEL
indicating far more limited genetic diversity within the population. In comparison, the
ratio of LDU/Mb is also variable between breeds (5.37, 5.13 and 2.85 LDU/Mb for
BRO, BEL and WEL respectively across the autosomes). This ranking of the breeds
by LDU length is consistent with the trend obtained from the F statistic, in line with
expectations and previous literature[330,331,335]. This suggests that the array-based LD
maps are appropriately estimating the population diversity.
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In all breeds, the LDU length is also strongly correlated with the cM length of the
linkage map (ρ > 0.8, p < 2.5 × 10−7 for all breeds); there is a breakdown in this
correlation driven by particularly poor correlation for the smaller microchromosomes
(Figure 11.3). There is also a general trend towards a lower LDU/cM ratio in the
smaller chromosomes (Figure 11.3; Table 11.2). In humans, this ratio is consistently
∼20 LDU/cM[106]. As expected, there is a very strong correlation between LDU and
physical length of the chromosome (ρ > 0.95, p < 2.5 × 10−7 for all breeds); this is
expected due to the d term in the Male´cot-Morton model.
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Figure 11.3: Relationship between physical chromosome length and LDU/cM ratio for all
autosomes in the three breeds. There is a clear trend for the physically smaller chromosomes to
exhibit lower LDU/cM ratios, with a negative exponential relationship. Lines indicate best fit for
log10(length) vs. LDU/cM (r
2 > 0.75, p < 1.7× 10−9 for all breeds).
11.3.3 LD structure between breeds
Following map generation, we interrogated the fine map structure for the breeds,
specifically to what extent patterns of LD were conserved between the breeds. There
was a weak, though highly significant correlation between breeds for the LDU length of
corresponding 40 kb regions (ρ < 0.21; p < 2.2 × 10−16 for all pairwise comparisons;
Figure 11.4).
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Figure 11.4: Comparison of LD breakdown intensity on GGA2 for the three breeds of G. gallus.
LDU/40 kb is shown in sliding windows for the three breeds, a common region of high LD is seen
following ∼50,000 kb, corresponding to the centromere. There are minimal other trends apparent
in the localisation of LD intensities between breeds.
Regions spanning a few kb in which there is strong breakdown of LD are known
to align with recombination hotspots for which there is a high degree of concordance
in, for example, human populations[114,115,128,340]. We investigated the extent to which
narrow regions with LD breakdown are conserved across the three breeds. In humans,
recombination hotspots span 1–2 kb[113], so we investigated whether 5 kb regions (in
order to allow for the resolution of the genotyping array) with the longest LDU lengths
within a breed were conserved between populations[106,109,308]. When comparing paired
chicken breeds, there is a low concordance in the top LDU length percentile 5 kb
windows, with ∼5% concordance between breeds for the top 5 percentile (Figure 11.5).
All breed pairwise comparisons show little concordance between LDU lengths although
there remains greater concordance than expected in a randomised dataset.
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Figure 11.5: Pairwise concordance of regions of LD breakdown between populations. Shown is
the proportion of regions in the top n percentile which intersect between the breeds. For pairwise
comparisons between BRO/BEL/WEL ∼5% of regions in the top 5 percentile are concordant.
This proportion is also similar where two separate BRO lines (BRO2/BRO3) are compared.
When the largest population is bisected (BRO3a/b), this proportion is ∼27%, still far lower
that the equivalent comparison between human populations[109]. All actual comparisons show a
greater proportion of concordance than random, indicating some shared mechanism.
11.3.4 Characteristics of regions of LD breakdown
Despite the low concordance seen in the inter-population comparisons for the chickens,
the concordance seen is consistently almost 2-fold greater than that expected by chance.
One potential reason for this is expected biases in recombination rate dependent upon
sequence context[329,334]. One key determinant of recombination rate, GC content[329],
was found to be significantly increased in 5 kb regions in the top 1 percentile of any
breed when compared to regions of 0 LDU length in all breeds (42.0% and 39.2%
respectively, p < 2.2× 10−16). We further compared LDU/kb for the 5kb regions with
distance to the nearest of CpG islands and TSS; this was found to be highly significant,
though weak, negative correlation in our data for both TSS and CpG islands, consistent
with findings in the finches (Figure 11.6)[334].
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Figure 11.6: Association of LD breakdown with displacement from nearest functional element,
namely CpG islands and TSS. There is a strong negative correlation between the distance from the
functional elements and LDU/kb (ρ = −0.12 for CpG islands, ρ = −0.10 for TSS, p < 2.2×10−16
for both). Shown is the mean LDU/kb ratio for 5 kb bins, shaded area indicated 95% confidence
interval.
In order to better characterise the relative contributions of TSS and CpG islands
to recombination patterns we constructed a 2× 4 contingency table for 5 kb regions
exhibiting ≥ 0.003 LDU/kb against whether the regions are within 125 kb of a CpG
island, TSS, both or neither (Table 11.3). These values were selected based upon the
approximate points on inflection in Figure 11.6. There was a highly significant deviation
from expected distributions under the null hypothesis (p = 9.5× 10−224, χ2 test). This
shows that the increase in the number of regions with LDU/kb ≥ 0.003 where the
nearest TSS and CpG island are both within 125 kb is greater than the sum of the
increase where only one feature is within this range. This would indicate that it is an
interplay of features which contribute to hotspot localisation, and that CpG islands
have a greater effect than TSS.
Table 11.3: 2× 4 contingency table of LDU/kb intensity and genomic features within 125 kb
LDU/kb
≥ 0.003 < 0.003 Odds ratio Fold increase
Neither 5255 12974 0.79 -
CpG only 1997 4208 0.88 1.12
TSS only 3746 8483 0.84 1.06
Both 33290 50836 1.08 1.37
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11.4 Discussion
The analysis of LD maps for the three breeds indicates extensive LD genome-wide.
Since one LDU represents the distance over which LD declines to background levels, the
genome-wide Mb/LDU ratio gives an indication of the average physical extent of LD
(termed the ‘swept radius’). Figures for the three breeds are 246 kb for BRO, 272 kb
for BEL and 488 kb for WEL (Table 11.2). In contrast, the corresponding figures for
human populations are ∼55 kb for human European populations and ∼39 kb for African
populations[316]. Although extensive LD is expected for chicken lines which have been
subject to intense selection, profound differences in fine-scale LD structure between the
three breeds are less expected.
Although some large scale genomic features such as centromeric regions which typic-
ally have extensive and intense LD are shared across breeds for some chromosomes (e.g.
GGA2) there is relatively little concordance in LD structure genome-wide. The contours
of the LD maps show many genome regions with widely divergent LD structure (Fig-
ure 11.4) and the overall correlation in LDU lengths of 40 kb windows is only ρ = 0.21.
In contrast, the fine-scale LD structure of human populations is sufficiently concordant
to support a ‘cosmopolitan’ LD map which recovers 91-95% of the information within
population-specific maps[341].
The LDU/cM ratio of chromosome lengths is known to be virtually constant in
human populations strongly suggesting that recombination is the primary determinant
of LD structure[128]. However, for the three chicken breeds the linear relationship breaks
down. Smaller chromosomes are shown to have a lower LDU/cM ratio. The breakdown
in correlation between LDU and cM map lengths may be for several reasons. One
possibility is that the linear relationship between LD and cM lengths breaks down under
intense selection that has underpinned the three chicken breeds. If the breakdown in
correlation is considered from a recombination standpoint it suggests that historical
recombination intensity (based on LD maps) is lower than current recombination
intensity (based on the linkage map) for the smaller chromosomes.
The possibility of complex interplay between historical and present day recombination
intensity and selection is worthy of further study. Alternative possibilities recognise that
the reference genome sequence is incomplete for several chromosomes, and particularly
smaller chromosomes. Since the construction of linkage maps requires lower density
markers and linkage extends much further than LD the construction of a complete
linkage map of a chromosome is not highly sensitive to regions of missing or unreliable
sequence[329]. In contrast LD is much shorter range and LD maps may be truncated in
regions where SNP coverage is incomplete due to sequence gaps. Incomplete physical
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maps for the smaller chromosomes may therefore contribute to truncated LDU maps
as suggested by variable LDU/cM ratios[327]. This is however unlikely to be the sole
explanation for the lower LDU/cM ratios in the smaller chromosomes due to the close
negative exponential relationship between the physical chromosome size and LDU/cM
ratio, indicative perhaps of an underlying biological mechanism as opposed to solely a
technical artefact due to the incomplete assemblies.
Megens et al.[328] also found that recombination rates estimated from LD data were
discordant with those obtained from the linkage map. Specifically they found that the
recombination frequency for two microchromosomes (GGA26 and GGA27) estimated
from LD was only 2.8 times greater than that of macrochromosomes (GGA1 and GGA2)
when the expectation from the linkage map was 4.5 fold greater recombination on the
microchromosomes[329]. This discrepancy was attributed to biases in fitting a model
using effective population sizes computed in physical rather than genetic distance
windows. The indication from this study that historical LD-based recombination rates
appear discordant with the linkage map of different chromosomes is worthy of further
investigation.
Our finding that the LD structure across the three breeds in highly discordant is
in marked contrast to comparisons across human populations. Specifically narrow
regions of LD breakdown which align with recombination hotspots in humans and are
highly concordant across populations show little concordance across chicken breeds.
Comparisons between major lines, and even between sub-populations with a major line
(BRO2-BRO3, Figure 11.5) show alignment of such regions which is only slightly greater
than ‘random’. Concordance within a random split of a subpopulation (BRO3a-BRO3b)
is much higher but even then does not approach the degee of alignment in the hotspot
landscape human CEU and YRI populations. Although the different extent of LD
genome-wide between the breeds has been known for some time[331] and the LD pattern
between white and brown egg layers has been recognised as clearly different[342], this
is the first study to recognise highly divergent fine-scale LD structure between breeds.
This finding has implications for trait mapping since it suggests that to ensure coverage
panels of tagging SNPs would be optimally selected only within breed and that, unlike
in human analyses, a ‘standard’ linkage map may be less useful if it is not representative
of the breed-specific recombination landscape.
Analyses of human LD maps have established that the recombination landscape can be
recovered from LD structure[114,127,128]. From the derived recombination landscape the
chromatin-modifying zinc-finger protein PRDM9 was shown to regulate recombination at
40% of human hotspots by binding to a degenerate 13 base pair motif[343]. Remarkably,
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despite genomic similarity between humans and chimpanzees, there is virtually no
sharing of recombination hotspot locations. Myers et al.[344] found that chimpanzee
PRDM9 has a dramatically different predicted binding sequence. PRDM9 sequences are
known to exhibit extremely rapid evolution which explains lack of hotspot conservation
in other species which have PRDM9. However, chicken genomes, along with all other
avian genomes tested (48 species) are known to lack PRDM9[333].
It may appear that our results herein are in direct conflict with the recent results of
Singhal et al.[334], who showed that 73% of recombination hotspots were shared between
the zebra finch (Taeniopygia guttata) and long-tailed finch (Poephila acuticauda). Like G.
gallus, these finches lack PRMD9, a strong determinant of recombination localisation in
humans and other mammals[115,334]. Due to this, Singhal et al.[334] posit that alternative
binding motifs such as CpG islands and TSS play the analogous role of PRDM9 in
humans. We see evidence of the clustering of low LD regions near these motifs, in
agreement with them, however, it is possible that the overall LD landscape is so highly
discordant between lines due to the short population histories and intense selection
acting on these populations.
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Thesis Summary
Recent advances in genotype data acquisition technologies have facilitated huge
leaps forward in genetic research. The decreasing costs, in addition to the increased
throughput, quality and data density have all facilitated improved studies. As NGS
technologies are increasingly validated for both quality and utility, they are making
the transition into clinical genetics. Large national projects working to integrate NGS
into clinical care, such as the Deciphering Developmental Delay and 100,000 Genomes
Projects, are increasingly making the transition across the vague delineation between
research and clinical practice.
A critical aspect in clinical application of any process is that samples to be analysed
are appropriately tracked and managed so as to avoid sample mix-ups. Tools such as
barcoded tubes and liquid handling robots minimise the risk. However, intrinsic markers
of the sample are the least fallible approach. As such, I designed and evaluated the
SNP panel reported in Chapter 6 to provide a suitable tool for tracking DNA samples
directly, as well as tying them to the resultant WES data. This has been commercialised
in partnership with LGC Genomics, who offer the panel as both a service and kit. The
SNP panel has been utilised for several WES studies, and has been incorporated into
custom targeted sequencing experiments by some groups, both internationally and
locally.
Sensitivity is also of the utmost importance in clinical testing, arguably more so
than the specificity of a test. The identification of the pathogenic variant(s) in a
patient is clearly the primary goal of any clinical genetic investigations. As such, in
Chapter 7 I detailed five exomes with pathogenic variation refractory to identification
using standard analytical pipelines and filtering. The eventual identification of this
variation, and the elucidation of issues associated with their identification will serve to
inform future pipeline optimisation and analyses. These lessons will be applied within
the Wessex Clinical Exome Pilot project, a joint venture between the University of
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Southampton, University Hospital Southampton NHS Foundation Trust and Salisbury
NHS Foundation Trust.
In Chapter 8 I discussed a number of families with cleft lip/palate phenotypes who
were subjected to WES analysis. In these families a clear aetiology was identified in the
families displaying syndromic presentations, with known pathogenic variants in IRF6,
IKBKG and SF3B4. In patients with non-syndromic phenotypes however, no strong
candidate pathogenic variants were identified. This is in accordance with expectation,
with syndromic presentations usually being Mendelian in nature, and non-syndromic
being complex. It is clear that studies with a far larger sample size than that analysed
herein are required to truly evaluate the genetic contribution to non-syndromic cleft
lip/palate. Where there are variants in families determined as possibly pathogenic
candidates, such as the MSX1 :p.P260T in Family NSCLP4, segregation analyses should
be performed, providing that it is practicable to source further genetic material for the
extended pedigree.
In Chapter 9, we utilised a targeted sequencing panel investigating FSGS, sequencing
39 genes in 83 patients. This TruSeq Custom Amplicon panel was shown to be an
effective tool for the cost effective investigation of the genetic aetiology of FSGS. This
was the first work to show that COL4A5 underlies some cases of apparent FSGS, though
other groups have recently reported the role of COL4A3 /4 in patients diagnosed with
FSGS.
Overall, the work in clinical applications of NGS discussed in Part II serve to highlight
the extensive utility of NGS technologies in clinical contexts. The routine evaluation of
variants in order to assess pathogenicity is likely to require minimal input, though will be
reliant on effective curation of databases such as HGMD. This will allow the refocussing
of expertise onto the improvement of in silico analytical tools for improved variant
detections. Furthermore, the ever increasing swathes of data will facilitate massive
cohort studies, affording greater power for the detection of more subtle aetiological
signals. This will allow for improved genotype–phenotype correlations, as well as the
identification of associated variation contributing to common disease.
In Part III I described two bodies of work applying the Male´cot-Morton model of
LD to multiple populations. Firstly, in Chapter 10 I generated LD maps using both
array-based and WGS data for CEU and YRI populations. It is clear from these
analyses that WGS data provides significant information gains, particularly in diverse
populations, where arrays do not fully capture the population variation. Following on
from this work, I am generating LD maps for the whole genome using WGS data for
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597 individuals from the Wellderly cohort. This work will aim to deliver the highest
resolution mapping of LD to date, and interrogate this for features associated with
recombination. Finally, the 100,000 Genome Project under Genomics England affords
U.K. researchers unprecedented access to WGS data. Within the Population Genomics
Genomics England Clinical Interpretation Partnership (GeCIP), we will have access
to this data, allowing multiple population LD maps to be generated. With maps for
multiple populations it will be possible to investigate differential selection between these
populations.
Finally, in Chapter 11, I presented work done on the evaluation of LD patterns in
commercial lines of G. gallus. In this, I identified highly discordant patterns of LD
between the lines, even within breeds. This is at apparent odds with recent work that
has shown that stable recombination hotspots in wild populations of finches lead to
highly concordant patterns. Despite this, the association of recombination hotspots
with sequence features seen in the wild still hold true for the commercial chickens. This
discrepancy is likely due to the pressures imposed on the populations by commercial
breeding, specifically population bottlenecks and selection pressures. This revelation
is informative for commercial breeders, as it allows them to optimise their tools and
analyses for genotype-led breeding programmes; as such, we have entered into a joint
funding bid with a large international breeding company in order to further this work.
Furthermore, through our collaboration with the Roslin Institute we have access to
WGS data from a commercial breed. This will allow for refinement of the LD map,
allowing maximal power to interrogate sequence features associated with recombination
in the domestic chicken.
Overall, we have shown that the Male´cot-Morton model continues to be a valuable
tool for the mapping of LD using large-scale genomic data, and is further empowered
by the increasing availability of WGS data on a population scale. These large datasets
will facilitate the investigation of questions such as the regulation of recombination and
population specificity of this regulation.
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Appendix A
Pertinent Code Custom-written for
Analyses
A.1 Code Developed for Chapter 6
generate fingerprint.pl
1 #!perl;
2 use warnings; use v5 .8.8; use strict;
3
4 ## Script to generate SNP fingerprint profiles from input of
minor -allele frequency data for multiple SNPs to be used for
population simulation of WES identification panel.
5 ## Usage: "perl generate_fingerprint.pl [MAF file] [n fingerprints ]".
6
7 open SOURCE , $ARGV [0] or die; ## Call source MAF file path as first
argument on calling. File layout should be: "^rsID\tMAF\n"
8 chomp(my @data = <SOURCE >);
9 close SOURCE;
10
11 ## Generate cut -offs for genotypes according to Hardy -Weinberg
equilibrium.
12 ## 1 = p^2 + 2pq + q^2
13 my (%het , %ref , @rsIDs);
14 foreach my $line (@data) {
15 my @split = split /\t/, $line;
16 $het { "$split [0]" } = (2 * ($split [1] * ( 1 - $split [1]))); ## 2pq
17 $ref { "$split [0]" } = ((1 - $split [1]) * ( 1 - $split [1])); ## p^2
18 push @rsIDs , $split [0];
19 }
20
21 my $n = $ARGV [1] or die "Enter desired number of fingerprints to be
generated on calling\n"; ## User input for number of desired
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fingerprints to be generated.
22 my $iteration = 1;
23 while ($iteration <= $n) {
24 my @fingerprint;
25 foreach my $rsID (@rsIDs) {
26 my $state;
27 my $determinant = rand;
28 if ($determinant <= $het{$rsID}) { ## Take heterozygotes.
29 $state = ’TA’; ## T used for ref , A for alt arbitrarily , so can
still utilise phylogenetic software for downstream analysis.
30 push @fingerprint , $state;
31 next;
32 }
33 if (( $determinant > $het{$rsID}) and ($determinant <=
($het{$rsID} + $ref{$rsID}))) { ## Take reference
homomozygotes.
34 $state = ’TT’;
35 push @fingerprint , $state;
36 next;
37 } else {
38 $state = ’AA’; ## Presume remainder to be homozygous for
alternative.
39 push @fingerprint , $state;
40 next;
41 }
42 }
43 my $finger_to_print = join "", @fingerprint;
44 print "$finger_to_print\n";
45 $iteration ++;
46 }
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B.1 Supplementary Data for Chapter 6
Table B.1: Candidate SNPs for inclusion in WES tracking panel
Distance Allele Frequencies
Chr Position rsID Gene Strand Alleles 5’ SNP 3’ SNP GC KG HM-CEU HM-CHB HM-JPT HM-YRI
1 179520506 rs1410592 NPHS2 + A/G 84 154 48.1 0.43 0.59 0.62 0.54 0.53
1 228431095 rs1771455 OBSCN - C/T 61 140 53.5 0.37 0.73 0.57 0.60 0.66
1 209968684 rs2013162 IRF6 + A/C 273 69 52.3 0.40 0.35 0.50 0.62 0.25
1 167849414 rs203849 ADCY10 - C/T 87 244 47.9 0.48 0.47 0.30 0.43 0.64
1 209811886 rs2076356 LAMB3 + G/T 57 168 47.5 0.48 0.65 0.30 0.29 0.35
1 67861520 rs2229546 IL12RB2 + A/C 620 677 54.7 0.45 0.64 0.36 0.44 0.58
1 158582646 rs2251969 SPTA1 + C/T 94 192 44.9 0.45 0.60 0.67 0.58 0.37
1 45973928 rs2275276 MMACHC + A/G 93 231 50.9 0.49 0.47 0.51 0.57 0.37
2 44502788 rs3738985 SLC3A1 - G/T 227 854 54.1 0.33 0.77 0.37 0.45 0.77
2 75115108 rs10194657 HK2 + A/G 269 271 47.7 0.45 0.60 0.43 0.58 0.43
2 49381585 rs1394205 FSHR - A/G 332 85 44.7 0.36 0.30 0.48 0.52 0.25
2 169789016 rs497692 ABCB11 - A/G 542 290 45.5 0.48 0.55 0.65 0.51 0.22
2 170092395 rs2229267 LRP2 - C/T 263 260 42.7 0.41 0.23 0.27 0.35 0.67
2 179454394 rs1560221 TTN - C/T 120 813 41.5 0.45 0.20 0.64 0.66 0.62
2 179455207 rs2163009 TTN - A/G 813 1940 42.5 0.45 0.20 0.64 0.66 0.62
2 215820013 rs10498027 ABCA12 + A/G 160 547 40.1 0.33 0.40 0.21 0.22 0.26
2 227896976 rs10203363 COL4A4 + C/T 90 100 46.7 0.45 0.46 0.44 0.36 0.57
2 219941063 rs897477 NHEJ1 + A/G 117 164 45.9 0.35 0.75 0.44 0.47 0.67
3 4712413 rs2306875 ITPR1 + A/G 179 297 47.7 0.40 0.65 0.26 0.40 0.69
3 148727133 rs4938 GYG1 + A/G 166 303 40.9 0.31 0.30 0.30 0.37 0.33
3 45989044 rs2234358 FYCO1 + G/T 1064 79 47.7 0.46 0.49 0.64 0.53 0.25
3 4403767 rs2819561 SUMF1 - C/T 149 50 51.7 0.33 0.56 0.73 0.73 0.72
4 86915848 rs10003909 ARHGAP24 + C/T 141 75 42.5 0.32 0.21 0.29 0.32 0.43
4 88534235 rs2736982 DSPP + A/G 95 528 44.3 0.33 0.64 0.64 0.63 0.71
4 5749904 rs4688963 EVC - A/G 90 57 44.1 0.46 0.33 0.65 0.67 0.52
4 86844835 rs6824722 ARHGAP24 + A/G 353 113 41.7 0.35 0.24 0.23 0.42 0.47
5 13719022 rs30169 DNAH5 - A/C 295 67 41.3 0.41 0.41 0.41 0.45 0.51
5 13829799 rs1348689 DNAH5 - C/T 188 134 41.1 0.46 0.39 0.67 0.50 0.50
5 13845045 rs10041113 DNAH5 + A/G 171 62 41.5 0.47 0.46 0.66 0.47 0.58
Selected SNPs in bold typeface. Distance - distance to SNP with AF ≥ 0.01; GC - % GC of flanking 250 bp; KG - 1000 Genomes Pilot average; HM - HapMap Phase 3
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Table B.1: Candidate SNPs for inclusion in WES tracking panel continued
Distance Allele Frequencies
Chr Position rsID Gene Strand Alleles 5’ SNP 3’ SNP GC KG HM-CEU HM-CHB HM-JPT HM-YRI
5 40981689 rs1061429 C7 + A/C 291 79 50.7 0.35 0.42 0.32 0.31 0.36
5 53751988 rs7823 HSPB3 + C/T 87 430 45.7 0.42 0.65 0.40 0.35 0.77
5 55155402 rs1009639 IL31RA + C/T 407 188 41.7 0.39 0.71 0.43 0.49 0.63
5 82834630 rs309557 VCAN - A/G 331 915 45.5 0.48 0.49 0.34 0.52 0.50
5 135392426 rs4669 TGFBI + C/T 102 81 49.1 0.39 0.27 0.31 0.35 0.73
5 138456815 rs3088052 SIL1 - A/G 148 101 54.3 0.43 0.44 0.27 0.20 0.73
5 171849471 rs17074773 SH3PXD2B + A/G 182 182 50.1 0.38 0.30 0.70 0.62 0.25
6 152464839 rs2256135 SYNE1 + A/G 472 773 45.7 0.34 0.50 0.71 0.69 0.78
6 152466674 rs2747662 SYNE1 + C/T 92 212 46.7 0.34 0.26 0.30 0.26 0.31
6 146755140 rs2942 GRM1 + A/G 176 184 54.3 0.48 0.54 0.49 0.55 0.47
6 56471402 rs9382658 DST + A/G 299 127 40.1 0.37 0.40 0.23 0.26 0.50
6 152675854 rs9397102 SYNE1 + A/G 523 912 42.9 0.40 0.64 0.58 0.64 0.53
7 34009946 rs10265207 BMPER + C/T 714 66 48.1 0.43 0.45 0.45 0.41 0.34
7 100804140 rs1048303 AP1S1 + C/T 82 290 54.1 0.50 0.58 0.43 0.37 0.39
7 48450157 rs17548783 ABCA13 + C/T 60 97 52.5 0.48 0.46 0.72 0.53 0.48
7 50742180 rs1800504 GRB10 - A/G 62 365 54.7 0.49 0.53 0.40 0.31 0.65
7 55214348 rs2072454 EGFR + C/T 133 57 50.3 0.45 0.54 0.44 0.31 0.50
7 127250907 rs712700 PAX4 - A/G 76 281 45.7 0.34 0.78 0.36 0.34 0.69
7 43846603 rs7738 BLVRA + A/G 659 1085 44.7 0.42 0.33 0.43 0.33 0.61
7 151254175 rs8961 PRKAG2 + C/T 272 268 41.9 0.42 0.65 0.78 0.75 0.21
8 104337096 rs3808554 FZD6 - C/T 308 271 40.1 0.46 0.48 0.57 0.63 0.25
8 94935937 rs4735258 PDP1 + C/T 2314 595 41.7 0.50 0.40 0.64 0.66 0.46
9 100190780 rs1381532 TDRD7 - C/T 963 192 42.7 0.43 0.48 0.59 0.50 0.58
9 136304497 rs3124768 ADAMTS13 - C/T 265 231 54.9 0.47 0.46 0.78 0.79 0.38
9 80919756 rs3739474 PSAT1 + G/T 153 199 44.5 0.50 0.67 0.26 0.30 0.50
9 104184022 rs4577 ALDOB - C/T 53 476 45.1 0.40 0.42 0.42 0.45 0.31
9 27202870 rs639225 TEK - C/T 143 132 41.1 0.44 0.51 0.41 0.41 0.38
9 77415284 rs7859201 TRPM6 + A/C 284 465 40.9 0.45 0.34 0.37 0.42 0.77
9 97365642 rs9695 FBP1 - C/T 100 78 50.3 0.50 0.49 0.48 0.40 0.55
10 85972043 rs10749482 CDHR1 + A/G 259 555 50.9 0.40 0.28 0.32 0.23 0.80
10 100219314 rs10883099 HPSE2 + A/G 52 60 51.3 0.46 0.52 0.52 0.53 0.62
10 78944590 rs1131824 KCNMA1 - C/T 290 202 44.1 0.38 0.32 0.26 0.26 0.66
Selected SNPs in bold typeface. Distance - distance to SNP with AF ≥ 0.01; GC - % GC of flanking 250 bp; KG - 1000 Genomes Pilot average; HM - HapMap Phase 3
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Table B.1: Candidate SNPs for inclusion in WES tracking panel continued
Distance Allele Frequencies
Chr Position rsID Gene Strand Alleles 5’ SNP 3’ SNP GC KG HM-CEU HM-CHB HM-JPT HM-YRI
10 95791763 rs17109674 PLCE1 + A/G 150 702 42.1 0.40 0.31 0.49 0.48 0.54
10 117884950 rs2245020 GFRA1 + A/G 235 310 53.7 0.49 0.57 0.61 0.45 0.22
10 104814162 rs2275271 CNNM2 + C/T 1265 1106 43.5 0.43 0.38 0.53 0.45 0.30
10 113920465 rs2277207 GPAM - C/T 294 187 41.1 0.45 0.61 0.50 0.62 0.54
10 69926097 rs2673794 MYPN - A/G 164 222 48.5 0.50 0.68 0.24 0.42 0.29
10 73856984 rs3312 ASCC1 - C/T 340 607 41.1 0.44 0.44 0.30 0.30 0.71
10 104596924 rs6163 CYP17A1 + A/C 528 57 54.9 0.42 0.38 0.55 0.46 0.29
10 105819956 rs805701 COL17A1 + A/G 600 479 49.1 0.41 0.65 0.72 0.70 0.21
11 6629665 rs1043388 ILK + C/T 135 73 47.5 0.31 0.31 0.34 0.37 0.42
11 16133413 rs4617548 SOX6 + A/G 190 1118 42.1 0.47 0.52 0.65 0.61 0.51
11 30255185 rs6169 FSHB + C/T 502 638 43.5 0.40 0.38 0.67 0.69 0.79
12 8757481 rs2028373 AICDA + A/G 188 1062 41.9 0.48 0.63 0.62 0.42 0.32
12 52200742 rs60637 SCN8A + A/C 714 927 52.7 0.43 0.74 0.47 0.50 0.24
12 993930 rs7300444 WNK1 + C/T 246 84 44.9 0.44 0.46 0.55 0.48 0.28
13 25466955 rs3742165 CENPJ + C/T 181 186 44.7 0.49 0.54 0.67 0.69 0.23
13 39433606 rs9532292 FREM2 + A/G 477 183 45.9 0.40 0.29 0.41 0.44 0.54
14 76045858 rs2287016 FLVCR2 + A/G 167 105 54.7 0.44 0.22 0.59 0.57 0.69
14 50769717 rs2297995 L2HGDH + A/G 262 142 42.9 0.43 0.55 0.65 0.67 0.59
14 74992800 rs699374 LTBP2 + A/G 217 61 51.1 0.37 0.29 0.41 0.33 0.50
14 64637147 rs7161192 SYNE2 + A/C 584 837 49.1 0.39 0.29 0.57 0.52 0.34
14 35871217 rs8904 NFKBIA - C/T 124 190 41.5 0.42 0.39 0.37 0.27 0.70
15 89401615 rs3825994 ACAN - A/C 236 199 53.3 0.42 0.77 0.44 0.52 0.29
15 34528948 rs4577050 SLC12A6 + A/G 360 329 44.9 0.39 0.68 0.75 0.63 0.32
15 89402596 rs698621 ACAN - A/C 357 300 52.5 0.49 0.66 0.40 0.45 0.20
16 68729785 rs17715450 CDH3 + A/C 259 581 53.9 0.50 0.60 0.48 0.61 0.28
16 70303580 rs2070203 AARS - C/T 162 79 54.7 0.46 0.53 0.28 0.51 0.49
16 68713823 rs2296408 CDH3 - G/T 93 633 52.5 0.37 0.62 0.58 0.68 0.69
16 68713730 rs2296409 CDH3 - C/T 157 93 51.5 0.37 0.62 0.58 0.68 0.69
16 70546234 rs3762171 COG4 - C/T 555 162 47.3 0.44 0.34 0.70 0.49 0.28
17 71197748 rs1037256 COG1 + A/G 309 455 53.1 0.44 0.50 0.67 0.65 0.56
17 71192663 rs1052706 COG1 + A/G 195 210 51.7 0.49 0.50 0.67 0.65 0.27
17 71192873 rs11544800 COG1 + A/G 210 82 53.1 0.49 0.48 0.69 0.59 0.24
Selected SNPs in bold typeface. Distance - distance to SNP with AF ≥ 0.01; GC - % GC of flanking 250 bp; KG - 1000 Genomes Pilot average; HM - HapMap Phase 3
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Table B.1: Candidate SNPs for inclusion in WES tracking panel continued
Distance Allele Frequencies
Chr Position rsID Gene Strand Alleles 5’ SNP 3’ SNP GC KG HM-CEU HM-CHB HM-JPT HM-YRI
17 7192091 rs222842 YBX2 + C/T 1030 107 52.1 0.50 0.66 0.36 0.31 0.27
17 10542471 rs2285475 MYH3 - A/C 579 237 44.9 0.50 0.74 0.38 0.39 0.22
17 10536018 rs2285479 MYH3 - C/T 257 166 49.1 0.49 0.74 0.40 0.39 0.24
17 42449789 rs5910 ITGA2B - C/T 273 277 51.9 0.40 0.38 0.48 0.34 0.46
18 21413869 rs9962023 LAMA3 + C/T 565 231 48.7 0.34 0.67 0.81 0.75 0.51
18 12351342 rs11080572 AFG3L2 - A/G 837 210 41.1 0.37 0.77 0.67 0.60 0.48
18 47455923 rs2298628 MYO5B + C/T 67 400 49.9 0.42 0.58 0.33 0.27 0.37
19 55494740 rs10412915 NLRP2 + C/T 89 141 54.5 0.31 0.25 0.27 0.31 0.25
19 33353464 rs11084673 SLC7A9 + A/G 107 390 53.9 0.30 0.36 0.27 0.27 0.27
19 10267077 rs2228611 DNMT1 - A/G 66 175 42.7 0.46 0.47 0.73 0.56 0.48
19 38994910 rs2229144 RYR1 + A/G 230 242 52.1 0.36 0.28 0.33 0.26 0.45
19 13445208 rs2248069 CACNA1A - A/G 64 161 47.9 0.37 0.70 0.69 0.69 0.44
19 12989560 rs2293682 DNASE2 + A/G 1132 400 54.5 0.36 0.24 0.69 0.67 0.24
19 55441902 rs269950 NLRP7 + C/T 92 54 47.7 0.43 0.48 0.72 0.68 0.52
19 16591464 rs9305079 CALR3 + A/G 226 231 42.7 0.36 0.69 0.67 0.65 0.52
20 6100088 rs10373 FERMT1 - C/T 57 142 46.7 0.49 0.54 0.31 0.35 0.58
20 19970705 rs2076584 RIN2 - A/G 404 183 48.3 0.45 0.35 0.67 0.76 0.44
20 2413320 rs2076652 TGM6 - A/G 194 58 54.1 0.48 0.33 0.46 0.53 0.70
20 52786219 rs2296241 CYP24A1 + A/G 146 187 42.1 0.47 0.54 0.44 0.42 0.46
20 35865054 rs4608 RPN2 + C/T 325 297 46.9 0.31 0.76 0.48 0.58 0.70
21 46908355 rs11702425 COL18A1 + C/T 118 214 49.1 0.32 0.30 0.24 0.32 0.35
21 47773103 rs2249057 PCNT + A/C 248 74 51.9 0.31 0.39 0.47 0.40 0.23
21 44323590 rs4148973 NDUFV3 + G/T 129 130 49.9 0.48 0.65 0.33 0.38 0.73
22 21141300 rs4675 SERPIND1 + C/T 510 92 51.3 0.45 0.46 0.62 0.51 0.57
22 37469591 rs4820268 TMPRSS6 + A/G 391 230 52.1 0.46 0.52 0.49 0.37 0.79
Selected SNPs in bold typeface. Distance - distance to SNP with AF ≥ 0.01; GC - % GC of flanking 250 bp; KG - 1000 Genomes Pilot average; HM - HapMap Phase 3
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B.2 Supplementary Data for Chapter 7
Table B.2: Technical details for whole-exome datasets
Reads Variants
On Target (%) Target covered (%) Heterozygosity (%)
Family ID Kit Sequencing FastQCa Total Aligned Baits ± 150 DOC 20 X 10 X 5 X 1 X Called Autosomal ChrX
A Proband V5 HiSeq 2000 GC 46,341,632 42,707,333 75.2 86.7 56.9 87.8 96.3 98.4 99.3 25,139 61.5 13.1
B I1 V5 HiSeq 2000 55,689,034 53,089,120 77.6 85.5 70.6 86.3 95.8 98.7 99.8 23,488 59.8 6.5
B II2 V5 HiSeq 2000 53,054,034 50,490,602 77.4 85.2 67.0 85.2 95.4 98.6 99.8 24,577 63.6 6.6
B II3 V5 HiSeq 2000 45,684,120 42,871,207 81.2 89.4 59.7 82.3 94.3 98.3 99.8 23,886 62.7 6.8
C Proband V5 HiSeq 2000 49,451,613 46,401,925 76.2 88.4 58.5 86.3 95.0 98.0 99.6 24,955 61.3 15.1
D Lesionb V5 HiSeq 2000 GC 91,045,365 83,122,511 88.7 91.9 100.0 95.8 98.3 99.0 99.4 - - -
D Germline V5 HiSeq 2000 GC 45,115,828 40,501,403 87.7 91.3 48.4 84.3 95.5 98.2 99.3 25,663 62.9 62.3
E I1 V5 HiSeq 2000 49,372,504 47,046,558 79.1 86.7 63.9 84.0 94.9 98.4 99.8 23,055 60.5 8.2
E I2 V5 HiSeq 2000 53,246,902 50,168,377 78.9 86.5 68.0 85.6 95.5 98.5 99.7 23,797 59.9 64.0
E II1 V5 HiSeq 2000 47,342,860 45,248,551 79.4 87.2 61.6 83.5 94.8 98.3 99.8 23,297 60.0 9.2
Quality values outside of range are highlighted in bold and discussed in main text. Kit - whole-exome capture kit utilised: V4/V5 - Agilent SureSelect Human All Exome V4/V5;
FastQC - criteria of read quality failures: GC - per sequence GC content, Quality - Per base sequence quality; Aligned - reads mapping to reference with an alignment phred-scaled
quality ≥ 20; ±150 - bait regions padded by 150 bp; DOC - mean depth of coverage for baited regions of genome.
aNote that FastQC results are highly sensitive; a ‘Fail’ does not constitute an issue in the use of data in downstream analyses, provided that no other quality issues are apparent.
bData not subjected to variant QC due to somatic nature of the tissue.
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B.3 Supplementary Data for Chapter 8
Table B.3: Technical details for whole-exome datasets
Reads Target covered (%)
Sample Total Aligned Unique Mapped ±150 Mapped target 1 X 5 X 10 X 20 X DOC
SCLP1 46,341,632 45,995,191 45,230,995 86.5 82.9 99.3 98.4 96.3 87.8 56.9
SCLP2-1 102,525,932 101,596,662 100,154,970 89.5 85.3 99.3 99.0 98.6 97.4 127.9
SCLP2-2 92,357,604 91,426,256 90,117,254 89.1 84.6 99.4 99.1 98.6 96.9 113.7
SCLP2-3 102,409,746 101,335,363 99,904,666 89.8 85.5 99.4 99.1 98.7 97.4 127.3
SCLP3-1 88,367,648 87,481,021 86,218,963 88.6 83.3 99.3 99.0 98.5 96.9 108.0
SCLP3-2 66,687,586 66,633,760 62,443,807 79.9 73.0 98.5 96.8 93.6 83.3 56.8
NSCLP1-1 54,956,672 54,558,769 53,763,584 91.1 76.8 99.3 98.8 97.7 92.9 68.8
NSCLP1-2 74,355,880 73,326,222 72,878,819 95.2 84.4 99.9 99.3 98.1 93.7 94.6
NSCLP2-1 53,630,678 53,245,840 52,373,414 88.2 74.8 99.3 98.7 97.1 90.7 65.2
NSCLP2-2 46,509,220 46,179,091 45,401,788 87.9 75.3 99.2 98.4 96.4 88.3 57.3
NSCLP3-1 43,363,414 43,032,505 42,300,126 87.9 75.3 99.2 98.3 95.7 85.9 52.6
NSCLP4-1 41,622,776 41,312,749 40,618,226 88.2 75.5 99.2 98.2 95.5 85.0 50.9
NSCLP4-2 46,087,918 45,762,033 44,987,196 87.6 74.4 99.2 98.4 96.3 87.8 56.6
NSCLP5-1 49,254,976 48,875,805 48,031,749 84.5 72.0 99.3 98.5 96.4 88.2 59.2
NSCLP6-1 100,068,158 99,055,310 97,692,151 91.5 86.6 99.4 99.1 98.6 96.9 109.2
NSCLP6-2 99,974,938 98,831,948 97,384,564 87.2 81.8 99.4 99.1 98.8 97.4 119.1
NSCLP7-1 95,428,304 94,564,501 93,168,229 88.3 84.7 99.3 99.0 98.5 97.1 118.5
NSCLP7-2 97,299,918 96,408,611 95,022,993 89.8 85.7 99.3 99.0 98.6 97.3 123.1
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